Nutritional status and quality of life in HIV positive pre- and post- kidney transplant recipients, from HIV positive donors. by Martin, Claire Juliet.
NUTRITIONAL STATUS AND QUALITY OF LIFE IN HIV POSITIVE PRE- 











Submitted in fulfilment of the  
requirements for the degree of  
Doctorate of Philosophy (Dietetics) 
Dietetics and Human Nutrition, 
School of Agricultural, Earth and Environmental Sciences 
College of Agriculture, Engineering and Science 














I, Claire Juliet Martin declare that:- 
 
a) This thesis has not been submitted for a degree at any other institution. 
b) The work contained within this thesis is my own, original work. The work of other 
authors are acknowledged and referenced.  
 
Signed        Date 26 August 2019 
Claire Juliet Martin      
  
 
Signed              Date 26 August 2019    
Supervisor: Dr Susanna Maria Kassier 
 
 
Signed                         Date 26 August 2019    





Background: Kidney transplantation from a HIV-positive donor to a HIV-positive recipient is 
now a treatment option available for patients with ESRD. Impairments in nutritional status are 
common, and increase the risk of adverse clinical and health-related quality of life (HRQOL) 
outcomes. Therefore Optimising nutritional status is therefore an important adjunct of medical 
care that begins with a nutritional status assessment. 
 
Aim: To describe the nutritional status and HRQOL of HIV-positive kidney transplant 
recipients from a HIV-positive donor and candidates on the waiting list to receive one. 
 
Objectives: To determine nutritional status through the assessment of body composition, bone 
mineral density (BMD), dietary intake, biochemical indicators and gastrointestinal symptoms 
(GIS). To determine HRQOL based on the patient’s perception of their health.  
 
Methods: The frequency and severity of GIS was determined using a previously validated 
questionnaire;  the gastrointestinal symptom rating scale (GSRS). BMD and body composition 
were measured by dual-energy x-ray absorptiometry (DEXA). Dietary intake was evaluated 
using a 24-hour recall. Biochemical indicators of albumin, prealbumin fasting glucose, lipids 
and serum 25-hydroxyvitamin D [25(OH)D] were analysed. Adiposity and musculature were 
determined through anthropometric indices of weight, body mass index (BMI), waist 
circumference (WC) and mid-arm muscle circumference (MAMC). HRQOL was assessed using 
a validated questionnaire; the Short form-36 (SF-36) and semi-structured interviews. With the 
exception of DEXA, all other assessments were done at baseline and at six months. 
 
Results: The study sample consisted of 76 participants (n=22 transplant recipients, n=54 
transplant candidates), who were predominantly black (93.4 %) and male (60.5%), with a mean 
age of 43.6 ± 8.1 years. The frequency of GIS was high for both groups.  Indigestion was a 
frequent and severe GIS. Amongst transplant candidates, females had significantly higher GSRS 
severity scores for selected subscales and the overall global mean score (p=0.030) compared to 
males. Age and duration of treatment correlated with selected subscales in transplant candidates. 
WC correlated positively with constipation amongst transplant recipients. BMD was assessed in 
56 participants. Osteoporosis was more prevalent amongst transplant recipients (20.0%), while 
osteopenia was more prevalent amongst transplant candidates (27.8%).  T-scores strongly 
correlated with lean mass at the BMD of the spine (r = 0.707, p = 0.007), and moderately with 
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each side of the total hip (r = 0.455, p = 0.007 and r = 0.420, p = 0.007). Serum 25(OH)D  
vitamin D levels was low for the group as a whole, with a mean of  22.04 ±12.74  ng/ml, and 
was not related to BMD. There was a significant positive association between dietary calcium 
and all BMD sites for transplant recipients. In a subset of participants (n = 34), there was a 
significant positive association between anthropometry and DEXA derived indices of adiposity.  
These were BMI and percent body fat (%BF) (r = 0.773, p < 0.001), WC and truncal fat (TF) (r 
= 0.799, p = 0.00) and visceral adipose tissue (VAT) (r = 0.885, p < 0.001). The indicator of 
muscularity (MAMC) correlated with appendicular lean mass index (ALMI) (r = 0.511, p = 
0.011), establishing these anthropometric indices as suitable proxy measures of overall and 
regional adiposity (including visceral adipose tissue) as well as musculature. The majority of 
transplant candidates were overweight (38.5%), or had normal BMI (36.5%) At six months, 
62.7% had a statistically significant weight loss t (50) = 2.072, p = 0.043). Metabolic syndrome 
(MetS) was present in 47.5% and 51.0% of candidates at baseline and six months respectively. 
The mean daily energy and protein intake were below recommendations for dialysis. The 
majority of transplant recipients had a normal BMI (71.4%). At six months, 52.4% showed a 
weight gain trend and a significant increase in WC (t (14) = -2.861, p 0.013). MetS was present 
in about 35% of transplant recipients.  At baseline, weight correlated with total protein (r = 
0.609, p = 0.003), animal (r = 0.513, p = 0.017) and plant protein (r = 0.534, p = 0.013) intake. 
At six months, WC correlated with animal protein (r = 0.517, p = 0.028) intake. 68 patients 
completed the SF-36 at baseline and 6 months. Transplant candidates had lower HRQOL than 
recipients. The main mental stressors were income, employment and waiting for a donor. 
Physical health complaints were body pain and fatigue. In transplant recipients, the composite 
physical and mental scores were above the average for the general population.  Prealbumin, 
BMI, albumin and MAMC showed positive correlations with selected SF-36 domains.  
 
Conclusion: A series of studies showed altered nutritional status and HRQOL in a substantial 
proportion of transplant candidates and some transplant recipients. These results can be used to 
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1.1 Study background  
 
Global estimates of people living with human immunodeficiency virus (HIV), average 36.9 
million (1), with the majority (71%) residing in Sub-Saharan Africa (2). About 1.8 million were 
newly infected and 940 000 died of Acquired Immunodeficiency Syndrome (AIDS) - related 
causes in 2017 (1). South Africa (SA) bears one of the heaviest healthcare burdens (3), with a 
HIV prevalence of 7.5 million or 13.1% of the population (4), and is currently running the 
largest antiretroviral (ART) programme in the world (3). By 2018, the estimated number of 
adults and children on ART was in excess of 4.3 million (3).   
 
ART has significantly reduced morbidity and mortality, such that HIV is now regarded as a 
chronic condition with a greater life expectancy (5). As a result, corresponding increases in the 
number of comorbidities affecting the ageing HIV population have been observed (6,7). The 
attention originally placed on infectious complications has broadened to the management of 
non-communicable diseases (NCD) such as cardiovascular disease, diabetes mellitus, 
osteoporosis, and renal disease increasing the burden of the disease on the individual and the 
health system (8,9,10,11,12).  
 
Renal disease, both chronic and acute, is a co-morbid, non-AIDS-defining condition of 
increasing prevalence in the HIV population (13,14) with some form of renal dysfunction 
identified in as many as 30% of the HIV-positive population (15). In sub-Saharan Africa, the 
prevalence of kidney disease in the HIV-positive population is reportedly between 6% and 
48.5% (16). HIV-associated nephropathy (HIVAN) is however the most frequent aetiology in 
chronic kidney disease (CKD) (17), responsible for 27% to 62% of CKD in patients of black 
ethnicity (18,19). Early prevalence studies listed HIVAN as the third leading cause of end stage 
renal disease (ESRD) amongst African Americans (20), and the foremost aetiology in patients 
of African descent in South Africa (18,21).  Based on early United States (US) HIVAN 
prevalence, statistical projections for Africa were that as many as 3.1 million people will 





HIVAN is thought to be caused by direct viral infection of the kidney cells, presenting with 
excessive proteinuria and collapsing focal and segmental glomerular sclerosis on histology. 
CD4 counts of < 200 cells/mm3 and elevated viral loads are considered predisposing risk factors 
(13,23). Without treatment, prognosis is bleak, with patients developing ESRD within months 
(18). In South Africa, State hospitals have limited dialysis resources and patients can only 
access dialysis if they are eligible for a transplant.  Therefore, for HIV-positive state patients, a 
renal transplant remains the most favourable treatment option (24). 
 
A HIV-positive status was formerly contraindicated for kidney transplantation (25), and an 
exclusion criterion for being placed on transplant waiting lists (26). However, over time, many 
centres across the globe have published their experience, demonstrating the viability of kidney 
transplantation in HIV-infected individuals (25,27,28,29). It was found that, despite recurrent 
acute rejection in 67% of recipients, outcomes with respect to the graft and patient survival at 
three years were reported to be 83% and 94%, respectively, similar to that of HIV–negative 
transplant patients (30). In addition, CD4 counts and viral loads showed no evidence of 
hastened HIV disease progression. Donor kidneys, at this stage, were only sourced from HIV-
negative donors for fear of an emergent ‘superinfection,’ consequential drug resistance and 
hastened progression to AIDS, should positive donors be used (31). 
 
In 2008 however, a South African (SA) surgeon pioneered the first ever kidney transplants 
involving four HIV-positive donors and recipients, with a view that South Africa’s high HIV 
infection rate may offer a greater opportunity of finding donor kidneys, thus providing a chance 
to improve prognosis in patients, who would otherwise have demised within months (32). 
Qualifying recipient criteria include good adherence to ARVs and low viral loads of less than 50 
copies per millilitre for longer than six months. Patients previously treated for Tuberculosis 
(TB) were not excluded from the transplant programme. In SA, virus resistance is fortunately 
still minimal and augmented dosages of protease inhibitors were used to reduce the transplanted 
viral strain (32). Since 2008, 43 HIV-positive patients have received transplants at Groote 
Schuur Hospital in Cape Town (33). 
 
1.2 Significance of this study  
 
While transplantation extends survival (34), malnutrition, obesity and co-morbidities in the pre- 
and post-transplant phase can present a threat to patient and graft survival as well as quality of 
life (35,36,37). Underlying HIV places patients at a greater risk since HIV itself is a health 
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burden with a myriad of on-going nutrition-related problems (38). To date however, nutritional 
aspects in this group have remained unexplored. Hence, the emphasis of related literature to 
date, has primarily focused on clinical and pharmaco-therapeutic strategies to extend survival 
(15), with nothing being documented about the nutrition related morbidity and quality of life the 
extended life expectancy affords.  
 
Nutritional care is always preceded by an assessment of nutritional status as a baseline or 
reference point for decision making and the planning of intervention strategies (39,40). As no 
previous evaluation has been conducted, there is no guidance regarding patient nutritional 
status, or selection of the most appropriate nutritional assessment tools, for this patient group. 
As such, conducting an objective evaluation of nutritional health, with the inclusion of 
subjective health related quality of life (HRQOL) measures (40), it was anticipated that the data 
generated by this research will:   
 
 Contribute significantly to the current body of knowledge by providing insight into the 
physical and metabolic changes that may occur in pre- and post-renal transplanted HIV 
positive patients. 
 Identify patients at risk of developing clinical complications that could have an impact 
on their health and quality of life. 
 Generate suggestions regarding appropriate nutritional indicators for monitoring and 
assessment of nutritional status. 
 Identify dietary factors that will optimise post-transplant nutritional status and 
contribute to sustaining graft function and delay the development of co-morbidities. 
 Provide a baseline assessment of HIV-positive kidney transplant patients that could be 
used for future evaluation of dietary intervention or related research.   
 
1.3 Problem Statement 
 
Both pre- and post-renal transplant patients present with nutritional challenges that pose serious 
morbidity and mortality risks. To date there is a paucity of data documenting the nutritional 
status or quality of life of HIV-positive pre- and post-renal transplant patients who have 
received a kidney from a HIV-positive donor, or who are on the waiting list to receive a kidney 





1.4 Research aims  
 
The aims of this study were to conduct nutritional status and quality of life assessments in: 
 HIV-positive kidney transplant recipients, who have received a kidney from a HIV-
positive donor;  
 HIV-positive kidney transplant candidates, who are on the waiting list for a kidney 
transplant from a HIV- positive donor.  
 
1.5 Specific objectives 
 
To evaluate participant nutritional status, the following objectives were formulated:  
 To determine body composition by measurement of selected anthropometric indicators 
at baseline and six months follow-up. 
 To determine dietary intake using a 24-hour recall at baseline and at six months follow-
up. 
 To determine gastrointestinal symptoms using a validated questionnaire at baseline and 
six months follow-up. 
 To obtain bone mineral density and body composition using dual energy X-ray 
absorptiometry at baseline. 
 To obtain biochemical indicators of nutritional health, namely lipid profile, protein 
status, blood glucose and vitamin D status at baseline and at six months follow-up. 
 
To evaluate participant HRQOL using mixed methods, the following objective was formulated:  
 
 To quantify and describe HRQOL using a validated questionnaire and semi-structured 





Based on the study objectives, a diagrammatic representation of the study plan is shown in 
Figure 1.1 
 
HIV+ candidates awaiting a kidney from a 
HIV+ donor 
Recipients of a kidney from a HIV+ donor that 
is HIV+ 









- Anthropometric indicators 






Six month follow-up 
Body composition                         
- Anthropometric indicators  




Figure 1.1: Outline of the study plan 
 
1.6 Background to study sample data collection 
 
The HIV “positive-to-positive” kidney transplant programme is a national programme with 
candidates and recipients resident across South Africa, however it is run from a single centre - 
Groote Schuur Hospital (GSH) in Cape Town. Potential candidates are referred by their 
attending nephrologist to determine whether they meet the waiting list inclusion criteria.  Whilst 
awaiting a donor, candidates continue to receive dialysis at a private or state run dialysis centre 
in their home province. When a donor becomes available, patients travel to GSH to undergo the 
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transplant and return to their home province where they are again followed up by their 
nephrologist. At the time of the study, the programme was still in its infancy and was in the 
process of establishing a formal database. For the purposes of this study, the most recent list of 
transplant recipients and potential candidates was obtained from GSH. The number of 
candidates and recipients in this programme are still small, but represent 100% of the global 
population of this unique group. There were 92 prospective participants listed (68 transplant 
candidates, 24 transplant recipients) that were contactable either telephonically or at outpatient 
clinics, and were resident in six provinces. Of these, two transplant candidates and two 
transplant recipients declined participation, and 12 candidates were excluded due to missed 
appointments (typically two or more without reason), became ill or lost interest. 
 
Written informed consent was obtained from the seventy six participants and they were assigned 
to two categories namely (i) HIV-positive transplant recipients who received a kidney from a 
HIV-positive donor; and (ii) HIV-positive transplant candidates who were on the waiting list to 
receive a kidney from a HIV-positive donor.  
 
The map below (Figure 1.2) indicates the geographical distribution of study participants. Table 




                    Figure 1.2:  National distribution of study participants  
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Table 1.1 provides an overview of the stakeholders involved, and the resources required to 
facilitate data collection for this multi-centre study. 
 
Table 1.1: Resources and logistics required for data collection 
Stakeholders  Number 
Patients in six provinces residing in 13 cities/towns  76 
Private laboratories groups  3 
Radiology practices  10 
Nursing staff  5 
Administrative/medical records personnel  2 
Drivers/ patient transport  3 
Dietitians  22 
Dialysis centres  22 
 
Ethics approval was obtained from the University of KwaZulu-Natal’s Biomedical Research 
Ethics Committee (BREC) (Approval number BE 327/13). Where necessary, site permission 
was obtained from state hospitals (Groote Schuur Hospital and Livingstone Hospital) as well as 
the Eastern Cape Department of Health. Permission was also sought from the Clinical 
Governance departments of major South African private healthcare care providers that manage 
private dialysis centres throughout the country. The doctors of all participants were contacted to 
inform them about the purpose and scope of the study, as many patients wanted to discuss their 
participation in the study with their doctors before providing consent. Approval was also 
required from clinical trial facilitators at private laboratories, and radiologists (for DEXA) for 
establishing accounts, payment of fees, and to ensure specimen collection from laboratories 
service points countrywide. Results were also sent to all the participants’ doctors to be used for 
patient management.  
 
Due to cost constraints, the follow-up period was six months. There were no crossovers during 
this period. Each participant received R150.00 after completion of assessments done at the 
baseline and again at six months (an amount suggested by the ethics committee), to minimise 
drop-out from the small patient population. In addition, where necessary, a transport stipend 
was provided or transport and a snack was arranged for participants to comply with their 
appointments. 
Private practicing dietitians with practices close to the area where patients resided were 
recruited and trained to assist with data collection.  To ensure that the information and training 
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provided was of a high standard, the training was accredited by the Health Professions Council 
of South Africa (HPCSA) as a continuing professional development (CPD) activity. Dietitians 
and all other individuals that assisted with data collection were remunerated in accordance with 
the University’s hourly rate. The necessary equipment for data collection was couriered to 
fieldworkers.  
1.7 Definition of terms 
 
Anthropometry: Refers to measures of total body mass (including fat and fat-free mass), body 
dimensions and adiposity (41). 
 
Antiretroviral therapy: Refers to a combination of three of more drugs that are used to 
suppress HIV viral replication (42). 
Biochemical assessment: Within the context of nutritional assessment, biochemical assessment 
refers to objective laboratory assessment of nutritional status of serum/plasma values (43). 
Chronic kidney disease (CKD): Refers to damage to the kidney (regardless of the cause) or 
when the eGFR is < 60mL/min/1.73m2  for a period of  ≥ three months (44). 
Chronic rejection: Occurs when the immune system of the transplant recipient, slowly and 
continuously attacks the transplanted kidney, causing a progressive loss of kidney function (45). 
Clinical assessment: Includes a medical history and physical examination. It includes (but is 
not limited to) information on comorbidities, infectious diseases, pharmacotherapy and its side-
effects, gastrointestinal and other symptoms that impact on nutritional status (41). 
Delayed graft function: This term is used when the kidney does not start functioning 
immediately following the transplant. It may take between three to four weeks to resume 
adequate function. Dialysis will be required until then (45). 
Dietary intake: Refers to the description of food and liquid intake (39). 
Donor: The person from whom a kidney has been recovered to use for transplantation (46). 




Graft survival: Refers to the period of time that the transplanted organ continues to function 
optimally from the time of transplantation (45). 
Health-related quality of life: Refers to multiple dimensions of health which incorporates 
physical, mental, emotional, and social functioning (47). 
HIV- positive: Refers to a person who has the presence of antibodies against HIV (42). 
Immunosuppression:  Medications taken by the transplant recipient to prevent their immune 
system from rejecting the transplanted organ (45) . 
Induction therapy: Medications given during the perioperative period to prevent acute 
rejection, and may be continued for a brief period following transplant (45). 
Kidney transplant:  Refers to the transfer of a human kidney from a donor to a recipient for the 
purpose of restoring kidney function (46). 
Nutritional status: Takes into consideration multiple parameters of nutritional health including 
anthropometric, biochemical and clinical parameters as well as dietary intake (39). 
Registry: A repository of data with information on individuals who are waiting for a transplant 
and who have received a transplant. It includes personal information, clinical notes and 
information on cells and tissue typing (46). 
Socio-demographic status: Socio-demographic data identifies characteristics of the sample 
population (41). 
Transplant candidate: An individual registered on the organ transplant waiting list (45). 
Transplant recipient: An individual into whom the donated kidney is transplanted  (45). 
Waiting list: The list of candidates registered to receive a human cell, tissue or organ transplant 
(46). The list contains a range of candidate information especially information pertaining to 
genetic compatibility (45). 
1.8 Abbreviations 
AIDS:   Acquired immune deficiency syndrome 
ALMI:  Appendicular lean mass index 
AMA:  Arm muscle area 
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ART:   Anti-retroviral therapy 
BCM:  Body cell mass 
BMD:  Bone mineral disease 
BMI:  Body mass index 
BP:  Bodily pain 
CKD:   Chronic kidney disease 
CKD-MBD: Chronic kidney disease-mineral and bone disease  
CVD:  Cardiovascular disease 
DEXA:  Dual energy X-ray absorptiometry 
eGRF:  Estimated glomerular filtration rate 
ESRD:  End stage renal disease 
FN:  Femoral neck 
GH:  General health 
GIS:  Gastrointestinal system 
GORD: Gastro-oesophageal reflux disease 
GSRS:  Gastrointestinal symptom rating scale 
HAART:  Highly active antiretroviral therapy 
HD:  Haemodialysis 
HIV:   Human immunodeficiency virus 
HIVAN: HIV-associated nephropathy  
HRQOL:   Health related quality of life 
Ht:  Height 
LDL:  Low density lipoprotein cholesterol 
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LM:  Lean mass 
LS:  Lumbar spine 
MetS:  Metabolic syndrome 
MAMC: Mid arm muscle circumference 
MH:  Mental health 
MUAC: Mid upper arm circumference 
NHANES:  National health and nutrition examination survey 
NKF KDOQI: The National Kidney Foundation Kidney Disease Outcomes Quality Initiative  
NCD:   Non-communicable disease 
NODAT: New-onset diabetes after transplantation 
PD:  Peritoneal dialysis 
PF:  Physical functioning 
PEM:  Protein energy malnutrition 
PEW:  Protein energy wasting 
PI:  Protease Inhibitor 
PTH:  Parathyroid hormone 
QOL:  Quality of life 
RE:  Role emotional 
RP:  Role physical 
SAT:  Subcutaneous adipose tissue 
SF:  Social functioning 
SF-36:  Short form - 36 
TAT:  Total abdominal adipose tissue 
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TH:  Total hip 
TF:  Truncal fat 
TSF:  Triceps skinfold 
UGIS:  Upper gastrointestinal symptoms 
VAT:  Visceral adipose tissue 
VL:  Viral load 
VT:  Vitality 
WC:  Waist circumference 
WHR:  Waist to hip ratio 
WHtR:   Waist to height ratio 
WT:  Weight 
25(OH)D: 25-hydroxyvitamin D 
 
1.9 Thesis Structure 
 
This thesis consists of eight chapters. In preparation for publication, each chapter was written as 
a stand-alone publication, including methodology, study design, validity and reliability specific 
to each chapter.  
 
Chapter one, the introductory chapter, provided the background to the study and significance of 
the research. It includes the problem statement and research objectives that were investigated, 
relevant to the result chapters that followed.  
Chapter two includes a review of the related literature on the topic under investigation. Five 
chapters (chapters three to seven) presenting the results, follow thereafter. 
Chapter three describes the clinical assessment of gastrointestinal symptoms.  
Chapter four is a cross-sectional study that evaluated the bone mineral density and prevalence of 
osteoporosis in transplant candidates and recipients.  
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Chapter five describes the findings of a correlational study that compares anthropometric 
measures of adiposity and musculature against a reference standard, namely dual-energy X-ray 
absorptiometry. Body composition is an important component of nutritional status. In order to 
accurately report on body composition requires verification of measurements that can be 
described as a form of quality assurance of the chosen method portrayed in this chapter. 
Chapter six is a longitudinal assessment of overall and central obesity and dietary intake.  
Chapter seven is a longitudinal study using a mixed methods approach to determine 
participants’ health related quality of life and the association with musculature.  
Chapter eight, the concluding chapter, puts forward the conclusions and recommendations based 
on the results presented in chapters three to seven.  
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NUTRITIONAL STATUS IS RELATED TO CLINICAL OUTCOMES AND HEALTH-




Significant impairments to nutritional status accompany end stage renal disease (ESRD), and for 
patients on dialysis awaiting a transplant, one of the most serious complications being 
malnutrition. Malnutrition is associated with a higher mortality in the dialysis population, and 
continues to impact negatively on graft and patient outcomes after transplantation. Nutritional 
status improves after a transplant, but obesity and metabolic disorders threaten graft function, 
increase the risk of cardiovascular disease and impair health related quality of life (HRQOL). 
Hence, it is widely recognised that improving post-transplant prognosis begins in the pre-
transplant period, by optimising nutritional health through regular nutritional assessment.  
 
Studies show that clinical health, nutritional status and HRQOL in ESRD are made worse in the 
presence of various comorbidities. However, no such data has been published on HIV-positive 
ESRD patients, in particular transplant candidates and recipients from HIV-positive donors. 
 
This review explores the topic of nutritional status and quality of life impairments in kidney 
transplant candidates and recipients with consideration to the probable impact of comorbid HIV. 
The literature also provides a framework for appropriate pre- and post- transplant nutritional 
status assessment, and the selection of the most appropriate nutritional and HRQOL indicators 
within the context of this patient group. 
 
Keywords: Kidney transplant candidates, Kidney transplant recipients, Human 









2.1 Transplant candidates – pre-transplant protein energy wasting (PEW) 
 
Poor nutrition-related health in the pre- and post-transplant period can predispose transplant 
candidates and recipients to malnutrition and metabolic complications respectively, which in 
turn has an impact on graft failure and patient survival. Improving post-transplant prognosis 
therefore begins in the pre-transplant period, through early identification and management of 
nutritional problems (1). 
 
2.1.1 Pathophysiology of PEW 
 
Although pre-transplant candidates on haemodialysis (HD) or peritoneal dialysis (PD) face a 
variety of challenges making it difficult to maintain an optimal nutritional status, one of the 
most overriding nutritional concerns is protein energy wasting (PEW). PEW, also referred to as 
malnutrition and uremic malnutrition (2,3), is the proposed nomenclature as it conveys with 
greater accuracy, the changes in nutritional status observed in chronic kidney disease (CKD) 
(4). It is argued that malnutrition in general, occurs due to a lack of food and nutrients. In 
addition, it is an adaptive process resulting in protective physiological responses that includes 
the sensation of hunger, a decline in energy expenditure and the selective use of fat over muscle 
reserves. Conversely, the PEW of CKD produces maladaptive responses, with persistently high 
energy expenditure and anorexia rather than hunger. Muscle and lean body mass is lost, and the 
body is said to be in a state of reduced protein and energy stores. Unlike malnutrition resulting 
from starvation, it cannot be treated by dietary intervention alone (4,5). 
 
Identified as the ‘strongest risk factor for adverse outcomes and death’, PEW takes precedence 
over other nutritional issues in CKD, on account of the time discrepancy hypothesis. This 
premise applies to patients on dialysis who are thought to have higher short-term mortality risk 
from the consequences of under-nutrition, as they are unlikely to survive long enough to die as a 
result of health risks related to over-nutrition.  Therefore strategies aimed at improving 
nutritional status by addressing wasting, have greater life-saving benefit when compared to 
usual long-term strategies that focus on hypercholesterolemia, obesity and other cardiac risk 
factors for individuals on dialysis (6,7). Despite the advancements in dialysis over the last 50 
years (8), PEW unfortunately remains a persistent problem among dialysis populations globally. 
Differences in nutritional indicators and terminology notwithstanding, it has been identified in 
15% to 66.7% of individuals in HD populations (9,10,11), and in between 58% and 85% of 




Interrelated nutritional and non-nutritional pathways underlie the pathophysiology of PEW (14) 
that relate to the kidney’s role in a host of homeostatic mechanisms (2). As PEW is 
independently associated with estimated glomerular filtration rate (eGFR), prevalence increases 
relative to the progression of CKD (15).  Over time, the metabolic imbalances have an impact 
on several body systems and nutritional health (14). Early in the disease process, uraemia 
activates inflammation, producing inflammatory cytokines and increasing resting energy 
expenditure. Persistent inflammation, uremic toxins, metabolic acidosis and changes in 
hormonal activity produce a state of hyper metabolism that hastens protein catabolism, yet 
simultaneously reduces normal rates of synthesis (14). Dialysis improves uraemia but the 
procedure itself is associated with nutrient losses and an increase in resting energy expenditure, 
which if unmet, is fuelled by protein catabolism as a source of energy (16). Unfortunately, the 
requirements for protein and energy within this milieu are difficult to meet, due to additional 
factors such as dietary inadequacy and comorbidity (2,14), both of which are relevant to the 
current research.  
 
2.1.2 Inadequate nutrient intake, utilisation and increased losses  
 
The decrease in food intake, especially protein and energy, accompanies declining eGFR 
through the stages of CKD (17). Mehrotra et al reported an improvement in protein intake as 
well as nutritional status parameters six months after the initiation of haemodialysis (18).  
However, appetite remained reduced in up to a third of patients (19), ironically, being worse on 
dialysis versus non-dialysis days (20). An observation in PD patients suggests that at some 
point, an appetite threshold may be reached due to volume overload, satiety peptides, and 
inadequate dialysis which inhibits optimal intake (21). Added to this, there is interference with 
nutrient utilisation and absorption due to digestive disturbances or disease of varying severities 
(4,22,23,24) and loss of nutrients, especially amino acids, through the dialysates (25,26). 
 
Studies conducted on patients in ESRD also show that an inadequate dietary intake can be 
attributed to the patient and their situational factors.  These include complicated dietary 
restrictions (27), alterations in taste sensitivities (28,29), as well as dental and oral inflammation 
which could affect chewing and swallowing (30). Furthermore, financial difficulties are a 
barrier to obtaining a diet of a good quality (31,32), while psychological and social factors 




2.1.3 The impact of comorbid HIV 
Nutritional status is independently influenced by the presence of comorbidities (15), and is an 
additional factor in the development of PEW and malnutrition (14,34). Although little is known 
about comorbid HIV in the ESRD patient, it is likely to be significant, as the physiological 
impact of HIV, antiretrovirals (ARVs) and opportunistic infections on nutritional status is well 
documented (35,36). 
 
One of the most significant and widely recognised effects of HIV is wasting (36). Weight loss, 
wasting and loss of lean body tissue commence in the early stages of HIV infection and can 
occur throughout the disease process, even in the era of highly active antiretroviral therapy 
(HAART) (37). The extensive use of HAART has reduced the prevalence of wasting to 17.2% 
(38). However, unintentional weight loss continues despite adequate viral suppression and 
higher CD4 cell counts (39). Determinants of weight loss in HIV are multifactorial, and 
according to Mangili and colleagues, can be categorised into two groups namely alterations in 
metabolism and insufficient nutrition (37).  With regards to the former, HIV predisposes the 
individual to weight loss due to the physiological and metabolic effect of the virus, hormonal 
irregularities and cytokine dysregulation, which are intensified by the metabolic demands of 
ART (37). Metabolic changes in comorbidity alter nutritional status by increasing energy needs.  
In a small group of HD patients (n = 12), those with diabetes exhibited enhanced muscle 
breakdown as well as a trend towards higher resting energy expenditure when compared to 
matched non-diabetic HD controls (40). Oral and gastrointestinal manifestations are prevalent in 
approximately 50% of all patients, occurring at various stages during the course of the disease, 
thereby affecting nutrient assimilation. Symptoms include anorexia, abdominal pain, diarrhoea, 
vomiting, odynophagia or dysphagia (41) which reduces nutrient assimilation, absorption and 
utilisation (42). Inability to meet nutritional requirements could diminish immunity and increase 
susceptibility to opportunistic infections such as pulmonary tuberculosis, which can lead to a 
preferential loss of weight (80% - 90%) from protein stores (35). 
 
Wasting and gradual depletion of body cell mass (BCM) may not be initially evident, as it is 
masked by fluid shifts or changes in adipose tissue (36,43), yet preservation of BCM is crucial 
for several reasons. Firstly, BCM influences patient survival regardless of CD4 or viral load 
(36). Secondly, being metabolically active, deterioration in BCM can affect the efficient 
metabolism of medication and essential nutrients (35). Thirdly, it is positively associated with 
quality of life parameters of improved physical ability, feelings of health and fewer sick days. 
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Hence the majority of dietary and lifestyle changes recommended for the management of HIV 
aim to preserve BCM (43). 
 
2.1.4 The consequences of PEW as it relates to clinical outcomes 
 
The resultant muscle and fat loss and a negative nitrogen balance indicated by various markers 
of nutritional status increase morbidity, mortality and predict outcome (23, 44). Malnutrition, 
using a composite PEM-score, was associated with increased infections (45). Anorexia, based 
on an appetite questionnaire was associated with a greater number of hospitalisations, reduced 
quality of life and a four to five fold higher mortality risk than HD patients with a normal 
appetite (19). Dialysis patients with a diet characterised by a low protein intake (< 1.0 g/kg/d) 
and low energy intake (< 25 kcal/kg/d), were significantly associated with poorer survival 
outcomes, as was a lower muscle mass estimated by mid arm muscle circumference (MAMC) 
(46). Similarly, in a five year cohort of 149 HD patients, an elevated mortality risk was 
observed relative to low subjective global assessment (SGA) scores, normalised protein 
equivalent of nitrogen appearance (nPNA) of < 1.15 g/kg per day, and lower phase angle values 
of body composition values determined by bioelectrical impedance (47).  However, of all 
nutritional indicators, the preponderance of literature on outcomes associated with BMI. As a 
single index of nutritional status, BMI was historically recorded for eligible transplant 
candidates (48). Resultantly over time, decades of accumulated pre-transplant BMI data made 
retrospective analysis possible, linking pre-transplant BMIs to outcomes in the pre- and post-
transplant phase (1,49). 
 
2.1.5 Pre-transplant BMI on clinical outcomes 
 
The effect of pre-transplant BMI on clinical outcomes while on dialysis: 
A review by Park and co-authors listed a collection of studies demonstrating an inverse 
association between BMI and mortality in maintenance dialysis populations, and even a 
“reverse J-shaped” relationship. Lower BMIs were associated with a higher risk of mortality, a 
phenomenon confirmed by several larger cohorts of maintenance dialysis patients (50) as well 
as in candidates waitlisted for a transplant (51).  With reference to the latter, research by Molnar 
et al reported on 14 632 waitlisted candidates, who as a group are typically  in better health that 
HD patients who are not candidates for a transplant. They again confirmed a poorer survival in 
low BMI candidates and/or in those who experienced unintentional weight loss (51). Since this 
is contradictory to the relationship between BMI and survival in the general population (52), 
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this reverse epidemiological phenomenon was termed the obesity paradox (53) and has been 
documented among dialysis patients in Asian (54) and European populations (55) across gender 
(55), comorbidities (56), and across a number of ethnicities, with a greater strength of 
association amongst those of black ethnicity (57,58). 
 
Attempts to identify the component of weight that offered the survival advantage was limited by 
the inability of BMI to differentiate between fat and muscle.  Studies then used creatinine as a 
proxy for muscle mass, and this showed that the protective effect offered by the obesity paradox 
was due to the presence of a larger muscle mass.  It was observed that a lower BMI or muscle 
mass (using creatinine) and/or unintentional weight loss or loss of muscle mass was 
significantly associated with higher mortality, while higher BMIs were related to enhanced 
survival. In the Dialysis Outcome and Practice Patterns Study (DOPPS), a lower relative risk in 
mortality was seen in patients above the BMI range of 23.0-24.9kg/m2, even in those with 
moderate obesity (35.0-39.9 Kg/m2). The best outcome was seen in patients with low body 
weight and a high muscle mass leading to recognize the important role of muscle mass in the 
obesity paradox (51,59). Despite the survival benefit of a high BMI while on dialysis, its effect 
on post-transplant outcomes are less consistent. 
 
The effect of pre-transplant BMI on post-transplant outcomes: 
Although some studies like the one by Marcén et al, showed that pre-transplant BMI was not 
associated with overall graft failure or patient survival over two years (60). A recent meta-
analysis combining the data from 56 studies (n = 209 000) investigated the surgical, metabolic 
and mortality outcomes associated with BMI. It was determined that transplant recipients with a 
higher pre-transplant BMI do incur some post-transplant risk with respect to a greater 
probability of delayed graft failure and acute rejection, diabetes and hypertension (61).  
 
2.2 Kidney transplant recipients – post transplant obesity and metabolic disorders 
 
Transplantation improves quality of life and many of the nutritional anomalies associated with 
ESRD and dialysis. Thereafter, attention is turned to physical and metabolic changes that are 
caused or aggravated by immunosuppressive therapy (62,63). Equally important, in the current 
context, would be the physical and metabolic changes applicable to the context of HIV (64). In 
addition to immunosuppressive therapy, lifestyle factors such as diet and exercise are also 
thought to play a role  and, according to Fong and Moore, attention to lifestyle factors has the 
potential to avert adverse post-transplant consequences of cardiovascular disease (CVD), 
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dyslipidaemia, diabetes and bone loss (65). Therefore, with consideration to metabolic 
abnormalities relevant to both transplantation and HIV, and which fall within the scope of long-
term nutritional monitoring, the most pertinent ones are those indicated in Figure 2.1 (64,66). Of 
these, one of the earliest and most apparent is weight gain.  
               
Figure 2.1:  Theoretical framework of long term nutrition complications following a kidney     
                     transplant 
 
2.2.1 Weight and body composition changes 
 
Weight gain following a transplant is common. Increases in weight of between 5 kg to 13.6 kg 
during the first year have been documented (67,68,69), with the greatest extent of weight gain 
occurring in the first few months following transplantation. Cashion et al reported a 9.18 ± 6.59 
kg weight gain over one year, although the greatest incremental gains were observed within the 
first three months (67). Similarly, Elster et al reported a rapid 5.0 kg weight gain in the first six 
months which gradually increased to 9.9 kg over 3 years (70).   
 
The extent of post-transplant weight gain is notably higher among African Americans (69), and 
seems to occur irrespective of whether patients receive steroid inclusive or avoidance regimens 
(70). Determinants and predictors of weight gain are multifactorial.  Factors that are responsible 
for weight gain in the general population, including reduced physical activity and inappropriate 
dietary intake, contribute to weight gain especially as appetite improves from pre-transplant 
















Obesity is associated with known CVD risk factors such as hypertension, dyslipidaemia, and 
diabetes (73). CVD is the leading cause of death among transplant recipients (74). In fact, a high 
risk of premature CVD exists for all patients with ESRD, regardless of treatment modality. 
Compared to the general population, there is a 10 to 20 times and three to five time’s greater 
risk of early CVD in transplant candidates and transplant recipients respectively (73). HIV-
positive ESRD patients may, in all likelihood, have an even greater risk of CVD, given the fact 
that compared to uninfected individuals, they have a 1.5 to 2 fold higher relative risk of a 
myocardial infarction or coronary artery disease (75). But this would require investigation. 
Therefore, an important treatment goal among recipients is to address obesity and any factors 
that may increase the risk of CVD, as early as possible.  
 
2.2.2 Dyslipidaemia following renal transplantation 
The frequency of dyslipidaemia in kidney transplant recipients is generally high (73), especially 
hyperlipidaemia (76). In Iranian patients with dyslipidaemia, hypertriglyceridemia was the most 
prevalent form of dyslipidaemia, documented in 86.6% of recipients (77). 
Hypertriglyceridaemia and hypercholesterolaemia peaks between four to twelve months post-
transplant, while high density lipo-protein cholesterol (HDL) and low density lipo-protein 
cholesterol (LDL) progressively worsened by one year post transplant (77). Dyslipidaemia is 
fuelled by  immunosuppressants (73), age, genetics and donor source (hypercholesterolemia and 
hypertriglyceridemia is higher among recipients with kidneys from cadaveric donors than from 
living donors) (77) and are hence some of the non-modifiable determinants of dyslipidaemia, 
while obesity and a diet high in saturated fats, cholesterol and carbohydrates are modifiable risk 
factors (76).  
 
How the presence of HIV in the renal transplant recipient is likely to alter or exaggerate the 
pattern of dyslipidemia, is uncertain, since both the virus and ART exert independent effects on 
lipid metabolism (78). HIV lowers HDL and LDL levels but causes an increase in triglyceride 
levels, while disease-related weight and protein loss lowers total cholesterol and LDL-
cholesterol (78). The introduction of ART alters the lipid profile somewhat by increasing LDL, 
while HDL remains low (78). LDL abnormalities were observed among 33.1% of a sample of 
308 HIV patients on ART, although hypertriglyceridemia was the most prevalent, affecting 
59.1% of the sample, followed by hypercholesterolemia (41.9%) (79). ART also causes post-
prandial lipaemia, a strong contributor to atherosclerosis, while hyperlipidemia is more 
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prevalent in individuals with lipodystrophy than those without (80). Of all ART drug categories, 
protease inhibitors have a significant lipid altering effect and are associated with 
hypercholesterolaemia. In the case of HIV-positive kidney transplant recipients receiving a 
kidney from a HIV-positive donor, dosages of protease inhibitors are augmented to subdue viral 
resistance (81), hence necessitating the regular monitoring of lipid levels.  
 
2.2.3 Hyperglycaemia and post-transplant diabetes   
 
There is a high prevalence of hyperglycaemia (46%) within the first year post-transplant. New 
Onset Diabetes Mellitus after Transplantation (NODAT) occurs in 4% to 20% of the transplant 
population in the first year (73).  There is a known diabetogenic effect of post-transplant 
medication (82). However, influences during the pre- and post-transplant period that are also 
applicable to the general population, include ethnicity, age, gender, obesity and family history. 
Obesity, along with hepatitis C infection, and the type of anti-rejection therapy were identified 
as potentially modifiable risk factors, and compared to the other risk factors, obesity (defined as 
a BMI ≥ 30kg/m2) conferred one of the highest risks (83). 
The prevalence of type 2 diabetes in the HIV population increased from 6.8% in 2005 to 15.1% 
in 2015 (84). Although several factors were associated with the development of diabetes, weight 
gain after commencing antiretroviral therapy was a major factor (84). This was observed in a 
study of 1844 HIV-positive individuals where the probability of multi-morbidity was 
significantly greater in individuals that were classified as obese (85). HAART is associated with 
body fat re-distribution (lipodystrophy), especially as a result of the combined use of protease 
inhibitors and non-nucleoside reverse transcriptase inhibitors, with associated insulin resistance 
and dyslipidaemia (78). 
 
Protease inhibitors are associated with the development of lipid abnormalities and insulin 
resistance (64). Hypertension is very prevalent among South Africans (86), and in combination 
with abdominal obesity, can be used to determine the presence of metabolic syndrome. The 
prevalence of metabolic syndrome in HIV-positive patients ranges from 17% to 42%, with a 
higher prevalence being documented among those with viraemia and an elevated BMI (78). 
Abdominal obesity can be prevalent prior to transplantation, as HD patients have presented with 
excess visceral fat (VAT), and possibly linked to alterations in lipid levels (87). The presence of 
the metabolic syndrome predisposes to diabetes, contributes to early graft loss and substantially 
increases the risk of a cardiovascular event (88).  
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2.2.4 Bone disease 
Bone disease, such as osteoporosis, is an additional long term comorbidity that falls within the 
scope of the nutritional management of the kidney transplant recipient (88). Prior to undergoing 
a transplant, CKD‐mineral and bone disorder (CKD‐MBD) increases bone frailty and fracture 
susceptibility (89). Compared to the healthy population, both dialysis and transplant patients 
have a 17.2 times higher frequency of fractures, especially of the hip which affects quality of 
life and survival (89). Following a renal transplant, fracture risk increases. Retrospective 
information from the US Renal Data System which analysed 68 814 recipients over a ten year 
period found that 22.5% of the study sampled had a fracture within five years of transplantation 
(90). 
 
Post-transplant prednisone, worsens the negative impact on bone mineralisation through 
reduction of calcium absorption, hyperparathyroidism and abnormal vitamin D metabolism 
(66). Kidney transplant recipients with HIV would be at an additional risk of developing bone 
complications related to alterations in bone metabolism and reduced bone mineral density 
(BMD) due to HIV (64). A meta-analysis by Brown and Qaqish (2006) found reduced BMD in 
67% of patients infected with HIV and a greater than three-fold prevalence of osteoporosis in 
HIV-positive subjects compared to negative controls (91), possibly due to the viral effects of 
HIV, infections, and a low CD4 cell count (92). With the initiation of anti-retrovirals, decreases 
of up to 2.5% of total BMD over a two years period were observed (93), although there was a 
slight increase in mean BMD after 72 weeks related to virological suppression and an improved 
CD4 cell count (94). 
 
Together with nutritional deficiencies, Efavirenz and protease inhibitors may interfere with 
vitamin D metabolism. The prevalence of vitamin D deficiency may be as high as 70% and the 
resultant osteomalacia causes bone pain, muscle weakness and stiffness (92). Therefore, a 
nutritional recommendation for the maintenance of optimal bone health focuses on an adequate 
intake of calcium, vitamin D and lifestyle changes (66). The important role of vitamin D in HIV 
continues to emerge as it is found to have a complex relationship involving ARVs and immunity 
as well as affecting disease progression and mortality (95). In view of these important 
associations between nutritional status and clinical outcomes, an accurate assessment of 





2.3 Nutritional assessment 
 
Since no single indicator is an all-encompassing indicator of nutritional health, multiple 
parameters provide a more comprehensive picture. The commonly recommended “ABCD” 
method, is a composite evaluation of anthropometric, biochemical, clinical and dietary  
indicators (35). Within each category, selecting the most suitable from a range of simple or 
sophisticated indicators requires consideration of the assessment goals and context of the 
patients under evaluation, as well as available resources.   
 
2.3.1 Anthropometric evaluation of body composition  
 
Body composition is used to determine protein-energy status, diagnose and classify the severity 
of over-nutrition (overweight/obesity) and under-nutrition (PEW) (49). The ISRNM 
recommends the evaluation of low body weight, weight loss and reduced adiposity and 
musculature to identify PEW (5). Most suitably, this involves the anthropometric indicators 
BMI, triceps skin-fold (TSF) thickness, and mid arm muscle circumference (MAMC) (96). 
 
Total and regional body fat: BMI estimates overall adiposity, moderately correlating with 
adiposity measured by underwater weighing and dual energy X-ray absorptiometry (DEXA) 
(97). In the context of CKD, weight and BMI are easy indicators to determine, as all dialysis 
units would be equipped with digital scales to record pre- and post-dialysis weights. Although 
the World Health Organisation (WHO) cut-off for underweight is 18.5kg/m2, a higher cut-off of 
23kg/m2 is suggested by the ISRNM, with caution regarding its applicability to all population 
groups (5). BMI is useful as prognostic tool of survival (1) but has limitations as single indicator 
of health risk (49).  
The differentiation between fat and fat-free or muscle mass as well as regionally distributed fat, 
exceed the limitations associated with BMI. Highly sophisticated methods are costly and 
impractical in resource-limited settings (98,99). In South Africa, as is the case with countries of 
a similar economic standing, the unequal distribution of medical resources, technology and 
infrastructure are important considerations (100). Sophisticated methods are options for single-
site studies in well- resourced areas or could be used as reference methods.  Hence skinfold and 
circumference measurements are an alternative for multiple sites that are unequally resourced.  
 
An estimation of total body fat determined from subcutaneous fat as measured by skinfold 
thickness correlates strongly with DEXA in HD patients [r = 0.868 (P < .001)] (101). Although 
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multiple body sites can be included for estimating overall body adiposity, triceps skinfold 
thickness has comprehensive reference standards, is quick and practical, and can be used in the 
calculation of muscle circumference and muscle area (98).  It should however be borne in mind 
that the equations and reference standards used are based on data from the general population, 
and varies with age and gender (101-103). As a possible criterion for PEW, body fat should not 
be less than 10% (5).  
Like BMI, triceps skinfolds are not indicative of regional fat distribution. However, abdominal 
fat, especially visceral adipose tissue (VAT) is associated with an increased risk of type 2 
diabetes mellitus and CVD (104). In pre-dialysis patients, there was a strong association 
between waist circumference and visceral fat and harmful serum lipids (105). Of the various 
indicators of abdominal obesity, waist circumference is most often used (98) as a simple, 
inexpensive means of identifying truncal obesity, even in those with a low BMI (106). 
 
Lean body mass: Mid arm muscle circumference (MAMC) and arm muscle area (AMA) are 
calculated using measurements of upper arm circumference and triceps skinfolds to measure an 
estimate of muscle stores (98,102). The European Society for Clinical Nutrition (ESPEN) 
guidelines for HIV-positive patients recommend that nutritional status is ideally represented by 
muscle mass representing the body’s protein stores, because muscle loss and BCM may not be 
detected by weight (36). 
Muscle is affected by hydration status (107), and therefore an important concern in dialysis, or 
in HIV during acute illness, or increases in tissue fluids (108). Nevertheless, lean body mass 
changes using anthropometry shows good agreement with dual energy X-ray absorptiometry 
(DEXA) in HIV positive patients and has superior agreement with DEXA compared to 
bioelectrical impedance (108).  
 
2.3.2 Biochemical parameters of selected nutritional status outcomes 
 
Serum albumin is usually available via routine blood testing. More than 50% of all patients on 
maintenance HD have serum albumin <38g/L (109). It is more often used as a marker of illness 
and inflammation than an indicator of nutritional status and protein stores, as it is unrelated to 
dietary intake in CKD, and poorly correlates with other nutritional markers in patients 
undergoing dialysis    (110,111). A possible reason for this is due to the opposing effects that 
inflammation and nutrition have on albumin catabolism and synthesis respectively (112). 
Nonetheless, it still has prognostic value in CKD, as it is associated with the risk of 
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hospitalisation (113) and is a strong predictor of mortality. In the 5058 patients from the renal 
data base study, each 10g/L decrease in serum albumin increased cardiovascular mortality risk 
by 39% (114). As a parameter of illness, clinical measures to improve albumin in CKD will also 
improve nutritional status (109). In addition, lower serum albumin during the pre-transplant 
period predicts greater post-transplant mortality, graft failure and delayed graft function (115). 
Prealbumin is the recommended alternative to evaluate visceral protein stores (5, 116). With a 
shorter half-life of two to three days, it is more sensitive to alterations in nutritional status, and 
low serum levels are an independent risk factor for mortality in PD patients (116). However, 
prealbumin is also subject to misinterpretation, as inflammation decreases prealbumin, while it 
increases in CKD (116). Prealbumin correlates with other markers of nutritional status and 
demonstrates good sensitivity and specificity (116,117). Serum-cholesterol is not affected by 
acute illness, and as amalnutrition screening tool is more reflective of energy rather than protein 
intake (5). Nonetheless, as a risk factor for CVD, total cholesterol is routinely assessed, while a 
fasting lipid profile is required when screening for dyslipidaemia (76).  
 
Biochemical indicators are objective, but are not reliable as stand-alone nutritional status 
indicators as they are also sensitive to changes that accompany disease states (118). Hence it is 
recommended that clinical assessment is viewed as superior, especially in the evaluation of 
malnutrition (118,119). 
 
2.3.3 Clinical evaluation of gastrointestinal symptoms (GIS) 
 
The clinical component of the evaluation of nutritional status is frequently assessed by the 
subjective global assessment (SGA), which combines medical history and a physical assessment 
(120). However, as Gupta et al pointed out, its dependence on subjectivity and judgement makes 
it susceptible to the partiality of the observer (121), and is potentially limiting in multi-centre 
studies with numerous fieldworkers. An additional limitation is that it is restricted to 
recognising degrees of malnutrition rather than nutritional risk (122). So, although the SGA in 
its entirety is inappropriate for this study, the section related to GI disturbances is relevant, 
especially in the context of HIV (41). Therefore, it would be more prudent to use a GIS specific 
tool than the SGA.  Amongst the dialysis populations, GIS have been gauged by questionnaires, 
interviews, prospective diaries and stool analysis (123). The appeal of questionnaires is that they 
are easy to administrator, non-invasive and inexpensive. Ideally, the instrument should be as 
inclusive as possible, have good psychometric properties and be suitable for the goals of the 
population. For example, the disease specific GERD Symptom Frequency Questionnaire 
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(GSFQ) used to screen for gastro-oesophageal reflux disease (124), is useful in CKD, however 
symptoms of the lower gut may be missed if they are relevant to the condition under 
investigation. The Gastrointestinal Quality of Life Index (GIQLI) specifically assesses the 
burden of GIS on five quality of life domains (125). The gastrointestinal symptom rating scale 
(GSRS) is inclusive of both upper and lower gastrointestinal symptoms.  It is one of the most 
widely validated instruments used in the dialysis population (123), and along with the GIQLI, 
shows very good discriminant ability in kidney transplant recipients (125). 
 
2.3.4 Evaluation of nutrient intake 
 
The detailed description of macro- and micronutrient intake is feasible for small research 
samples and are valuable in clinical practice (102), as nutrients are associated with nutritional 
status and can be targeted for intervention. For example, in a study of HIV-positive men, BCM 
determined by bioelectrical impendence, correlated with dietary protein obtained via 24-hour 
recall (43). Similarly, a three day dietary recall helped to identify inadequate dietary protein as 
the key factor associated with malnutrition in 67.8% of study participants undergoing HD (34). 
The 24-hour recall has the advantage of being quick and simple to administer and does not rely 
on respondent literacy levels. Recall is immediate and does not alter dietary behaviour (126). 
Daily dietary differences in the general population imply that more than a single 24-hour recall 
is preferable to obtain an accurate representation of usual intake. Irrespective of the dietary 
assessment tool, accuracy is improved when attention is given to the estimation of portion size, 
and the use of professionals with experience in obtaining dietary information (102).  
 
2.3.5 Evaluation of bone mineral density 
Screening for osteoporosis and fracture risk is typically done by measuring bone mineral density 
using DEXA. DEXA is a quicker, more cost effective method with less radiation exposure than 
imaging techniques such as computed tomography or magnetic resonance imaging (127). The 
two sites most commonly measured are the lumbar spine and hip area. BMD scores are 
converted to T-scores which are used in the classification of osteoporosis (91).  
 
2.4 Health-related quality of life 
 
The purpose of a transplant is not only to prolong survival, but also to improve quality of life 
(128). Resultantly, health-related quality of life (HRQOL) has become an increasingly 
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important health outcome measure among recipients of a kidney transplant (129). Going beyond 
traditional indicators of morbidity and mortality, HRQOL evaluates multiple dimensions of 
health and well-being in daily life (130). In doing so, it is a more accurate reflection of one’s 
condition as it incorporates a subjective view of health and the consequence of disease on daily 
living (129). 
 
2.4.1 The concept health related quality of life 
 
Quality of life (QOL) and HRQOL are separate concepts, although they have been used 
interchangeably, possibly because a clear definition of either remains elusive (131). HRQOL is 
more applicable to health and disease and is a multi-dimensional concept that captures the 
effects of a disease and its treatment on the physical, mental and social functions of an 
individual (132). It also draws on perceptions shaped by individual beliefs and culture and is 
inclusive of their aims and expectations, as well as aspects of life that they find concerning 
(132). 
 
2.4.2 HRQOL of transplant candidates and recipients  
 
HRQOL is reduced in ESRD patients on renal replacement therapy (133,134), affecting both 
mental and physical health. A study of 90 patients receiving dialysis, found that 40.8% were 
depressed, 39.6% were anxious, while 24.1% were afflicted with both conditions (135). In other 
studies, a higher prevalence of up to 72.5% of moderate to severe depression among HD 
patients have been reported (136). In addition, patients suffer from a deterioration in physical 
functioning (137) and chronic pain (138). HRQOL scores show an improvement after a 
transplant, closer to that of healthy subjects (139). One of the largest systematic reviews 
comparing clinical outcomes between dialysis and transplant recipients pooled the findings of 
110 studies, thus including 1 922 300 participants. The results showed that transplantation is 
associated with a superior quality of life, regardless of research instrument used or context 
(140). However, psychological distress (141), and chronic pain (138) still persist.  
 
Efforts to improve HRQOL gained considerable momentum as it became apparent that HRQOL 
is also predictive of clinical outcomes. Better quality of life scores were associated with 
improved treatment compliance (142), and depression was predictive of mortality risk in HD 
patients (143). A two year longitudinal study with a sample size of 14 815 patients on HD 
showed that both poor mental health and physical functioning scores were associated with 
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increased mortality (144). A later smaller cohort of the CONTRAST study including 714 HD 
patients from three countries, identified physical and social functioning as well as emotional 
health as the HRQOL domains associated with mortality risk. The strongest association 
documented between physical functioning and mortality (HR = 1.72, 95% CI = 1.02–2.73), 
showed that compared to participants with an adequate baseline physical functioning score, 
those with lower scores had a 3.6 times greater mortality risk (145). Similarly, in a 12 year 
study of transplant recipients, physical limitations increased the risk of both graft failure and 
death after adjusting for clinical, social and demographic factors (146).  In another long term 
follow-up study on ten year post kidney transplant recipients, higher graft and host survival 
rates were observed in recipients with both higher physical and mental component scores of 
HRQOL (147). Given that one’s personal view of health influences treatment and survival 
(130), assessment of HRQOL and related factors will help identify patients at risk of adverse 
outcomes and will be valuable in planning strategies for improving HRQOL (145). 
 
2.4.3 Factors affecting HRQOL  
 
There are numerous socio-demographic and clinical determinant of HRQOL in patients on renal 
replacement therapy (148). A national survey of kidney transplant recipients in France identified 
multiple socio-demographic and clinical factors that were associated with a significant 
reductions in HRQOL. These included being female, unemployed, less educated and residing 
alone. Clinical factors included, but were not limited to, infections, illness, longer duration of 
dialysis and hospitalisation, and high BMI (149).  Two additional variables known to affect 
HRQOL, and relevant to the scope of the current study are comorbidity (150) and nutrition 
(151).  
 
Lower HRQOL scores were found in ESRD patients with a higher number of comorbidities 
(150). Transplant recipients with more comorbidities according to the Charlson comorbidity 
index, had a lower HRQOL, particularly in the dimension of physical function (134). Despite 
the lack of corroborative research, it is highly likely that HIV, which in itself is a burdensome 
disease, will contribute to an unfavourable dynamic to the HRQOL of kidney transplant 
candidates and. HIV- positive individuals in the United Kingdom, who had considerably lower 
HRQOL than the general population, despite the fact that the majority of participants had stable 
viral suppression and immune-competence (152). Given the longevity that ART now affords, 
understanding the determinants of HRQOL in HIV is important in order to focus interventions 
that aim to improve HRQL. Research on populations consisting of HIV-positive individuals, 
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documented a number of factors (indicated in Table 2.2), that impact on HRQOL (42,153-156) 
Although several factors that are prevalent among ESRD populations are not modifiable, there 
are potentially modifiable factors in ESRD (130), including nutritional status.  
 
Table 2.1 Factors contributing to a worse HRQOL and improved HRQOL in HIV-positive 
samples 
 









CD4 count < 300cells/mm3   
Lack of support 
Decline in work function 
Medication therapy 









ART with fewer pills 
ART adherence 
 
2.4.4 The effect of nutritional status on HRQOL in HIV and kidney transplantation 
 
In ESRD, a compromised nutritional status is associated with lower HRQOL scores, specifically 
in the physical domain (130). In HD patients, Noori et al demonstrated that a high MAMC, 
indicative of whole body muscle, is linked to improved QOL and survival (151). On the other 
hand, worse SF-36 mental and physical health scores were associated with lower serum albumin 
and creatinine levels and a higher total body fat percentage (157). In a study of HD patients by 
Raimundo et al (2006), weight loss negatively impacted on overall health, mobility, anxiety or 
depression, as well as usual activities in patients receiving haemodialysis (158). Psychological 
well-being has also been shown to be inversely related to gastrointestinal disturbances in CKD, 
regardless of treatment dialysis modality (159).  
 
Less is documented about the influence of indicators of nutritional status on the HRQOL of 
transplant recipients. The few studies that were identified are summarised in Table 2.3. A 
decline in mental health was associated with increasing BMI (160), and increasing severity of 




Table 2.2: The association of nutritional status indicators with HRQOL of transplant recipients 
 
Author, year Sample Study type Instrument  Health related quality of life outcomes 
 
Czyżewski et al  
2014 (160) 
 







(3 months, 12 months) 
SF-36 
KDQOL-S. 
Mental component score correlated negatively with BMI (r= –0.47; p < 0.05)  
at 1 year post- transplant. 
 








BMI > 30 kg/m2  was negatively associated with physical functioning domain 
of the SF-36; (r = -5.8, p < 0.0065) 
BMI > 30 kg/m2   was negatively associated with the physical health domain  
(r =  -4.6, p <0.0021), and the treatment domain of the ReTransQoL;  
(r = -3.2, p = 0.0030) 
 













GSRS score correlated with SF-36 scores for all dimensions. Greater severity 
of gastrointestinal symptoms related to worse HRQOL 
 






(baseline, 3 months,  
6 months, 12 months) 
GSRS  
GIQLI 
Significantly lower HRQOL in the presence of GIS (patient & doctor reported) 
Presence of GIS was associated with reductions in All five GIQLI domains 
(P<0.0001), especially emotional and physical function domains  with 
moderate‐to‐severe GIS  
 
SF-36: Medical Outcomes Study 36 - the Short Form, KDQOL-SF: Kidney Disease Quality of Life Short Form, ReTransQol: French version of the SF-36,  
GSRS: Gastrointestinal Symptom Rating Scale, GIQLI: Gastrointestinal Quality of Life Index. 




2.4.5 Measurement of HRQOL 
 
Numerous quantitative and qualitative methodologies exist to interpret patients’ subjective 
experience of their health (130). Whether it be for practice or research, the most appropriate 
method should be selected based on its suitability to the objectives of the investigation (153), 
the population under study and the context of the study.  Interviews and focus groups are 
examples of qualitative techniques that aim to understand an individual’s thoughts and feelings 
and how it shapes their perceptions and behaviour (163). Quantitative instruments which are 
used more often, are either used in economic analysis or the quantification of HROL and 
identification of the factors that can be modified to improve HRQOL (164). Quantitative 
instruments are classified into one of two types namely disease- specific and generic (130).  
 
Disease specific tools include aspects of the condition and treatment peculiar to that disease. For 
example, the Kidney Disease-Quality of Life (KDQOL) for use in CKD (129) and the Medical 
Outcomes Study (MOS)-HIV tool for use in the HIV population (153). Disease-specific tools 
have the advantage of being sensitive to health changes during the course of the disease. On the 
other hand, highly specific instruments may be limiting following major changes in the course 
of treatment. For example, a recipient may be evaluated using a kidney transplant questionnaire 
that considers the effect of immunosuppressants (129). If kidney function deteriorates and the 
recipient needs to revert to dialysis, a dialysis specific instrument would then be more 
appropriate (129,164).  However, in this way, continuity in follow-up is broken. A disease 
specific instrument also limits comparisons of HRQOL across healthy populations and among 
those with other disease conditions (164). Moreover, they may not capture the impact of a 
significant comorbid condition such as HIV. The alternative is a generic instrument.  
Several generic instruments are available but two common tools are the Short-form (SF-36) and 
the WHOQOL-BREF (129,165). The former is one of the most widely used, featured in more 
than 2000 publications (129). As a very versatile tool, the SF-36 is used in comparative studies 
between healthy populations, different diseases and across renal replacement modalities (164).  
 
The validity of the SF-36 has repeatedly been demonstrated. In transplant recipients, it has been 
found to be reliable; i.e. internal consistency, valid (high correlation with general HRQOL 
assessments), and discriminant (can distinguish changes in clinical status and is perceptive to 
longitudinal differences between waiting list patients and transplant recipients) (129,139,166). 
Similarly, in the HIV-positive population, the SF-36 is a recommended generic measure, that is 
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well substantiated by psychometric evidence. It has demonstrated adequate responsiveness to 




The literature drives home the point that unfavourable changes in nutrition status are highly 
prevalent, and predictive of adverse clinical and quality of life outcomes surrounding 
transplantation. However, there is a need for understanding the possible implications of 
underlying HIV with ESRD on nutritional health. Therefore the nutritional complications in 
HIV are also reviewed. Finally, the most suitable indicators, to optimally assess the nutritional 
status and HRQOL of both diseases during the pre- and post-transplant phase are discussed. 
Fortunately, nutrition is modifiable and improvements in nutritional status could potentially 
contribute to meaningful changes in health, and thereby maximise the quality and quantity of 
life that a transplant affords.  
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GASTROINTESTINAL SYMPTOMS IN HIV-POSITIVE KIDNEY TRANSPLANT 
CANDIDATES AND RECIPIENTS FROM A HIV-POSITIVE DONOR  
 
ABSTRACT  
Background: Gastrointestinal symptoms (GIS) often occur among those with chronic kidney 
disease (CKD). Pre- and post-kidney transplant recipients infected with HIV may be at an even 
greater risk of developing GIS. However, this has not been investigated.  
Objective: To determine the frequency and severity of GIS in HIV-positive kidney transplant 
patients from HIV-positive donors, and those awaiting a transplant.  
Methods: 76 participants completed the gastrointestinal symptom rating scale (GSRS) at 
baseline and six month follow-up. GIS frequency was defined as having at least one symptom 
(GSRS > 1). Severity was indicated by GSRS score.  
Results: Transplant candidates: GIS frequency was 88.9% and 86.3% at baseline and six 
months respectively.  Indigestion was the most frequent (79.6% and 66.7% at baseline and six 
months), and severe GIS (GSRS 2.3). Females had a significantly higher GSRS scores 
compared to males for abdominal pain, indigestion, diarrhoea and the overall global mean (p = 
0.030) at either or both assessments. Negative correlations were found between global and 
reflux scores and age. Indigestion, constipation and reflux scores were related to increased 
duration on dialysis. 
Transplant recipients: GIS frequency was 95.2% and 76.2% at baseline and 6 months 
respectively. At both assessment points, indigestion occurred most frequently (85.7% and 
61.9% respectively). Highest GSRS was reported for indigestion at baseline (2.33) and at six 
months (1.33). Waist circumference (WC) was positively associated with the severity of 
constipation GSRS.  
Conclusion: The presence of GIS was high among HIV-positive transplant recipients and those 
awaiting a transplant from a HIV-positive donor. For candidates on a waiting list managed on 
dialysis, GIS severity decreased with age, but increased with a longer period on dialysis. The 
level of symptom severity experienced by transplant recipients was associated with increasing 
WC. 
 
Keywords: Kidney transplant candidates, Kidney transplant recipients, Human 





Patients with impaired kidney function very often experience gastrointestinal symptoms (GIS) 
at all stages of chronic kidney disease (CKD) (1).  Symptoms begin early, appearing well before 
end-stage renal disease (ESRD), at stage 3 (eGFR 45 ml/min/1.73 m2), and become increasingly 
burdensome as kidney function declines (2). Uraemia and dialysis predispose patients to 
gastrointestinal (GI) mucosal lesions and functional disorders (3) that may or may not cause 
GIS (4). In two recent studies, ESRD dialysed and non-dialysed patients reported a prevalence 
of GIS of 61.6% to 81.0% (5,6).  Following a transplant, renal function is restored, however, the 
occurrence of GIS remain frequent and is often an under-estimated problem (7). At this point 
however, GIS is largely attributable to opportunistic infections and immunosuppressant therapy  
(8,9). 
 
CKD often coexists with other illnesses that affect the GIT through the disease process and its 
treatment. In HIV-positive individuals, replication of the virus in gut-associated lymphoid 
tissues (10), pharmacological side-effects and opportunistic as well as non-opportunistic 
infections (11),  are known determinants of GIS. Resultantly, GIS may present at any time, in 
any area of the GIT (12). Despite a paucity of data, in all probability the prevalence of GIS 
among HIV-positive patients with ESRD will be higher than among uninfected patients with  
HIV. 
 
Regardless of aetiology, the severity of GIS range from mild to severe, thereby compromising  
nutritional status, (13) psychological health, (14) and quality of life (7). More importantly, GIS 
could be indicative of high risk complications such as upper gastrointestinal intestinal (UGI) 
bleeding in dialysed patients (15) or graft failure in transplant recipients (16). 
 
Individually, both CKD and HIV have a significant impact on the GIT. However, the nature of 
GIS in ESRD together with HIV is unknown.  For this reason, the primary aim of this study was 
to describe GIS in terms of frequency and severity as experienced by HIV- infected pre- and 
post-transplant recipients at baseline and six month follow-up. In addition, the study 







Participants were recruited through the kidney transplant programme for HIV-positive patients 
at Groote Schuur Hospital, Cape Town, to take part in this longitudinal observational study. 
Participants were recruited based on whether they were transplant recipients or were awaiting a 
transplant and hence managed with dialysis. From the outset they were therefore categorised as: 
(i) HIV-positive kidney transplant recipients who have received a kidney from a HIV-positive 
donor and (ii) HIV-positive transplant candidates on the waiting list to receive a HIV-positive 
donor kidney. Prospective participants were contacted telephonically or at their respective 
outpatient clinics and invited to participate. Patients did not qualify for participation if they were 
severely ill, were not contactable, were uncooperative or missed several interview appointments 
(typically more than two without reason). In total, 76 patients agreed to participate after the 
purpose of the study and practical implications were explained to them. This was followed by 
obtaining written informed consent. The study was approved by The University of KwaZulu-
Natal’s Biomedical Research Ethics Committee (Approval number BE 327/13). Data was 
collected over a one year period, commencing in June 2015, with patients being followed up 
across six provinces. Assessments were conducted at two time points namely baseline and at six 
month follow-up.   
 
3.2.2 Socio-demographic and clinical characteristics 
 
Socio-demographic information was collected using an interviewer-administered structured 
questionnaire, developed for the purpose of the study. Clinical information was obtained from 




Weight (WT), height (Ht) and waist circumference (WC) measurements were taken according 
to the National Health and Nutrition Examination Survey (NHANES) guidelines (17) by a 
qualified dietitian. The mean of three readings were used for data analysis. Weight was 
determined post dialysis.  BMI was classified according to the World Health Organization 
(WHO) categories as kg/m2: Underweight (< 18.5), Normal (18.5 - 24.9), Overweight (25.0 – 




3.2.4 Measurement of gastrointestinal symptoms  
 
The Gastrointestinal Symptom Rating Scale (GSRS) was used to determine the frequency and 
severity of GIS (19). Although originally designed for GIS assessment of gastrointestinal 
diseases, it has been used in all stages of CKD including dialysis (14) and transplant recipients 
(20). It consists of 15 items that are collapsed into 5 symptom subscales viz; abdominal pain 
(abdominal pain, hunger pain and nausea), reflux syndrome (heartburn and acid regurgitation), 
diarrhoea syndrome (diarrhoea, loose stools and urgent need for defecation), indigestion 
syndrome (borborygmus, abdominal distension, eructation and increased flatus) and 
constipation syndrome (constipation, hard stools and a feeling of incomplete evacuation) 
(19,21). 
 
GIS Frequency: The frequency of GIS was defined as having at least one symptom or a GSRS 
score > 1 (14,21,22). 
 
GIS Severity: To determine the severity of a symptom, each question is rated using a seven-
point Likert Scale ranging from one (no discomfort at all) to seven (severe discomfort) to obtain 
a total score ranging from 15 (minimum) to 105 (maximum)  or  mean values between one and 
seven. The combined severity scores of the five subscales, are presented as a global mean score 
and a mean score per subscale. Higher GSRS scores are indicative of a higher symptom burden. 
GSRS severity scores were correlated with patients’ clinical, demographic and nutritional 
parameters. 
 
3.2.5 Statistical analysis 
 
Data was analysed using the Statistical Package for Social Sciences (SPSS®) version 25.0.  
Means and standard deviation were calculated for all continuous variables, and frequencies with 
percentages were determined for categorical variables. The means of groups were compared 
using the independent samples t-test. Cronbach’s alpha was used to determine the internal 
reliability of the GSRS. Spearman’s correlation was used to determine the relationship between 







3.3.1 Patient characteristics 
 
As all 76 patients completed the GSRS at least once, at either time points, no participants were 
excluded. At baseline, one patient did not complete the GSRS and four did not complete it at six 
month follow-up for reasons that included hospitalisation, missed appointments and the demise 
of two participants.  Of the 76 participants surveyed, 22 HIV-positive kidney transplant 
recipients received a kidney from a HIV-positive donor, while 54 HIV-positive patients were on 
the waiting list to receive a kidney from a HIV-positive donor. The latter group were managed 
with haemodialysis (HD) (n = 51) or peritoneal dialysis (PD) (n =3). 
 
Characteristics of the study population are given in Table 3.1 and 3.2.  The study sample, who 
were predominantly black (93.4 %) and male (60.5%), had a mean age of 43.6 ± 8.1 years. 
Transplant candidates were on dialysis for a mean duration of 3.9 ± 3.0 years (range: 0.3 - 11.5 
years), while transplant recipients averaged 2.7 ± 22.3 years (range: 0.0 – 6.75 years) since 
transplantation. The majority of participants were hypertensive (92.1%), while only four had 
hypercholesterolemia. There were significantly more patients with diabetes in the dialysis group 
compared to the transplant group (29.6% versus 4.5%, p = 0.017). Transplant recipients had a 
higher mean CD4 count (447.3 ± 282.70 cells/µL versus 382.1 ± 178.02 cells/µL), and higher 
viral loads (94.7% versus 79.6% of participants with levels lower than detectable limits) when 
compared to transplant candidates. This difference was non-significant. Serum albumin levels 
were higher in the transplant group, 43.1 ± 4.1 and 41.3 ± 4.1 versus 35.9 ± 4.5 and 37.2 ± 4.8 
in the dialysis group. The majority of participants in the transplant group had a normal weight at 
each assessment time point (71.4% and 59.1%), although two additional participants were 
classified as obese class I. In the dialysis group, 38.5% and 40.8% of participants were 
classified as overweight and 36.5% and 38.85 with normal weight at baseline and six month 
follow-up respectively.   
 
3.3.2 Gastrointestinal symptoms 
The frequency of at least one GIS (GSRS score of > 1) in the study sample is shown in Figure 
3.1, being 90.7% and 83.3% at baseline and six month follow-up respectively.  
 
The final Cronbach’s Alpha for the global mean at baseline and six month follow-up, was 0.813 
and 0.862 respectively. GSRS for all GIS in the whole group (Figure 3.2) was higher at baseline 
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than at six month follow-up. At baseline, the global mean GSRS was 1.80 ± 0.76 and lower at 
six months at 1.55 ± 0.74. The individual GIS show a similar order of severity at each 
assessment time point. Indigestion and diarrhoea had the highest and lowest GSRS respectively. 
 
Frequency and severity of GIS in transplant candidates 
 
Overall, 88.9% of dialysed participants reported at least one GIS at baseline and 81.5% at six 
month follow-up (Figure 3.1). At baseline, indigestion (79.6%), abdominal pain (64.8%) and 
reflux (48.1%) were the most commonly reported GIS, while diarrhoea and constipation were 
experienced to a lesser extent at 44.4% and 42.6%, respectively (Figure 3.3). At six month 
follow-up, indigestion was still the most frequent GIS, albeit to a lesser extent (66.7%).  
However, more participants complained of constipation, increasing in frequency to 51.0%.  
 
The GSRS scores indicated the severity of symptoms (Table 3.3) for each treatment group. The 
most severe GIS for PD patients (n=3) was diarrhoea at six months (GSRS 4). For HD patients, 
indigestion was slightly more severe than the other GIS at both times (GSRS 1.67). Females had 
significantly higher median GSRS for several GSRS subscales as well as the global mean at 
baseline (p = 0.030).  
 
In the transplant candidate group, Spearman’s correlations with GSRS (Table 3.4) were positive 
for the global mean score with the length of time on dialysis at baseline and six months 
(baseline rho = 0.287, p =0.036 and rho=0.440, p= 0.001). Age correlated negatively with GIS 
global mean (rho= -0.338, p= 0.015). 
 
Prevalence and severity of GIS in transplant recipients 
 
Over nine out of ten (95.2%) of the transplant group experienced GIS at baseline. However, the 
prevalence of symptoms decreased by 19.0% to 76.2% at six month follow-up.  The frequency 
of symptoms across the five subscales is depicted in Figure 3.4. Transplant recipients reported 
indigestion as the most prevalent symptom at baseline (85.7%), this was followed by abdominal 
pain (81.0%), reflux (42.9%), with diarrhoea and constipation both occurring at a prevalence of 
38.1%.  At six month follow-up, frequency of GIS symptoms deceased by 19%, from 95.24% 
to 76.19%. The frequency in each symptom category also decreased but maintained a similar 
frequency sequence. Indigestion was the most frequently experienced GIS in the transplant 
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group with 85.7% prevalence at baseline and 61.9% at six month follow-up. Only one 
participant reported diarrhoea (4.8%) at six month follow-up.   
 
Indigestion was the most severe GIS with the highest median GSRS score of 2.33 at baseline 
and 1.33 at six months (Table 3.3). All GSRS were lower at six month follow-up with the global 
mean decreasing from 1.86 to 1.15. In the transplant group, WC was positively associated with 
















Patient Characteristics  Whole group 
(N = 76) 
 
Transplant 
(n = 22) 
 
Dialysis 
(n = 54) 
 
Age (years): mean ± SD   43.6 ± 8.1 
range: 28.0 – 63.0 
  
Gender     
  Male  46 (60.5)   
  Female  30 (39.5)   
Ethnicity     
  Black  71 (93.4)   
  Coloureda  4 (5.3)   
  White  1 (1.3)   
Type of treatment     
Transplant   22 (28.9)  
Haemodialysis    51 (67.1) 
Peritoneal dialysis    3 (3.9) 
Length of time on  
current treatment (years) 
  2.7 ± 2.3 
range: 0.0 – 6.8 
3.9 ± 3.0 
range: 0.3 - 11.5 
Chronic illness     
Diabetes   1 (4.5)* 16 (29.6)* 
Hypertension   19 (86.4) 51 (94.4) 
Hypercholesteraemia   1 (4.5) 3 (5.6) 
CD4 (cells/µL)b   447.25 ± 282.70 382.12 ± 178.02 
Viral load (copies /ml)c     
 LDL   18 (94.7) 39 (79.6) 
≤ 10 000   1 (5.3) 7 (14.3) 
> 10 000   0 (0.0) 3 (6.1) 
Data expressed as percentages or means with standard deviation 
a Coloured is the term used in South Africa denoting mixed racial ancestry 
b transplant patients: n = 20, dialysis recipients: n = 52 
c transplant patients: n = 19, dialysis patients: n = 49  
*Significant difference in the number of  patients with diabetes between transplant recipients and 
transplant candidates patients (p = 0.017) 






Table 3.2: Nutritional characteristics of transplant candidates and recipients (N = 76). 
 
  Nutritional 
Characteristics 
Transplant 
(n = 22) 
 Dialysis 
(n = 54) 
 n Baseline n 6 months  n baseline n 6 months 
Albumin (g/L) 20 43.1 ± 4.1 22 41.3 ± 4.1  48 35.9 ± 4.5 52 37.2 ± 4.8 
BMI (kg/m2)  21 24.5 ± 4.6 22 25.6 ± 5.8  52 26.3 ± 4.8 49 25.7 ± 4.8 
Underweight     1 (4.5)   1 (1.9)  1 (2.0) 
Normal   15 (71.4)  13 (59.1)   19 (36.5)  19 (38.8) 
Overweight   2 (9.5)  2 (9.1)   20 (38.5)  20 (40.8) 
Obese Class I   4 (19.0)  6 (27.3)   11 (21.2)  8 (16.3) 
Obese Class II        1 (1.9)  1 (2.0) 
WC (cm) 18 89.6 ± 13.1a 18 95.8 ± 12.3a  36 92.2 46 90.7 ± 4.2 
Data expressed as percentages or means with standard deviation or frequency with percentages 


















Figure 3.1:  Frequency of gastrointestinal symptoms for the whole group and per treatment 
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Figure 3.3:  Frequency of gastrointestinal symptoms in transplant candidates at baseline and six 
month follow-up.  
     
 
 
Figure 3.4: Frequency of gastrointestinal symptoms in transplant recipients at baseline and six 
























































































Haemodialysis Peritoneal Dialysis 
  
Transplant 
Dialysis (HD + PD) 
 Subscale  Baseline 6 months Baseline 6 months Baseline 6 months Baseline 6 months 
n = 51 n = 48 n = 3 n = 3 n = 54 n = 51 n = 21 n = 21 
Abdominal pain  1.67 (4) g 1 (2.5)  2 (2.67)  1 (6)  1.67 (1) a 4 (6) e 1.67 (4.67)  1 (1)  
Reflux  1 (5)  1 (4)  1 (4)  1 (5.5)  1 (1)  5 (5.5)  1 (4)  1 (5)  
Indigestion  1.67 (6) h 1.67 (5)  2 (1)  1 (3)  1.67 (1.67) b 6 (5) f 2.33 (3)  1.33 (2.33)  
Constipation  1 (6)  1.33 (6)  2 (4.5)  1 (1.67)  1 (1.33)  6 (6)  1 (2)  1 (2)  
Diarrhoea  1 (3)  1 (4.5)  1 (6)  4 (5)  1 (1) c 6 (5)  1 (2)  1 (0)  
Global mean   1.57 (3.14)  1.38 (3.62)  1.5 (3.5)  1.77 (3.62)  1.57 (1.38)d  3.93 (3.62)  1.86 (1.79)  1.15 (1.46)  
GSRS scores as median (range) 
a Significantly higher for females (mean rank = 32.66) than  males ( mean rank=23.95),  p = .040 
b Significantly higher for females (mean rank = 34.00) than  males ( mean rank= 23.03),  p = .011 
c Significantly higher for females (mean rank = 32.27) than  males ( mean rank= 22.22),  p = .022 
d Significantly higher for females (mean rank = 33.09) than  males ( mean rank= 23.66),  p =  .030 
e Significantly higher for females (mean rank = 30.85) than  males ( mean rank= 22.87),  p =  .025 
f Significantly higher for females (mean rank = 31.83 ) than  males ( mean rank= 22.24),  p =  .020 
g Significantly higher for females (mean rank = 30.83 ) than  males ( mean rank= 22.62),  p = .045   






Table 3.4:  Correlations of GSRS scores with clinical and nutritional parameters in transplant candidates and recipients at baseline 
                   and at six month follow-up                                       
 
Variable     Global mean Reflux Indigestion Constipation Diarrhoea Abdominal pain 




            
       Baseline 54  0.287* 0.036 0.279* 0.041       
       6 months 51  0.44** 0.001   0.457** 0.001 0.3** 0.033   
  Age             
       Baseline 54            
       6 months 51  -0.338* 0.015 -0.317* 0.023       -0.354* 0.011 
 
  Transplant 
   
  WC (cm)             
      Baseline 18        0.471* 0.048   
                                
*Correlation is significant at the 0.05 level (2-tailed)  






The occurrence of at a least one GIS (GSRS > 1) in the total group, at baseline and at 6 months 
was high.  At 90.7% and 83.3% respectively, this finding supports previous research that renal 
patients experience a greater frequency of GIS than non-renal patients (23) and the general 
population (14,24,25). 
 
3.4.1 Transplant candidates 
 
Frequency and severity of GIS 
The frequency of GIS amongst dialysed participants was fairly consistent at both time points 
(88.9% and 81.5%). These values fell within the 76% - 90% GIS frequency range experienced 
by HD and PD populations elsewhere (26,27). Across the five subscales indigestion, abdominal 
pain and, to a lesser extent, reflux occurred at higher freqency than constipation and diarrhoea at 
baseline. At six month follow-up  however, more participants suffered from constipation, and 
with greater severity . These findings are in agreement with a systematic review of GIS in 30 
studies conducted among 5161 HD and PD  participants. Despite differences in methodology, 
these studies also reflected  constipation, indigestion, abdominal pain and reflux as the most 
frequently reported GIS (3). Constipation in particular, affects up to 71.7% of HD patients (28) 
and is attributed to restrictive diets, medication, inactivity and ignoring the urge to defaecate 
whilst on dialysis (29). Although constipation affected about half of the participants on dialysis, 
it was not the most bothersome GIS. Indigestion was a frequent and severe GIS at baseline and 
at six month follow-up.  
 
Indigestion, or dyspepsia is a common occurrance in the HD and PD population, with a 
frequency ranging between 30.0% - 72.3% and 31.5% - 93.1% respectively and is responsible 
for the regular consumption of acid suppressants in 41.0% - 76.4% of patients (30,31). 
Endoscopy in dyspeptic patients shows upper gastrointestinal (UGI) pathology in 60.0% - 
68.0% of patients, with erosive and ulcerative changes found in the stomach, oesophagus and 
duodenum. The causes of UGI morbidity are complex. In addition to risk factors in the general 
population (32), CKD determinants include hypergastrinaemia, inflammation and high levels of 
ammonia (33). Delayed gastric emptying or heparin use in dialysis (4,34,35) adds to GIS such 
that dialysed patients may have a greater symptom burden than non-dialysed ESRD patients 
(14). Within the dialysed group itself, PD participants (albeit only three), had more pronounced 
GIS than HD participants. This is a common (36,37) but inconsistent finding (5) related to the 
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effects of the dialysate present in the abdomen (37). Between the sexes, females reported 
significantly higher GSRS, similar to that observed in a Turkish HD group (38). However, this 
is not exclusive to CKD. In the general population, women experience more dyspeptic and 
irritable bowel syndrome symptoms (39,40,41) on account of gender specific psychosocial 
factors, hormonal activity, as well as anatomical and functional differences in pain transmission 
pathways affecting sensitivity (42,43). 
 
Correlations between GSRS severity scores, clinical and nutritional variables 
This study examined the relationships between severity (GSRS scores), rather than frequency of 
GIS, with selected clinical and nutritional parameters. Although expected, no significant 
associations were found between GSRS and serum albumin. Lower serum albumin is likely due 
to underlying illness or inflammation, such as infections rather than nutritional status (44), 
which could worsen the severity of GIS. Abdominal pain and reflux scores decreased with age, 
possibly due to the disinclination of older individuals to report symptoms. Furthermore, there 
appears to be an adaptation to intensity of chronic symptoms as well as symptoms becoming 
less specific, and more vague with advancing age (45,46). 
 
GSRS scores were positively associated with the duration of dialysis. The increasing severity of 
indigestion, constipation and reflux with a longer period on dialysis, is not a universal finding 
(45), as typically the opposite occurs. More GIS is noted at the start of PD (37) and in HD, 
related to hypotensive episodes at HD initiation (47).  
 
3.4.2 Transplant recipients 
 
Frequency and severity of GIS 
GI complications are a common occurrence following a solid organ transplant, potentially 
affecting any area of the GIT (9). Severe complications are rare (10.0%), occurring primarily in 
the first year post transplant (48). A transplant is expected to relieve GIS related to uraemia and 
dialysis, and explains the lower global GSRS scores in this study’s transplant candidates versus 
transplant recipients. However, for many transplant recipients GIS still persist, albeit with a 
lower level of severity. The transplant recipients in the current study had a high frequency of 
GIS at baseline (95.2%), similar to findings in European (88.3% - 92.0%) (7,22) and African 
(96%) transplant recipients (49). In a study by Ponticelli et al, with a cohort of 1130 kidney 
transplant recipients, patients demonstrated stable GIS throughout the year-long study period 
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(7). In contrast, the frequency of GIS dropped by 19.0% to 76.2% in the present study, for 
reasons that are unclear. 
 
As was the case in the dialysis group, indigestion was a frequent symptom. It was the most 
severe at baseline and at six month follow-up, possibly due to underlying gastropathology. 
Dyspeptic transplant recipients have shown a high prevalence of erosive changes on endoscopy, 
mainly gastritis (78.6%), that could be present pre-transplant (50) and/or is aggravated by 
immunosuppressants (8).  Tacrolimus, which has been linked to duodenitis (50), forms part of 
the anti-rejection regimen in addition to mycophenolate mofetil (MMF), and prednisone (51), 
and could be a contributing factor.  It is also interesting to note that indigestion, together with 
abdominal pain and reflux, were the three most frequent GIS at baseline and six month follow-
up, similar to a survey of 4232 transplant recipients across four north European countries (22). 
Taken together, these three GIS are typical of gastro-oesophageal reflux disease (GORD) (52), 
for which CKD,  transplantation and anti-rejection medication are risk factors (53). 
 
Anti-rejection medication also increases the risk of infectious and non-infectious diarrhoea by 
increasing vulnerability to infectious agents and compromising gut mucosal integrity and 
function (9). In 13 out of 25 (52.0%) transplant recipients with chronic diarrhoea, infections and 
drug-related colitis associated with MMF were identified via colonoscopy (47), while diarrhoea 
was linked to the toxicity profile of Tacrolimus (54). Despite the combination of these two 
drugs in the current study’s participants treatment regime, diarrhoea was not as bothersome as 
the other GIS. Diarrhoea affected eight transplant candidates (38.1%) and only one (4.8%) 
transplant recipient at baseline and six month follow-up respectively. Furthermore, the severity 
scores of diarrhoea were low (GSRS of 1.00).  Earlier studies report the frequency of diarrhoea 
to be between 22.8% - 53.0% and GSRS scores of between 1.44 ± 0.88 and 1.80 ± 1.10 in 
transplant recipients (7,22). In the majority of cases, diarrhoea is transient and resolved with 
appropriate pharmaceutical and dietary management (55). This is probably the reason for the 
difference in frequency at baseline and then at 6 months.   
 
Correlations between GSRS severity scores, clinical and nutritional variables  
Significant associations between GSRS constipation scores with WC were identified at baseline 
in the transplant group. In the general population, obesity is a risk factor for GORD and erosive 
oesophagitis in the long term (25), while central obesity is related to non-erosive oesophageal 
disease (56). However, the association of obesity with constipation and functional dyspepsia is 




It would therefore be sensible to ensure weight maintenance and a WC at optimum values.  In 
332 non-CKD participants who participated in a weight intervention programme that targeted  
behaviour, diet, and physical activity, participants reported an 81.0% and 55.0% decrease and 
resolution of GIS respectively (58).  In other research, weight management was less likely to 
improve symptoms in 211 participants for which the BMI – reflux relationship was independent 
of diet and exercise (59). This highlights the contribution of clinical, pharmaceutical and 
demographic factors to GIS.   
 
3.4.3 Gastrointestinal symptoms and HIV 
 
The contribution of coexisting illness to GIS in ESRD was clearly applicable to this patient 
group. HIV has always been associated with GIS, and it was not uncommon for HIV-positive 
individuals to experience regular episodes of diarrhoea (60). However, defining research by 
Mönkemüller et al has shown a change in the pattern of GI manifestations since the HAART 
era. The occurrences of opportunistic infections have reduced (61), while UGI manifestations 
have increased (11). HIV-positive Japanese patients, report higher UGIS severity scores than 
non-HIV infected patients (62). Findings of mucosal changes such as gastritis (48%) and gastric 
erythema (45%) (63), and reflux, H pylori infection, and GORD have increased (11). In all 
probability, these would aggravate UGI pathology of ESRD, and could underlie the higher 
frequency and severity of indigestion compared to the other GIS in the current study sample.  
 
This study has several strengths. It is the first to investigate the frequency and severity of GIS in 
pre- and post-kidney transplant recipients infected with HIV. Secondly, the GSRS which has 
been previously validated in South Africa and elsewhere (64) encompasses a range of symptoms 
applicable to the upper and lower GIT. Thirdly, despite the small study sample, the findings of 
this research are still generalizable as the majority of patients on the transplant lists were 
included in this study, and as such, are a fair representation of this group. A study limitation in 
this regard is that the number of PD patients (n=3) is extremely small. Thus, the power of the 
statistical analysis using this group is severely limited.  Hence, correlations were done using PD 
and HD combined into a single group (n=54). The lack of information on medication used to 
relieve GIS, as well as detailed renal function parameters, which would have benefited the 
analysis of the study results, is also a drawback. The study design, which provides a snapshot of 
GIS at two assessment points is suitable for prevalence studies, but limits the exploration of 
causal relationships (65). Finally, this study did not have a control group to compare GIS with 
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and without the presence of HIV, but should be considered in future research, along with a 
longer follow-up period to provide better insight into whether the symptoms documented are 
pervasive or transient. 
 
In conclusion, this research contributes to the body of evidence on GIS experienced by kidney 
transplant candidates and recipients but extends to an understanding of these symptoms among 
those infected with HIV. The data confirm a high prevalence of GIS in both treatment groups, 
although similar to that documented for non-HIV infected dialysis and transplant recipients.  
Indigestion was a prevalent and severe GIS in the whole group at both time points, while those 
on dialysis experienced a greater frequency of constipation at six month follow-up. A 
comparison of GSRS scores between groups showed the highest severity scores in transplant 
candidates, and Spearman’s correlations with specific GIS were positive for duration of dialysis 
and negative for age. In the transplant group, specific GIS were positively associated with WC. 
 
Both kidney transplants and dialysis are major medical interventions that are often accompanied 
by complications, and frequent hospitalisation. However, GIS (especially if they are chronic and 
low grade), may be discounted by patients and clinicians until they become severe and 
debilitating. Major gastrointestinal complications are rare, but do occur. The GSRS is a quick, 
simple, and cost effective monitoring tool that can be used for early identification of, or 
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PREVALENCE OF OSTEOPOROSIS AND FACTORS ASSOCIATED WITH BONE 
DENSITY IN HIV-POSITIVE TRANSPLANT CANDIDATES AND RECIPIENTS 




Background: Previous studies have shown that kidney transplant candidates and recipients 
have a low bone mineral density (BMD). Consequently, they have a higher prevalence of 
osteoporosis and a greater risk of fracture. However, little is known about the prevalence of 
osteoporosis and associated factors among transplant recipients and those awaiting a transplant 
who are infected with human immunodeficiency virus (HIV). 
Objective: To determine the prevalence of osteopenia and osteoporosis and investigate the 
socio-demographic, clinical and nutritional factors associated with BMD in HIV-positive 
transplant candidates and recipients from a HIV-positive donor. 
Methods: Fifty six HIV-positive patients participated in this cross-sectional study. Twenty were 
recipients of a transplant from a HIV-positive donor, while 36 were on haemodialysis (HD) and 
awaiting a transplant. BMD and body composition were measured by dual-energy X-ray 
absorptiometry (DEXA). Vitamin D status was measured using serum 25-hydroxyvitamin D 
[25(OH)D].  Vitamin D and calcium dietary intake was obtained from a single 24 hour recall.  
Results: There were 55.4% male participants, while the remainder (44.6%) were female. The 
majority of participants were black (92.9%). The mean age of all participants was 43.8 ± 8.3 
years. Serum 25(OH)D  levels were low for the group as a whole, with a mean of  22.04 ±12.74  
ng/ml. BMD was normal in 64.3% of all participants. Osteoporosis was more prevalent amongst 
transplant recipients (20.0%) than transplant candidates (13.9%). Conversely, more osteopenia 
was present amongst transplant candidates (27.8%), whereas only 1/20 (5.0%) transplant 
recipients had osteopenia.  T-scores strongly correlated positively, with lean mass and BMD of 
the spine (r = 0.707, p = 0.007), and moderately with each side of the total hip BMD (r = 0.455, 
p = 0.007 and r = 0.420, p = 0.007). Fat mass did not correlate with osteoporosis or BMD.  
There was a significant positive associations between dietary calcium and all BMD sites for 
transplant recipients. 
Conclusion: The prevalence of osteoporosis was similar, and in some cases, lower than in 
transplant recipients elsewhere. Lean mass was positively associated with BMD, but serum 
25(OH)D which was low in both groups, was not related to BMD. In transplant recipients only, 




Keywords: Kidney transplant candidates, Kidney transplant recipients, Human 
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4.1 Introduction  
 
Following a kidney transplant, bone mineral density (BMD) decreases by 2.9% to 9.0%, with 
the most apparent changes occurring within the first 18 months (1), before levelling off or 
increasing slightly (2). It is largely, though not exclusively, attributable to high doses of 
glucocorticosteroids in the early transplant period (1), as prior to transplantation, deterioration 
in bone density and micro-structure from chronic kidney disease-mineral and bone disease 
(CKD-MBD) is already present (3), and exacerbated during dialysis (4). Consequently, both 
transplant candidates and recipients have a greater prevalence of osteoporosis and a higher 
frequency of fractures than the general population (2,5).  
Human immunodeficiency virus (HIV) – positive individuals also have a lower bone density 
(6,7) and a three-fold higher prevalence of osteoporosis compared to HIV-negative controls (8). 
Viral effects on BMD have been implicated through inflammation and HIV proteins on bone 
modelling, exacerbated by factors such as infections, nutritional deficiencies and a low CD4 
count (9). Furthermore, with the initiation of antiretrovirals, BMD decreases by 2.0% to 6.0% in 
the first two years, while steadying or showing a slight increase thereafter (10-12). 
 
Considering the impact that both chronic kidney disease (CKD) and HIV have, independently 
on the skeletal system, it is highly likely that living with this double burden, increases the 
likelihood of significant changes in bone density. However, as this has not been investigated, 
the purpose of this study was to determine the BMD and prevalence of osteoporosis in this 
unique group, as well as their association with selected socio-demographic, clinical and 






For the purpose of this cross-sectional study, prospective participants were recruited through the 
kidney transplant programme for HIV-positive patients at Groote Schuur Hospital, Cape Town. 
Recruitment was based on whether they were transplant recipients or were awaiting a transplant 
and hence managed on dialysis. From the outset they were therefore categorised as: (i) HIV-
positive kidney transplant recipients who have received a kidney from a HIV-infected donor; 
and (ii) HIV-infected transplant awaiting candidates who were on the waiting list to receive a 
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kidney from a HIV-positive donor. Prospective participants were contacted telephonically or at 
their respective outpatient clinics and invited to undergo a dual- energy X-ray absorptiometry 
(DEXA) evaluation during the study period spanning a year. Patients were included if they were 
clinically stable at the time of recruitment. Patients did not qualify for participation if they 
declined participation, were severely ill, were not contactable, uncooperative or had missed 
several interview appointments (typically two or more without reason). Fifty six participants 
agreed to the DEXA assessment and written informed consent was obtained prior to them 
undergoing assessment. The study was approved by the University of KwaZulu-Natal’s 
Biomedical Research Ethics Committee (Approval number BE 327/13).  
 
4.2.2 Socio-demographic and clinical characteristics 
 
Socio-demographic information was collected using an interviewer-administered structured 
questionnaire developed for the purpose of the study. Clinical information was obtained from 
medical records or during participant interviews.  
 
4.2.3 Bone densitometry measurements 
 
DEXA assessments were conducted by experienced radiographers at a radiology centre closest 
to where participants resided. The Hologic (Models: Discovery or Horizon) were used at eight 
of the centres, and the GE Lunar Prodigy (Advance) at two of them. Only three of the ten 
centres were able to provide body composition information as well as BMD measurements.  
Assessments were done according to standard procedure, with height and weight being 
determined prior to DEXA assessment and body mass index (BMI) calculated as weight divided 
by height squared (kg/m2). Subsequently BMI was classified according to the World Health 
Organization categories: Underweight (<18.50), normal (18.50 – 24.99), overweight (≥ 25.00-
29.99), obese class I (30.00-34.99), obese class II (35-39.99) and obese class III (≥40) (13). 
   
BMD was recorded at L1 – L4 of the lumbar spine (LS), and each side of the total hip (TH) and 
femoral neck (FN) and presented as absolute values (g/m2), Z-scores and T-scores, based on 
machine software reference data. Z-scores, presented as standard deviations (SD) are preferred 
in younger patients, as it compares the individual’s BMD with the mean value in a population of 
similar age and gender (14). T-scores reflect comparisons as the SD above or below the mean 
values of a healthy population of young adults (15).  T-scores were used to classify BMD 
according to the World Health Organization (WHO) criteria: Normal (T-score ≥ -1.0); 
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osteopenia (T-score between -1.0 and -2.5); osteoporosis (T-score ≤ - 2.5); or severe 
osteoporosis (T-score ≤ - 2.5 with one or more fractures) (16). All DEXA results and 
classifications were reviewed by a clinician. Osteoporosis classification by region was made 
based on the BMD measurement site with the lowest T-score. 
 
4.2.4 Vitamin D measurement 
 
Serum levels of 25-hydroxyvitamin D [25(OH)D] was measured using chemiluminescence 
(Immunlite 2000, Siemens, USA). Normal and deficiency states were defined as deficiency: < 
20ng/ml; partial deficiency: 20 − 29 ng/ml; and optimal level: > 30 ng/ml (17). 
 
4.2.5 Dietary intake 
 
Information on dietary vitamin D and calcium intake was obtained from a single quantified 24-
hour recall. Participants recalled all foods and beverages consumed in the previous 24 hours, 
while being recorded according to the name of the dish and description of the preparation 
method or recipe, the time it was consumed and the amount eaten (18). A number of measures 
were put in place to improve accurate recall of food and beverage consumption during the 
interview process. These include the following: All 24-hour recalls were administered by 
registered dietitians with experience in recording of dietary intake data; training was provided to 
ensure the use of standardised protocols during the dietary interview technique such as the use 
of similar probing questions to minimise interviewer bias. These measures were based on the 
Nordic Cooperation Group of Dietary Researchers’ interview recommendations to reduce 
misclassification and misrepresentation of information (19). As a higher level of response 
accuracy is obtained from interviews conducted in the vernacular of participants (19), an 
interpreter was used when required. Portion size estimation was improved through the use of 
household measuring utensils (19) and a food-portion booklet that referenced food portions 
against common household objects, applicable to the South African context (20). All dietary 








4.2.6 Pilot Study 
The socio-demographic questionnaire and 24-hour recall was assessed for understanding and 
ease of administration during a pilot study. The pilot study was conducted on eight and four 
HIV-negative transplant candidates and recipients respectively. They were both deemed 




Data was analysed using the Statistical package for Social Sciences (SPSS®) version 25.0. 
Means and standard deviations were calculated for all continuous variables and frequencies with 
percentages for the categorical variables. Independent samples t-test was used to determine 
differences between transplant candidates and recipients and between males and females for 
clinical and nutritional variables. Chi-square tests and ANOVA was used to determine 
associations between osteopenia/osteoporosis and categorical and numerical variables 
respectively. Pearson’s correlation was used to determine the relationship between BMD and 
other scale scores. Results with a P value of <0.05 was taken as statistically significant. 
 
4. 3 Results 
4.3.1 Participant characteristics 
 
The study sample consisted of 56 HIV-positive participants with end stage renal disease 
(ESRD).  Of these, 20 had received a transplant from a HIV-positive donor and 36 were on 
haemodialysis (HD) while awaiting a transplant. Demographic and clinical characteristics are 
presented in Table 4.1.  There were more males 31/56 (55.4%) than females 25/56 (44.6%) with 
the majority of participants being black Africans 52/56 (92.9%). The mean age of all 
participants was 43.8 ± 8.3 years. The mean duration of treatment for the entire study sample 
was 3.9 ± 2.8 years, although that of candidates on dialysis was slightly longer than recipients of 
a transplant (4.4 ± 3.0 versus 2.9 ± 2.3 years). The majority of participants were hypertensive 
51/56 (91.1%), whereas diabetes was only present amongst those on dialysis. Three participants 
were receiving treatment for hypercholesterolaemia.  HIV parameters showed 47/56 (92.2%) of 
participants had viral loads lower than detectable limits, and the mean CD4+ count was 412.57 
± 230.00 cells/µL.  Vitamin D levels measured as serum 25(OH) D, was low across the entire 
study sample, with a mean value of 22.04 ± 12.74 ng/ml. Transplant recipients had a lower 
mean 25(OH) D compared to candidates. Optimal levels were observed among 9/36 (29.0%) of 
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transplant candidates, while 71.0% were either partially deficient or deficient. Even fewer 
transplant recipients had optimal levels 2/20 (11.1%), while more 18/20 (88.9%) were either 
partially deficient or deficient. There were no significant differences in laboratory values 
between the two treatment groups. 
 




 Total group 








n = 20 
Gender       
Male  31 (55.4)  19 (52.8)  12 (60.0) 
Female  25 (44.6)  17 (47.2)  8 (40.0) 
Age (years)  43.8 ± 8.3  45.1 ± 8.3  41.4 ± 7.7 
Male  44.5 ± 8.1  45.6 ± 8.4  44.5 ± 7.5 
Female  42.9 ± 8.6  44.5 ± 8.5  39.4 ± 8.2 
Ethnicity       
Black  52 (92.9)  33 (91.7)  19 (95.0) 
Coloureda  3 (5.4)  2 (5.6)  1 (5.0) 
White  1 (1.8)  1 (2.8)  0 (0.0) 
Duration of current treatment (years)  3.9 ± 2.9  4.5 ± 3.0  2.9 ± 2.3 
Chronic illness       
Diabetes  10 (17.9)  10 (27.8)  0 (0.0) 
Hypertension  51 (91.1)  34 (94.4)  17 (85.0) 
Hypercholesterolaemia  3 (5.4)  2 (5.6)  1 (5.0) 
CD4 (cells/µL)b  412.57 ± 
230.00 
 392.18 ± 
194.40 
 447.25 ± 
282.70 
Viral load (copies /ml)c       
Lower than detectable limit (LDL)  47 (92.2)  29 (90.6)  18 (94.7) 
≤ 10000 copies/ml  4 (7.8)  9.4  1 (5.3) 
25(OH) D ng/mld   22.04 ±12.74  23.74±14.03  19.19 ± 9.95 
Optimal (> 30ng/ml)  11 (22.4)  9 (29.0)  2 (11.1) 
Partial deficiency (20-29ng/ml)  9 (18.4)  6 (19.4)  3 (16.7) 
Deficiency (< 20ng/ml)  29 (59.2)  16 (51.6)  13 (72.2) 
Data give as means and standard deviation or frequency and percentages  
a Coloured refers to a person of mixed ancestry in South Africa 
b CD4: n = 54 (dialysis: n = 34 ,   transplant: n = 20),  c Viral load: n = 51 (dialysis: n =  32, n = 19) 
d 25(OH) D : n = 48 ( dialysis: n = 30, transplant: n = 18) 
 86 
 
4.3.2 Bone mineral density of participants 
 
BMD values and corresponding T- and Z- scores of the LS, TH and FN are presented in Table 
4.2. There were no significant differences in BMD values between the two treatment groups. 
According to the WHO classification, BMD was normal among 36/56 (64.3%) of participants. 
However, osteoporosis was more prevalent among transplant recipients (20.0%), especially in 
the spine, than transplant candidates (13.9%), while only 1/20 (5.0%) transplant recipient had 
osteopenia. Conversely, the prevalence of osteopenia among transplant candidates was 10/26 
(27.8%), while 5/26 (13.9%) had osteoporosis, mainly in the LS and FN. When categorised by 
gender, more women were osteoporotic than osteopenic, while the reverse held true for men 
(Figure 4.2).  
 








n = 20 
Measurement site 
 
n  n  
Lumbar Spine (L1—L4)      
BMD (g/cm2) 35 1.001 ± 0.181 20 0.962 ± 0.198 
T score 25 - 0.508 ± 1.622 8 -1.175 ± 2.245 
Z score 35 - 0.309 ± 1.390 20 - 0.725 ± 1.716 
Femoral Neck (Left)     
BMD (g/cm2) 31 0.770 ± 0.146 19 0.781 ± 0.125 
T score 22 - 0.723  ± 1.196 7 - 0.786 ± 1.358 
Z score 32 - 0.500 ± 1.276 19 - 0.426 ± 1.016 
Femoral Neck (Right)     
BMD (g/cm2) 27 0.758 ± 0.137 19 0.794  ± 0.168 
T score 19 - 1.006 ± 1.214 7 - 0.900 ± 2.246 
Z score 28 - 0.625 ± 0.950 19 - 0.311 ± 1.429 
Total Hip (Left)     
BMD (g/cm2) 29 0.872 ± 0.148 20 0.873 ± 0.144 
T score 21 - 0.514 ± 1.392 8 - 0.813 ± 1.626 
Z score 30 - 0.563 ± 1.305 20 - 0.565 ± 1.115 
Total Hip (Right)     
BMD (g/cm2) 28 0.870 ± 0.139 20 0.866 ± 0.173 
T score 20 - 0.660 ± 1.325 8 - 0.913 ± 2.122 
Z score 29 - 0.583 ± 1.120 20 - 0.615 ± 1.347 
BMD Classification 
 
36  20  
BMD normal  21 (58.3)  15 (75) 
Osteopenia  10 (27.8)  1 ( 5) 
Osteoporosisa   5 (13.9)  4 (20) 
Osteoporosis (LS)b  2 (5.6)  3 (15) 
Osteoporosis (FN)b  2 (5.6)   
Osteoporosis (TH)b  1 (2.8)  1 (5) 
Data expressed as means and standard deviations 
LS - lumbar spine, TH – total hip, FN – femoral neck 





Figure 4.1: Classification of osteoporosis and osteopenia by gender and treatment group 
 
4.3.3 Nutritional status parameters 
 
Body composition and dietary intake data presented in Table 4.3 indicate that the mean BMI of 
transplant recipients was 24.1 ± 4.5kg/m2 compared to the higher mean BMI (27.7± 4.5kg/m2) 
of transplant candidates.  
 
This was also evident in the higher lean and fat mass components in transplant candidates 
compared to transplant recipients, although this difference was non-significant. Significantly 
more transplant recipients had a normal BMI 13/20 (86.7%), compared to transplant candidates 
3/36 (16.7%) (p = 0.031), and significantly more transplant candidates were overweight 
compared to the transplant recipients (50.0% versus 6.7%, p = 0.031).  
 
In terms of micronutrients, mean daily calcium and vitamin D intake was 485.4 ± 227.0 mg and 
4.61 ± 4.5mg respectively, with no significant differences between the two treatment groups. 
 
Chi-square analysis showed no significant relationships between osteopenia/osteoporosis with 



































osteopenia/osteoporosis group categories with continuous variables showed that length of time 
on current treatment modality was significantly longer for participants with osteoporosis than 
those with normal BMD (p = 0.025).  In addition, lean mass was significantly lower for those 
with osteoporosis compared to normal and osteopenic participants (p = 0.016), while those with 
a normal BMI had significantly lower LS T-scores than overweight participants. 
Correlation analysis showed that absolute BMD and T-scores correlated with BMI at all three 
skeletal measurement sites.  T-scores strongly correlated with lean mass and BMD of the spine 
(r = 0.707, p = 0.007), and moderately with BMD at the left and right TH (r = 0.455, p = 0.007 
and r = 0.420, p = 0.007) respectively. Fat mass did not correlate with osteoporosis or BMD.  
For the study sample as a whole, serum 25(OH) D did not correlate with BMD or T-scores or Z-
scores.  Calcium intake was associated with the T-score of the TH.  However, when split by 
treatment group (Table 4.5), there was a significant positive association with dietary calcium 
intake at all BMD measurement sites for transplant recipients. No association was found 
between calcium intake and BMD amongst transplant candidates.  However, Z-scores of the FN 
were negatively associated with vitamin D intake (r = -399, p = 0.036).  
 89 
 






  Whole group 
N = 56 
 Transplant candidates 
n = 36 
 Transplant recipients 
n = 20 
 
 
Anthropometry (n = 33) 
       
Weight (kg)  71.63 ± 12.99  75.58 ± 11.14  66.89 ± 13.83  
Height (cm)  165.93 ± 8.80  165.53 ± 8.46  166.41 ± 9.47  
Body mass index (kg/m2)   26.1 ± 4.80  27.7 ± 4.54a  24.1 ± 4.50a  
- Normal  16 (48.5)  3 (16.7)b  13 (86.7)b  
- Overweight  9 (27.3)  9 (50.0)c  1 (6.7)c  
- Obese class I  6 (18.2)  5 (27.8)  1 (6.7)  
- Obese class II  2 (6.1)  1( 5.6)  0 (0.0%)  
DEXA body composition (n = 34)        
Total mass (kg)  65.36 ± 20.70  65.93 ± 25.56  64.73 ± 14.17  
Lean mass (kg)  48.08 ± 8.39  49.5 ± 7.78  46.4 ± 9.00  
Fat mass (kg)  19.48 ± 11.41  22.3 ± 10.82  16.3 ± 11.54  
 
Dietary intake 
       
Vitamin D intake (mcg)  4.61 ± 4.51  5.44 ± 4.88  3.10 ± 3.37  
Calcium intake (mg)  485.43 ± 277.00  480.94 ± 280.80  493.5 ± 277.03  
Data given as means and frequency and means and standard deviation 
a BMI of transplant candidates was significantly higher than transplant recipients (t = -2.264, p = 0.031) 
b Significantly more transplant recipients had a normal BMI compared to transplant candidates (p = 0.031) 




Table 4.4: Correlations between selected variables and BMD, T-scores and Z- scores of the spine, total hip and femoral neck for the whole group 
  Variable  Bone mineral density variable  Pearson’s correlation 
 n site BMD/T-score/Z-score  r P 
       
Age (years) 33 TH (left) Z-score  0.319 0.24* 
Current treatment duration (years)a 13 FN (left) T-score  - 0.401 0.031* 
25 (OH) Vitamin D  NS NS  NS NS 
BMI (kg/m2) 13 LS T-score  0.575 0.040* 
 13 FN (left) T-score  0.638 0.019* 
 13 FN (right) T-score  0.688 0.009** 
 13 TH (left) T-score  0.578 0.038* 
 13 TH (right) T-score  0.594 0.032* 
Fat mass (kg)  NS NS  NS NS 
Lean mass (kg)b 13 LS T-score  0.707 0.007** 
 34 TH (left) BMD  0.455 0.007** 
 34 TH (right) BMD  0.420 0.013* 
Calcium intake (mg) 29 TH (left) T-score  0.368 0.049* 
Vitamin D intake (mcg)  NS NS  NS NS 
BMD in g/m2 
a  significantly greater for osteoporosis participants than those classified as normal (p = 0.025) 
b significantly higher in normal and osteopenia than in osteoporosis (p = 0.16) 






Table 4.5: Correlations between dietary calcium and vitamin D intake and BMD, T-scores and Z-scores of the spine, total hip and femoral neck 
                per treatment group  
Measurement site 
Transplant candidates 
n = 36 
 Transplant recipients 
n = 20 
                 Calcium   Vitamin D  Calcium  Vitamin D 
   n r p  n r p   
Lumbar Spine (L1—
L4)  
NS   NS        
BMD (g/cm2)       20 0.509* 0.022  NS 
T-score       8 0.826* 0.012   
Z-score       20 0.495* 0.027   
Femoral Neck (Left) NS   NS       NS 
BMD (g/cm2)       19 0.686** 0.001   
T-score       7 0.833* 0.003   
Z-score       19 0.645** 0.003   
Femoral Neck (Right) NS   NS        
BMD (g/cm2)       19 0.643** 0.003  NS 
T-score       7 0.816* 0.025   
Z-score   28 - 399* 0.036  19 0.608** 0.006   
Total Hip (Left) NS   NS        
BMD (g/cm2)       20 0.682** 0.001  NS 
T-score       8 0.808* 0.015   
Z-score       20 0.623** 0.003   
Total Hip (Right) NS   NS        
BMD (g/cm2)       20 0.673** 0.001  NS 
T-score       8 0.831* 0.011   
Z-score       20 0.629** 0.003   






This study investigated the prevalence of osteopenia and osteoporosis in HIV-positive transplant 
candidates on dialysis, i.e. awaiting a transplant, and transplant recipients from a HIV-positive 
donor. 
 
Amongst transplant candidates, 13.9% were classified as osteoporotic or per skeletal region: 
5.6% (LS); 5.6% (FN); and 2.8% (TH). This finding is comparable to the 12.7% reported 
among 63 Taiwanese HD participants (21), but slightly lower than the 14.3% (LS) and 21.4% 
(FN) observed in a smaller sample (n = 37) of HD patients in Greece (22). Some HD 
populations samples report even higher frequencies of osteoporosis at 33.0% and 34.0% 
(23,24). In the sample of Greek subjects, twice as many (27.8%) were osteopenic, while also 
bearing similarities to other HD samples that reported two and up to a  five times higher 
frequency of osteopenia than osteoporosis among those on haemodialysis (22).  
 
By comparison, the transplant recipient group had more participants with osteoporosis (20.0%) 
than the transplant candidates. This is likely, given the added effect of immunosuppressants on 
bone already compromised by CKD (25). Previous studies on kidney transplant recipients, 
reported the presence of osteoporosis among 22.0% to 26.0% of patients (26,27) or regional 
values of 12.4% to 21.3% in the LS and between 9.8% to 45.1% in the FN (28,29). In the 
present study, osteoporosis by skeletal region among transplant recipients was 15.0% (LS), and 
5.0% (TH). Surprisingly, only one transplant recipient (5.0%) presented with osteopenia, in 
sharp contrast to the high prevalence of osteopenia (36.3% - 54.5%) reported among other 
transplant recipients (26-28). As the present study documented that 75.0% of transplant 
recipients had a normal BMD, this finding is unexpected given the presence of comorbid HIV, 
which in isolation is associated with lowered BMD (7). Typically, 67.0% of HIV-positive 
individuals have a reduced BMD (8). The findings of the current study can be explained in the 
context of the protective, as well as risk factors this patient group are exposed to. 
 
The length of treatment time either as transplant awaiting candidates on dialysis, or number of 
years post transplant was of significance in the present study. The treatment duration for the 
whole group correlated positively with osteoporosis and BMD T-scores at the right FN. The 
length of time on the current treatment was significantly longer for osteopenia participants than 
for those unaffected by bone disease. The effect of treatment duration on bone health has been 
previously demonstrated (4), although not consistently so (5,21,27). This effect was aptly 
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described in a cohort of 101 039 transplant awaiting patients where significant differences in 
fracture risks were found between the two groups, in that kidney transplant recipients had a 
higher fracture risk compared to those on dialysis in the critical period immediately following a 
transplant (30).  This finding corresponds to severe bone loss experienced due to high doses of 
immunosuppressants used in induction therapy in the early post-transplant period (31). This risk 
decreases over time following a transplant and the improvement of pre-transplant bone risk 
factors. Between one to three years post-transplant, the risk is lowered below those on dialysis 
(30), and normalized ten  years post-transplant (32). In the pre-transplant population, waiting 
time is also an important consideration as patients who spent more than one year on dialysis had 
a greater fracture risk after a transplant than those who were on dialysis for less than three 
months (30).  
 
In the general population, traditional risk factors for the development of osteoporosis include 
aging, female sex (particularly after menopause) and ethnicity (33). Regarding age, the current 
study found a weak association between BMD Z-score and age, probably due to the overall low 
mean age of the study sample. Although more women were diagnosed with osteoporosis, there 
was no significant association with BMD or osteoporosis and gender, or significant differences 
in these variables between males and females.  This is possibly due to the fact that the females 
in the current study, with a mean age 42.9 ± 8.6 years, were younger than the average 
menopausal age of 49.2 years for black  South African women, and still young enough before 
differences between the sexes become more pronounced (34,35). Some evidence of this 
phenomenon was documented in other studies. For example, no association was found between 
BMD and age or gender among young Iranian dialysis (mean age 38.0 ± 10.6 years) and 
transplant participants (39.0 ± 11.8 years) (5), while Huang et al found an inverse relationship 
between BMD and age among their older (55.7 ± 13.5 years) HD group (21).  Similarly, Kadam 
et al did not find a significant deterioration in BMD with age in healthy pre-menopausal women 
even among those older than 50 years of age, but a significant decline following menopause 
(36).  Lastly, 92.9 % of our study sample was black for whom higher BMDs have consistently 
been observed when compared to Caucasian and Asian populations (14, 37, 38). A possible 
reason for this disparity is related to differences in body weight as was documented in a study 
among black and white South African women (39). 
 
It is recognized that there is a relationship between weight, BMI and BMD (40).  Higher body 
weights accompany higher hip and vertebral BMDs.  Hence, overweight and obese individuals 
are at a lower risk of osteoporosis compared to their normal weight counterparts (BMI < 25.0 
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kg/m2) (41). This was also evident in the current study, where participants with a normal BMI 
had significantly lower T-scores at the LS than overweight participants. In addition, for all 
participants BMI correlated strongly to BMD at all measurement sites.  
Body weight is a combination of muscle and fat mass, and a recent meta-analysis that weighed 
the influence of each component on BMD, reported that both fat mass and lean mass have a 
relationship with BMD. However the cumulative results of 44 studies including 20 226 
participants, showed a stronger association between lean mass and BMD than fat mass (40). 
Likewise, in the current study, BMD positively correlated with lean mass, with a greater 
strength of association at the LS.  However, the same did not hold true for fat mass. This is an 
important finding, as it supports the importance of the muscle-bone unit as a potentially 
modifiable risk factor in skeletal health. This relationship, viewed as a biomechanical model of 
load-bearing muscle mass on bone (38), highlights the importance of skeletal muscle 
preservation through exercise and diet to delay bone loss (42). 
 
Preservation of muscle mass in CKD is challenging due to imbalances in synthesis and 
breakdown of muscle mass (43). Therefore muscle preservation strategies should optimise 
management of these abnormalities as well as support muscle synthesis. For example, 
correction of metabolic acidosis with alkali supplementation has demonstrated positive effects 
on muscle mass (44). Appropriate exercise can improve muscle mass, strength and balance to 
reduce falls (42,45,46) as exercise stimulates protein synthesis, which in turn will require 
adequate dietary support. This however, will necessitate an individualised approach to ensure 
that protein intake is of adequate quantity and quality, and appropriately timed to support 
muscle synthesis (42). Apart from protein, several other foods and nutrients have recently been 
linked to bone health (47). Two micronutrients synonymous with skeletal health are vitamin D 
and calcium.  
 
Consistent with findings in dialysis (22), kidney transplant (48) and HIV-positive populations 
(49,50) elsewhere, the majority of the current study’s study sample did not have sufficient 25 
(OH)D levels. Vitamin D deficiency was the most prevalent among transplant recipients where 
only 11.1% had optimal levels. There is a longstanding relationship between vitamin D and 
BMD (17,51). Vitamin D deficiency has a negative impact on calcium balance with secondary 
hyperparathyroidism affecting bone matrix and mineralization, resulting in osteomalacia, 
osteoporosis and fractures (17). Studies investigating the link between 25(OH)D and BMD yield 
conflicting results, by showing either a significant association between 25(OH)D and BMD 
(30,52), or no association at all (53) in different patient groups. One of the discrepancies in the 
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association between 25(OH)D and BMD is based on race and ethnicity, as noted in a study 
conducted among adult males, where a significant association between serum 25(OH)D and 
BMD in white males, but no correlation in black males was found (54). Similarly, the present 
study found no association between serum 25(OH) D and BMD or osteoporosis in this 
predominantly black study sample. The preservation of skeletal integrity despite suboptimal 
25(OH)D in the black population, is possibly due to the fact that black ethnicity may offer more 
resistance to the bone-resorption process (55). Another contributor to vitamin D deficiency is 
inadequate UV exposure, although this is an unlikely factor due to the geographic location of 
the current study sample in the Southern hemisphere.  However, this phenomenon does not 
appear to be specific to patients with a chronic disease. In a study conducted among healthy 
adults in Hawaii, found that participants had low vitamin D levels despite exposure to the 
tropical climate (56). 
 
The vitamin D intake of transplant candidates was close to recommended levels, although their 
daily intake requirements should ideally be determined based on serum calcium, phosphate and 
PTH levels (57), and will therefore require an individual approach. With the exception of a 
weak association at the FN amongst transplant candidates, there was no association between 
dietary vitamin D intake and BMD at any other site for either treatment group. Optimising 
25(OH)D still deserves due consideration in bone health, as a vitamin D deficiency increases the 
likelihood of falls through its negative affect on physical ability (58) and strength (49,58,59). 
More importantly, vitamin D deficiency is independently associated with disease progression in 
HIV (60), and reduced glomerular filtration rate (GFR), one year post transplant (61). It is 
therefore kidney function in the first year post-transplant that influences long term transplant 
outcome (62). 
 
The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, recommend 500mg of 
calcium from dietary sources, although a daily intake of 2000mg/day for peritoneal and 
haemodialysis patients should not be exceeded to prevent hypercalcaemia and vascular 
calcification (57,63,64). The dietary calcium intake in this study’s dialysis group (480.94 ± 
280.80mg/day) closely matched this amount, but not more recent recommendations of 800mg to 
1000mg/day (65). Dietary calcium was not associated with BMD at any site for transplant 
candidates. Similar results were described among haemodialysis patients in the UK where no 
association was found between dietary calcium and BMD, yet a positive correlation existed 
between calcium in the form of supplements and BMD at the FN. The lack of association was 
presumed to be due to low dietary calcium intake of less than 500mg (66). This reason is less 
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probable in the current study, as transplant recipients who had a similar dietary calcium intake 
of 493.5 ± 277.03mg/day was positively associated with BMD at all sites. Transplant recipients 
consumed a mean daily calcium intake of 493.5 ± 277.0 mg/day, which was lower than the daily 
calcium intake of 623.2 ± 208.2mg (67) and 868.0 ± 387.0mg (68) in transplant recipients one 
month and three years post- transplant respectively. This daily intake was much lower than the 
recommended daily intake of 1200-1500mg/day (57), and is a concern as calcium 
malabsorption, together with 25(OH) D deficiency, can cause further bone deterioration (63). 
Given the association with BMD, it could potentially be one of many contributors to the higher 
prevalence of osteoporosis in the transplant group.  However, this finding requires further 
investigation. Dietary adequacy can be improved through nutrition education, although 
monitored supplementation may be necessary (63). Vitamin D and calcium supplements have 
been used with some success in decreasing the extent of bone loss immediately post-transplant 
(69). 
 
This study is limited by its overall small sample size and partial availability of data due to 
differences in bone images, depth of information and reporting styles from the different 
assessment centres. The cross-sectional design is also limiting in terms of investigating causal 
relationships. Future studies should consider a prospective design that includes pre-transplant 
BMD with regular follow-up post- transplant to monitor change in BMD over time as well as 
the effects of intervention. A single 24-hour recall is less likely to be a valid reflection of 
habitual intake, lowering the likelihood of significant correlations with the micronutrients. On 
the other hand however, the intake information on calcium and vitamin D still provides some 
constructive dietary insight. The interpretation of results were also limited by the lack of certain 
biochemical parameters including PTH, bone markers and serum calcium, which were not 
assessed as they were beyond the resources of the current study. Moreover history of 
supplement use, a physical activity questionnaire and menopausal status would also add value to 
data interpretation, but would have contributed to respondent fatigue. Nevertheless, this study 
makes a significant contribution to the limited data on bone health in HIV especially in Sub-
Saharan Africa (70), and provides the first insight into the prevalence of osteoporosis in HIV-
positive transplant candidates and recipients from a HIV-positive donor. 
 
In summary, the prevalence of osteoporosis is similar to, if not slightly lower than that of 
transplant recipients and dialysed patients reported elsewhere. The higher prevalence of 
osteopenia among transplant candidates highlight the importance of introducing preventative 
strategies prior to transplant, given the rapid deterioration of BMD post-transplant and the 
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difficulty associated with treating osteoporosis after onset. The link between calcium intake and 
lean mass with BMD are important and optimistic findings, in that diet and exercise are 
potentially safe, cost effective interventions that can curb bone loss.  Hence, a lack of attention 
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CORRELATION OF ANTHROPOMETRIC MEASURES WITH DUAL ENERGY X-




Background: The evaluation of body composition (BC) is important for observing changes in 
musculature and adiposity. Obesity and low muscle mass are associated with adverse outcomes 
in kidney transplant candidates and recipients.  Therefore, practical measures of BC, with a high 
degree of accuracy are essential in the assessment of nutritional status.   
Objective:  To correlate anthropometric measures with dual-energy X-ray absorptiometry 
(DEXA) as a reference standard in kidney transplant candidates and recipients.   
Methods: 34 clinically stable kidney transplant candidates and recipients infected with HIV 
participated in this cross-sectional study. Body mass index (BMI), waist circumference (WC), 
waist-to-hip ratio (WHR), waist-to-height ratio (WHtR) and mid arm muscle circumference 
(MAMC) were compared to DEXA derived percentage body fat (%BF), truncal fat (TF) and 
visceral adipose tissue (VAT).  Mid arm muscle circumference (MAMC) was correlated with 
DEXA lean indices namely, lean mass (LM), lean mass index (LMI) and appendicular lean 
mass index (ALMI). 
Results: Pearson’s correlation coefficient between BMI and %BF was strong (r = 0.773, p < 
0.001). There was a greater statistical significance in the association between WC with TF (r = 
0.799, p = 0.00) and VAT (r = 0.885, p < 0.001), than WHtR with TF and VAT (r = 0.778, p = 
0.013 and r = 0.830, p < 0.001). There was a lack of significant correlation between WHR and 
TF or VAT. MAMC correlated best with ALMI (r = 0.511, p = 0.011). 
Conclusion: There was a strong significant correlation between anthropometric measures of 
adiposity and musculature with the reference standard DEXA. In particular, between BMI and 
%BF and WC with TF and VAT. MAMC correlated best with DEXA lean indices such as 
ALMI.  
 
Keywords: Kidney transplant candidates, Kidney transplant recipients, Human 






5.1 Introduction  
 
Body composition (BC) is an important component of physical health (1). Substantial changes 
in BC are known to affect morbidity and mortality in kidney transplant candidates and 
recipients (2,3,4). BMI is the most widely used indicator of nutritional status and is a surrogate 
measure of adiposity. However, it is unable to distinguish fat from muscle mass or regional 
distribution of fat (5). This differentiation is important to identify transplant candidates and 
recipients at risk of adverse outcomes. For example, under-nutrition characterized by a low 
body mass index (BMI), predisposed candidates to an increased mortality risk while awaiting 
transplant (2), or greater graft loss and post-transplant mortality (6). A higher BMI was 
associated with a lower mortality risk (7,8). This protective advantage is attributed to a higher 
muscle mass (3).  
 
Among transplant recipients, overall obesity negatively impacts graft and patient outcomes in 
some (4,9) although not all (10) transplant recipients. However, central obesity and excess 
visceral adipose tissue (VAT), is associated with increased cardio-metabolic risk in the general 
population (11,12) and is related to a higher all-cause mortality following transplantation (13). 
Less is known about the implications of co-existing human immunodeficiency virus (HIV) on 
BC in kidney transplant candidates and recipients. However, it is likely to be morphologically 
significant as HIV and antiretrovirals are related to muscle wasting and lipodystrophy (14). 
 
These links between adiposity, muscularity and clinical outcomes that have an impact on kidney 
transplantation are well described, and clearly necessitates the inclusion of in-depth BC 
measures for assessment, monitoring and prognosis. It is therefore essential that the methods 
used, provide information with a high degree of accuracy (15). Anthropometry is one of the 
more common BC methods (16) and is known to provide valid information on fat and muscle 
composition when compared to magnetic resonance imaging (17). Waist circumference (WC), 
waist-to hip-ratio (WHR) and waist-to-height ratio (WHtR) are commonly used proxy measures 
of abdominal obesity and the health risks accompanying obesity (18).  MAMC for example, is 
one of several proxy measures to estimate lean body mass (19). With the measurement of 
anthropometric indices however, there is potential for human error as it requires skill and 
equipment of a high quality (20).  
 
Dual-energy X-ray absorptiometry (DEXA) accurately measures BC, in agreement with more 
detailed methods (21). However, it is costly, and not always feasible for use in bedside and field 
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investigations. Moreover it involves some, albeit slight, exposure to X-ray radiation (22). It is 
therefore often used as a reference, to verify less precise methods (23), as is the focus of the 
current study.  Recognising that measurement accuracy is crucial to correctly identify and treat 
the individual, or to facilitate decisions and policy making at a group level (24), this study 
aimed to verify selected BC measures determined through anthropometry, against DEXA 







For this cross-sectional study, prospective participants  were recruited through the kidney 
transplant programme for HIV-infected patients at Groote Schuur Hospital, Cape Town. 
Participants were recruited based on whether they were transplant recipients or were awaiting a 
transplant and hence managed on who have received a kidney from a HIV-infected donor; and 
(ii) HIV-infected transplant candidates who were on the waiting list to receive a kidney from a 
HIV-infected donor. Prospective participants were contacted telephonically or at their respective 
outpatient clinics and invited to undergo a dual-energy X-ray absorptiometry (DEXA) 
evaluation. Participants were eligible for inclusion if they were clinically stable at the time of 
recruitment. Exclusion criteria included those who declined to participate, missed several 
DEXA appointments (typically two or more without reason) or were not willing to travel the 
distance to the radiology centre. Although 54 participants agreed to undergo the DEXA 
assessment, only three radiology centres were able to provide the measurement of body 
composition which 34 participants had access to. Before screening, written informed consent 
was obtained and participants were re-reimbursed for travel expenses incurred.  This cross-
sectional study was approved by the University of KwaZulu-Natal’s Biomedical Research 
Ethics Committee (Approval number BE 327/13). 
5.2.2 Socio-demographic and clinical information 
 
Socio-demographic information was collected using an interviewer-administered structured 
questionnaire developed for the purpose of the study. Clinical information was obtained from 




5.2.3 DEXA Body composition measurements 
 
Participants were assessed with the Hologic Discovery W (MA, USA) and the GE Lunar 
Prodigy (Advance, GE Healthcare, USA). All DEXA assessments were conducted by 
radiographers with relevant training and experience regarding the positioning of participants and 
machine operation according to standard procedures (1). DEXA provides information on bone, 
lean and fat mass with BC information based on X-ray beam variations as it passes through 
body matter of different densities. Two energy fields separates soft tissue into lean and fat 
components, thereby enabling the measurement of whole body and regional BC (25). This 
includes raw values and indices indicating total and regional fat and lean mass distribution. 
Adiposity indices used as reference values were percentage body fat (%BF), truncal fat (TF) and 
visceral adipose tissue (VAT). BF is calculated from fat mass divided by total mass and 
expressed as a percentage. TF in kg, representing abdominal fat, is presented in kilograms (kg) 
and VAT as area in cm2. Lean mass reference values were lean mass (LM), lean mass index 
(LMI) and appendicular mass index (AMI). LM (kg) represents fat free and bone free mass, but 
includes muscle, skin, tendons, and connective tissue. LMI is LM adjusted for height and is 
defined as total LM divided by height (H) in m2. ALMI is calculated from the lean mass of the 
arms and legs in kg divided by H (m2).  Appendicular lean mass refers to soft tissue found in 
arms and legs. A large percentage of whole body skeletal muscle is found in the arms and legs 
while a large percentage of appendicular lean tissue is present as skeletal muscle. This 
represents about 75% of whole body skeletal muscle (23).  
 
5.2.4 Anthropometric measurements  
 
Although dietitians that collected data for the study, served as fieldworkers, and were 
experienced in taking anthropometric measurements, they received a refresher training session 
which was followed by a post-training test to ensure standardisation of measurement techniques 
and thereby reduce inter fieldworker variability. Both the training and test were accredited for 
continuing education purposes with the Health Professions Council of South Africa. All body 
measurements namely weight (WT), height (Ht), triceps skinfold thickness (TSF), mid upper 
arm circumference (MUAC), waist circumference (WC) and hip circumference (HC) were 
measured using protocols described in the National Health and Nutrition Examination Survey 
(NHANES) and is described in detail in the NHANES anthropometry procedure manual (26). 
Heights in centimetres (cm) and weight (kg) were obtained using equipment already present at 
various outpatient and dialysis centres. Weight measurements on dialysis participants were 
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taken post dialysis (dry weight), on the non-access arm (19). Circumference measurements (cm) 
and TSF in millimetres (mm) were taken using standardized callipers (Slim Guide, USA) and 
measuring tape (SECA 201, Germany) on all participants. Measurements were taken to one 
decimal place and the mean value of three readings were recorded. BMI was calculated as WT 
divided by Ht squared (kg/m2) and classified according to the World Health Organization 
categories: underweight (<18.5), normal (18.5-24.9), overweight (≥ 25.0-29.9), obese class I 
(30.0-34.9), obese class II (35.0-39.9) and obese class III (≥40) (27). WHR was calculated as 
WC divided by HC. WHtR was calculated as WC divided by Ht. TSF and mid upper arm 
circumference (MUAC) were used to determine MAMC using the equation:-  
 




Data was analysed using the Statistical Package for Social Sciences (SPSS®) version 25.0. 
Means and standard deviation were calculated for all continuous variables and frequencies with 
percentages for categorical variables. Independent samples t-test was used to determine 
differences between transplant candidates and recipients’ clinical and nutritional variables. 
Pearson’s coefficient was used for correlation analysis between the anthropometric values and 




5.3.1 Participant characteristics 
 
Of the 34 participants, 18 were undergoing haemodialysis while on the waiting list for a 
transplant and 16 were already recipients of a kidney donated from a HIV infected individual. 
Participant characteristics are summarized in table 5.1. The majority were male (61.8%) and 
38.2% were female. The majority (91.2%) were black, with an average age of 43.9 ± 7.9 years. 
All participants were HIV positive, the majority were hypertensive (88.2 %), while two (5.9%) 
had hypercholesterolemia, and five (14.7%) had diabetes. The average CD4 count for the group 
was 374.85 ± 214.42 cells/µL. Transplant recipients had higher mean CD4 (417.69 ± 280.56  
cells/µL versus 334.53 ± 120.85 cells/µL) when compared to transplant candidates All 
transplant recipients had viral loads (VL) levels that were lower than detectable limits (LDL), 
while 87.5% of transplant candidates had viral loads at LDL. The majority of transplant 
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recipients had a normal weight (87.5%), and two (12.5%) were categorized as obese class I. In 
the transplant candidate group, only 28.7% were classified as normal weight. The majority were 




Table 5.1: Demographic, nutritional and clinical characteristics of the study group  
 
Patient Characteristics 
 Total group 
N = 34 
 
Transplant candidates 
n = 18 
 
Transplant recipients 
n = 16 
Gender       
Male  21 (61.8)  11 (61.1)  10 (62.5) 
Female  13 (38.2)  7 (38.9)  6 (37.5) 
Age (years)  43.9 ± 7.9  46.2 ± 7.6  41.2 ± 7.56 
Ethnicity       
Black  31 (91.2)  16 (88.9)  15 (93.8) 
Coloureda  3 (8.8)  2 (11.1)  1 (6.3) 
Duration of current treatment (years)  3.7 ± 2.6     
Chronic illness       
Diabetes  5 (14.7)  5 (27.8)  0 (0.0) 
Hypertension  30 (88.2)  17 (94.4)  13 (81.3) 
Hypercholesterolaemia  2 (5.9)  1 (5.6)  1 (6.3) 
CD4 (cells/µL)b  374.85 ± 214.42  334.53 ± 120.85  417.69 ± 280.56 
Viral load (copies /ml)c       
Lower than detectable limit (LDL)  29 (93.5)  14 (87.5)  15 (100.0) 
≤ 10000 copies/ml  2 (6.5)  2 (12.5)  (0.0) 
BMI        
Normal (18.5-24.9)  19 (55.9)  5 (27.8)  14 (87.5) 
Overweight (25.0-29.9)  6 (17.6)  6 (33.3)  - 
Obese class I (30-34.0)  9 (26.5)  7 (38.9)  2 (12.5) 
a In South Africa, refers to an individual of mixed race ancestry 
bCD4: n = 33 (dialysis: n = 17 ,   transplant: n = 16),  c Viral load: n = 31 (dialysis: n = 16  , transplant: n =15 ) 
BMI: body mass index 
Data expressed as means and standard deviation or frequencies with percentages 
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5.3.2 Body composition 
  
Table 5.2 depicts the body composition values obtained from DEXA and anthropometric 
measurements for each treatment group respectively. Although there were no significant 
differences between transplant candidates and transplant recipients, there was a trend towards 
greater adipose and muscle mass values in candidates on dialysis when compared to transplant 
recipients. BMIs amongst transplant candidates versus transplant recipients were 27.9 ± 4.2 
kg/m2 and 23.4 ± 4.6 kg/m2 respectively. WC and WHtR were also higher in the candidate group 
(93.5 ± 13.6 and 0.6 ± 0.1) compared to the recipient group (86.8 ± 11.4 and 0.5 ± 0.1). WHR 
ratio showed no significant difference between the two groups, with a mean value of 0.9 ± 0.1 
recorded for both.  Transplant candidates were also more muscular with a mean MAMC of 27.3 
± 4.4cm compared to 24.5 ± 4.4cm amongst transplant recipients. 
 
Similarly, all DEXA measurements of adiposity were higher amongst transplant candidates 
compared to transplant recipients.  %BF was 29.5 ± 11.4% versus 24.0 ± 11.8%. Mean TF 
among the transplant candidates was 11.4 ± 6.6 kg and 8.1± 5.1 kg among transplant recipients. 
VAT was 122.2 ± 57.5cm2 versus 104.0 ± 55.2cm2. LM and LM indices were also greater. LMI 
was 18.0 ± 1.53kg/m2 and 16.8 ± 1.9kg/m2 amongst transplant awaiting candidates and 
transplant recipients respectively. 
 
Correlation coefficients between BC derived from anthropometry and DEXA were determined 
for the whole group, and are given in Table 5.3. Strong correlations were observed between 
BMI (r = 0.773, p < 0.001) and TSF (r = 0.803, p < 0.001) with %BF.  
 
TF correlated strongly with WHtR (r = 0.778, p = 0.000), but even more so with WC (r = 0.799, 
p = 0.000). WC strongly correlated with the reference VAT (r = 0.885, p ≤ 0.001), as did WHtR 
(r = 0.802, p ≤ 0.001), and BMI (r = 0.716, p ≤ 0.001). No significant association was observed 
between WHR and TF or VAT. The strength of association between MAMC and lean mass was 







Table 5.2: Anthropometry and DEXA derived body compositional characteristics of the dialysis and transplant group 
Body composition  Transplant candidates  Transplant recipients 
  
  n   n  
Anthropometry  Weight (kg)  18 75.7 ± 11.5  16 64.9 ± 13.2 
Height (cm)  18 164.7 ± 10.3  16 166.6 ± 9.3 
BMI (kg/m2)  18 27.9 ± 4.2  16 23.4 ± 4.6 
Waist circumference (cm)  13 93.5 ± 13.6  14 86.8 ± 11.4 
Waist to hip ratio  13 0.9 ± 0.1  14 0.9 ± 0.1 
Waist to height ratio  13 0.6 ± 0.1  14 0.5 ± 0.1 
Mid upper arm circumference (cm)  12 30.4 ± 4.6  14 27.3 ± 5.2 
Triceps skinfold thickness (mm)  12 10.8 ± 5.2  14 9.0 ± 4.8 
Mid arm muscle circumference (cm)  12 27.3 ± 4.4  14 24.5 ± 4.4 
DEXA              Body fat (%)  18 29.5 ± 11.4  16 24.0 ± 11.8 
Fat mass (kg)  18 22.3 ± 10.8  16 16.3 ± 11.54 
Visceral adipose tissue (g)  13 589.31 ± 276.67  16 501.38 ± 266.28 
Visceral adipose tissue (cm2)   13 122.18 ± 57.38  16 104.01 ± 55.22 
Truncal fat (kg)  18 8.4 ± 5.9  16 8.1 ± 5.1 
Lean mass (kg)  18 49.5  ± 7.78  16 46.4 ± 9.0 
lean mass index (kg/ht2)  18 17.99 ± 1.53  14 16.84 ± 1.94 
Appendicular lean mass index  (kg/Ht2)  18 7.72 ± 0.93  14 7.08 ± 0.94 
Data expressed as means and standard deviation  




Table 5.3: Pearson’s correlation of anthropometric measurements with DEXA measurements for the whole group 
  %BF   TF (kg) VAT(cm2)  LM (kg)  LMI (kg/Ht2)  ALMI (kg/ Ht2) 
 n r p  n r p n r p  n r p  n r p  n r p 
BMI 34 0.773** <0.001  33 0.884** 0.000 29 0.716** <0.001             
TSF  26 0.803** <0.001                    
WHR     27 0.131 0.515 23 0.238 0.275             
WHtR     27 0.0.778** 0.000 23 0.802** <0.001             
WC      27 0.799** 0.000 23 0.885** <0.001             
MAMC             26 0.403* 0.041  24 0.475* 0.019  24 0.511* 0.011 
BMI: Body mass index, TSF: triceps skinfold thickness, WHR: waist to hip ratio, WHtR: waist to height ratio, WC: waist circumference, MAMC: mid arm muscle 
circumference, %BF: Percentage body fat, VAT: Visceral adipose tissue,  LM: Lean mass, LMI: Lean mass index, ALMI: Appendicular lean mass index 







Accurate measurements of BC are essential for the assessment of nutritional status. DEXA 
accurately quantifies adipose and muscle tissue (29), and for this reason, was used as a reference 
standard to correlate BC determined by anthropometry. 
 
BMI is a widely used indicator for whole body adiposity, based on the correlation that exists 
between BMI and direct measures of body fat such as underwater weighing and DEXA (5). The 
present study confirms this relationship, showing a strong correlation (r = 0.773, p < 0.001) 
between BMI and DEXA derived %BF. As to be expected, TSF showed a stronger relationship 
with %BF (r = 0.803, p = <0.001) than BMI in the current study, and other studies (30), as BMI 
is an indirect measure of adiposity (31). However, skinfolds provide a more direct measure of 
fat as they determine subcutaneous fat, which make up about 50.0% of whole body fat (32).  In 
addition, skinfolds at the triceps site demonstrate a highly correlational relationship with whole 
body fat (32).  Nonetheless, BMI is more routinely used, as skinfolds require skill and 
equipment that is not always available. It is therefore considered an expanded, rather than one of 
the core body measurements by the WHO (33). However, it could be considered in situations 
where the measurement of weight and height are not practical.   
 
Central/ truncal adiposity is abdominally located adipose tissue that incorporates both the intra-
abdominal visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) (34). The  
VAT component however, adversely affects the metabolic profile more so than the 
subcutaneous adipose tissue (SAT) (12). In recent years, it has become an increasingly 
important focus of research, since VAT was found to be associated with hypertension (35), pre-
diabetes and diabetes (36), dyslipidaemia (37) and the metabolic syndrome (38). In the current 
study, the performance of WC, WHR and WHtR as proxy measures of central adiposity was 
assessed using their associations with TF and VAT. Of these three indicators, WC demonstrated 
the strongest correlation to both TF and VAT. WHtR also showed strong associations, although 
to a lesser extent. Although not investigated in the present study, researchers also report that 
WC correlates strongly with total abdominal fat, SAT and BMI (39,40). 
 
The superior performance of WC in this study is an encouraging finding as numerous studies 
have shown its discriminative ability in predicting one’s risk for type 2 diabetes (41), metabolic 
syndrome (42), and cardiovascular risk factors (43,44). Moreover, WC is also highly sensitive 
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in detecting BC changes following a WC reduction intervention without any change in BMI or 
weight following a year-long exercise program (45).   
  
The current study found no correlation between WHR and TF or VAT. A possible reason for 
this finding is that unlike WC, WHR does not solely reflect adipose distribution in the truncal 
area, but also the hip area.  The latter comprises pelvic bone structure and gluteal muscle and 
fat. Given the individual variations in these body components, hip measurements are likely to 
affect WHR (46). 
 
Although BMI correlated well with %BF, there was also a similarly strong association with TF 
and VAT. This is probably due to the fact that increases in abdominal fat and total body fat 
occur simultaneously. Despite the correlation with overall and central adiposity, BMI is not a 
stand-alone indicator to be used for both, as it is not suitably predictive of disease risk (22). 
Evidence shows that measures of central obesity like WC is strongly associated with CVD risk, 
and is a better reflection than BMI, of adiposity in older individuals and is less affected by a loss 
of muscle associated with ageing. It is therefore and important indicator to include in nutritional 
assessment of adiposity (47). 
 
In addition to adiposity, measures of musculature have become an increasingly important 
component of body composition (23), with important implications for strength, function, 
mobility and longevity (48,49). 
 
In this study, MAMC was associated with LM.  This finding is in agreement with other studies 
conducted among CKD and HIV-positive populations that also showed a good association with 
MAMC and LM (19,50). In the present study, the strength of association is greater with lean 
mass adjusted for height (LMI) with the strongest association documented for ALMI. This is not 
surprising, as whole body LM includes muscle, skin, tendons and connective tissues, whereas 
appendicular soft tissue (in arms and legs), is largely skeletal muscle, and represents 
approximately 75% of whole body skeletal muscle mass (23). Therefore, a stronger relationship 
would exist between ALMI and whole body skeletal muscle (21).  
 
This study has strengths and limitations. The small sample size limits generalizability of the 
results as well as subgroup analysis according to gender or age, as is often seen in other studies 
(51,52). In addition, the time discrepancy between DEXA, anthropometric measurements and 
dialysis could be viewed as a limitation. However, logistical challenges such as the geographical 
 115 
 
location of participants impaired the ability to schedule the DEXA scan and anthropometric 
measurements on the same day, in addition to conducting these measures after dialysis. This is 
an important consideration, as muscle tissue is influenced by the hydration status of dialysed 
patients (53), and reliable LM estimates can only be obtained when participants are at their ideal 
dry weight (54). It was therefore unlikely that the obtained values would be similar. Statistical 
analysis was limited to correlational analysis, examining the strength of association between 
two variables. Future studies should consider agreement analysis to confirm agreement between 
two methods of the same variable (55). However, previous validation studies (56), between 
%BF and BMI have demonstrated good agreement, confirming the use of BMI as a proxy 
measure of overall adiposity. It is also encouraging to note that despite these challenges, the 
results were not unlike those reported in more controlled studies (52). A possible reason for this 
finding was the recruitment of dietitians for taking anthropometric measurements, as they have 
extensive training and experience in anthropometry.  Previous research showed good intra-
observer precision, even among newly trained dietitians with limited experience (57).   
 
An important strength of this study is that it is the first correlational study of this nature 
conducted among HIV-infected kidney transplant awaiting candidates and recipients from HIV-
infected donors. Furthermore, this study was able to quantify the VAT component of abdominal 
fat. Previously, DEXA was unable to distinguish VAT from SAT (58,59). Only recently, have 
advances in DEXA analysis allowed differentiation and quantification of total abdominal 
adipose tissue into VAT and SAT components with a high degree of accuracy (25).  
The present study concludes, that based on the correlations of BMI, WC and MAMC with 
DEXA derived %BF, VAT and ALMI respectively, these anthropometric measures suitably 
reflect overall and regional adiposity as well as musculature, and can confidently be used for 
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 CHAPTER 6 
ASSESSMENT OF OVERALL AND CENTRAL ADIPOSITY IN HIV-POSITIVE 




Background: Overall and abdominal obesity are closely related to health outcomes in kidney 
transplant candidates and recipients. Diet is one of several determinants of obesity. However, 
this has not been investigated in HIV-infected transplant candidates and recipients from a HIV-
infected donor. 
Objectives: 1) To determine weight, body mass index (BMI) and waist circumference (WC) at 
baseline and the changes in these indicators after six months; 2) To determine the prevalence of 
obesity, central obesity and the metabolic syndrome (MetS), and 3) to determine the relationship 
between dietary macronutrient composition, weight and WC.   
Methods: Weight, BMI, WC and biochemical parameters for the assessment of MetS were 
collected at baseline and six months. 
Results:  Transplant candidates: The mean baseline BMI was 26.3 ± 4.8kg/m2. The majority 
(38.5%) were overweight, followed by 36.5% with a normal BMI. At six months, 62.7% had 
lost weight. The mean weight lost was statistically significant t (50) = 2.072, p = 0.043). Mean 
WC from baseline to six months also decreased slightly although non-significantly.  The WHO 
cut-offs (WC ≥ 88cm for women and ≥ 102cm for men), classified 33.3% with central obesity at 
baseline and 30.4% at six months. MetS was present in 47.5% and 51.0% of candidates at 
baseline and six months respectively. The mean daily energy and protein intake at baseline and 
six months was 25.9 ± 7.8 and 26.4 ± 8.4 kcal/kg/day, and 1.0 ± 0.4g/kg/day and 1.1 ± 0.4 
g/kg/day respectively. Both were lower than that recommended by the South African (SA) 
Renal guidelines. There was a lack of association between macronutrient intake and weight or 
WC at either time point or with the weight change over six months. 
Transplant recipients: The mean BMI was 24.5 ± 4.6 kg/m2.. The majority had a normal BMI 
(71.4%). At six months, 52.4% had gained weight. The increase in weight and BMI was non-
significant. However, mean increases in WC were statistically significantly (t (14) = -2.861, p 
0.013). WC cut-offs classified 33.3% with central obesity at baseline and 44.4% at six months. 
MetS was present in 35.3% of transplant recipients at baseline and 35.0% at six months.  The 
macronutrient content of the diet was within recommended guidelines, at 28.6 ± 7.8 and 27.7 ± 
9.1kcal/kg/day, and 1.0 ± 0.3g and 1.1 ± 0.3g. At baseline, weight correlated with total protein 
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(r = 0.609, p = 0.003), animal (r = 0.513, p = 0.017) and plant protein (r = 0.534, p = 0.013) 
intake. At six months, WC correlated with animal protein (r = 0.517, p = 0.028) intake. 
Conclusion: Transplant candidates had significant weight loss after six months. Transplant 
recipients experienced a significant increase in waist circumference from baseline to six months. 
At baseline, weight correlated with total protein, animal and plant protein.  At six months, WC  
correlated with animal protein. 
 
Keywords: Kidney transplant candidates, Kidney transplant recipients, Human 
immunodeficiency virus (HIV), Adiposity, BMI, Waist circumference, Weight, Metabolic 







The increasing prevalence of overweight and obesity in the general population over the past 
three decades is of global health concern. Increasing body mass index (BMI) corresponds to a 
greater risk of certain cancers, cardiovascular disease (CVD), Type 2 diabetes mellitus and 
higher rates of mortality (1). In end stage renal disease (ESRD), overweight and obesity, defined 
by BMI are also related to health, although the implications in the pre- and post-transplant 
population are more complex.  
 
In candidates, wait-listed for a transplant, BMI has an inverse relationship with mortality. 
Higher BMIs afford greater survival benefits when compared to normal or underweight 
candidates. The lowest mortality rates have been observed among those in the >35 kg/m2 BMI 
category, while a low BMI (< 20 kg/m2), or muscle mass, and reductions in either of these 
indicators over time are associated with a higher mortality risk whilst on dialysis (2). The 
effects of pre-transplant BMI on post-transplant outcomes are less consistent. Obesity at the 
time of transplantation has been associated with delayed graft function (3), a higher risk of graft 
and death‐censored graft failure at BMI above 22–25 kg/m2, with the highest risk observed at 
BMI ≥ 34 kg/m2 (4). Other researchers however, failed to show any long term impact of pre-
transplant obesity on post-transplant outcomes (5).  
 
Following a transplant, increases in body weight of 10% to 35% are known to occur mainly 
during the first year post-transplant (6) and are usually attributable to increases in fat mass (7). 
Weight gain after the first year, is associated with chronic allograft nephropathy (8), new onset 
diabetes after transplantation (NODAT), and a greater risk of graft failure and death (9,10). 
 
Abdominal obesity determined by regional measurements such as waist circumference (WC) is 
also common in transplant recipients (11). It is associated with cardiovascular risk factors (11), 
and is predictive of recipients at high mortality risk (12). Together with CVD risk factors, 
hypertension, hyperglycaemia and dyslipidaemia, it constitutes the metabolic syndrome (MetS) 
(13), which is present in 52.8% of kidney transplant recipients (14). In the general population, 
MetS increases the risk of CVD, coronary heart disease (CHD) and overall mortality (15), 
impaired graft function in transplant recipients (16), and significantly reduces graft and recipient 
survival (17). 
 
Post-transplant weight gain is likely to be influenced by a number of factors including 
demographic clinical variables and lifestyle variables (18-20). Diet is an aspect of the latter and 
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is important in its influence on graft function and CVD risk factors (21). Diet is an important 
modifiable component of weight gain (7), and has previously been studied in transplant 
recipients (18,22,23), but not in the HIV infected population. Therefore the objectives in this 
study population were 1) to determine participants’ weight, BMI and WC at baseline and 
observe changes in these anthropometric indicators after six months, 2) to classify BMI and WC 
in order to determine the prevalence of obesity and MetS, and 3) to determine the relationship 





For this longitudinal study, observational study, prospective participants  were recruited through 
the kidney transplant programme for HIV-infected patients at Groote Schuur Hospital, Cape 
Town. Participants were recruited based on whether they were transplant recipients or transplant 
candidates awaiting a transplant and hence managed on dialysis. From the outset they were 
therefore categorised as: (i) HIV-infected kidney transplant recipients who have received a 
kidney from a HIV-infected donor and (ii) HIV-infected transplant candidates on the waiting list 
to receive a kidney from a HIV-infected donor. Prospective participants were contacted 
telephonically or at their respective outpatient clinics and invited to participate in the study 
which ran from May 2015 to June 2016.  Participants were included if they were clinically 
stable at the time of recruitment. Participants were excluded if they declined participation, were 
severely ill, were not contactable, uncooperative or had missed several interview appointments 
(typically two or more without reason). In total, seventy six patients agreed to participate, from 
whom written informed consent was obtained. The study was approved by The University of 
KwaZulu-Natal’s Biomedical Research Ethics Committee (Approval number BE 327/13).  
 
6.2.2 Socio-demographic and clinical information 
 
Socio-demographic information was collected using an interviewer-administered structured 
questionnaire, developed for the purpose of the study. Clinical information was obtained from 
medical records or during participant interviews. The socio-demographic questionnaire was 








Dietitians were recruited to take anthropometric measurements due to their training and 
experience in this area. In addition, all dietitians received a brief refresher training session 
which was followed by a post-training test. To ensure uniformity and appropriate standards of 
training, both the training and the test were accredited for continuing professional development 
(CPD) purposes with the Health Professions Council of South Africa (HPCSA). All body 
measurements namely weight (WT), height (Ht) and waist circumference (WC) were taken 
using protocols described in the National Health and Nutrition Examination Survey (NHANES) 
anthropometry procedure manual (24). Height in centimetres (cm) and weight in kilograms (kg) 
were obtained using equipment present at various outpatient and dialysis centres. Weights 
measurements of dialysis patients were taken post-dialysis (dry weight). WC (cm) was 
measured using standardised measuring tapes (SECA 201, Germany). A mean of three readings 
were recorded. BMI and WC were used as measures of overall and central adiposity 
respectively. BMI was calculated as WT divided by Ht squared (kg/m2) and classified according 
to the World Health Organization categories: Underweight (<18.5), normal (18.5 – 24.9), 
overweight (≥ 25.0-29.9), obese class I (30.0-34.9), obese class II (35.0-39.9) and obese class III 
(≥ 40) (1). WC cut-offs used, were WC ≥ 88cm for women and ≥ 102cm for men that indicated 
a substantially increased risk for metabolic complications (25).  
 
6.2.4 Biochemical metabolic parameters 
 
Participants had their blood samples tested through the National Health Laboratory Services 
(NHLS) or through any one of three private laboratories across the six provinces. The choice of 
laboratory was based on their proximity to the laboratory to their place of work or place of 
residence, whether they were state or private patients or whether the laboratory was their usual 
laboratory service provider. Serum glucose and lipids were measured in the morning after an 
overnight fast. Serum total cholesterol (TC) and glucose were determined enzymatically using 
cholesterol oxidase and glucose hexokinase respectively. Triglycerides (TG), high-density 
lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL) were determined 
using the enzymatic colour test on Beckman Coulter analysers. Serum albumin was measured 
using the bromocresol green colour reaction method, with a cut-off of < 38g/l set as a criterion 






6.2.5 The metabolic syndrome 
 
The presence of MetS was based on a recent consensus definition of MetS that encompasses the 
MetS definitions of the International Diabetes Federation (IDF), American Heart Association 
(AHA) and the National Heart, Lung and Blood Institute (NHLBI) (13).  Using this definition, 
MetS is diagnosed as the presence of any three of five given criteria listed in Table 6.1. It 
should be noted that the WC used in this MetS definition differs from the general WC cut-offs 
(paragraph 6.2.3). 
 
Table 6.1: Consensus definition of the metabolic syndrome   
 
Metabolic Syndrome Criteria 
Raised WC using ethnic specific cut-offs a, b 
Triglycerides ≥ 1.7 mmol/l 
HDL-Cholesterol < 1.03 mmol/l for males and < 1.29 mmol/l for females 
Blood pressure  ≥ 130/85mm/Hg 
Fasting plasma glucose ≥ 5.6 mmol/l 
a WC ≥ 94cm for males or ≥ 80cm for females, based on European data in the absence of suitable WC 
cut-offs for African ethnic groups. 
b In the absence of a WC measurement, BMI > 30kg/m2 assumed the presence of central obesity (27) 
Participants also met the criteria if they were receiving medication to manage hypertension, diabetes or 
were on treatment for lipid abnormalities (27) 
 
6.2.6 Dietary intake 
Macronutrient intake was obtained from a single quantified 24-hour recall. These were 
administered by registered dietitians with experience in recording of dietary intake data. 
Additional training was provided to ensure the use of standardized protocols during the dietary 
interview technique such as the use of similar probing questions to minimise interviewer bias. 
(28). Portion size estimation was improved through the use of household measuring utensils and 
a food-portion booklet that referenced food portions against common household objects, 
applicable to the South African context (29).  All dietary data was analysed using Foodfinder 3 
for WindowsR (The South African Medical Research Council), and macronutrient content of the 







Data was analysed using the Statistical package for Social Sciences (SPSS®) version 25.0.  
Means and standard deviation were calculated for all continuous variables, while frequencies 
and  percentages were calculated for categorical variables.  A p value of <0.05 was taken as 
statistically significant. 
Chi-square test of independence or Fisher’s exact test was used to test for differences in 
categorical variables between the two treatment groups. The means of groups were compared at 
baseline and 6 months using the independent samples t-test. The change in weight and WC from 
baseline to six months was calculated for all participants with both sets of weights, and 
expressed as a percentage. Paired samples t-test was used to determine whether the changes in 
weight between the two assessment points differed significantly. Pearson’s correlation 
coefficients were used to calculate the strength of the associations between macronutrients, 
weight and WC. 
 
6.3 Results 
6.3.1 Participant baseline characteristics 
 
Participants were divided into two groups. There were 22 HIV-infected kidney transplant 
recipients who had already received a kidney from a HIV-infected donor, and 54 HIV-infected 
kidney transplant candidates on the waiting list to receive a kidney from a HIV-infected donor. 
The latter were managed on haemodialysis (HD) (n = 51) or peritoneal dialysis (PD) (n =3). 
 
Demographic and nutritional characteristics of the study population are given in Table 6.2. The 
study population, who were predominantly black (93.4 %), had an average age of 43.6 ± 8.1 
years. More participants were male (60.5%) than female (39.5%). Transplant candidates were 
on dialysis for an average of 3.9 ± 3.0 years (range: 0.3 - 11.5 years), while transplant recipients 
averaged 2.7 ± 2.3 years (range: 0.0 – 6.8 years) since transplantation. In terms of pre-existing 
comorbidities, most participants were hypertensive (92.1%), while only four had 
hypercholesterolemia. There were significantly more patients with diabetes amongst the 
candidates compared to the transplant recipients (29.6% versus 4.5%, p = 0.017). Transplant 
recipients had higher mean CD4 cell count (447.3 ± 282.70 cells/µL versus 382.1 ± 178.02 
cells/µL), and higher viral loads with 94.7% versus 79.6% of patients with levels lower than 
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detectable limits. There were no other significant differences in demographic and clinical 
characteristics between the two groups. 
 
Table 6.2:   Socio-demographic and clinical characteristics of the study sample  
 
Patient Characteristics  Whole group 
N = 76 
Transplant 
candidates 
n = 54 
Transplant 
recipients 
n = 22 
Age (years)  43.6 ± 8.1 (28.0 – 
63.0) 
  
Gender     
Male  46 (60.5)   
   Female  30 (39.5)   
Ethnicity     
Black  71 (93.4)   
Coloureda  4 (5.3)   
White  1 (1.3)   
Type of treatment     
Transplant    22 (28.9) 
Haemodialysis   51 (67.1)  
Peritoneal dialysis   3 (3.9)  
Length of time on  
current treatment (years) 
  3.9 ± 3.0 
range: 0.3 - 11.5 
2.7 ± 2.3 
range: 0.0 – 6.8 
Chronic illness     
Diabetes   16 (29.6) a 1 (4.5) b 
Hypertension   51 (94.4) 19 (86.4) 
Hypercholesteraemia   3 (5.6) 1 (4.5) 
CD4 cell count 
(cells/mm3)c 
  382.1 ± 178.0 447.3 ± 282.7 
Viral load (copies /ml) d     
 LDL   39 (79.6) 18 (94.7) 
≤ 10 000   7 (14.3) 1 (5.3) 
> 10 000   3 (6.1) 0 (0.0) 
Data expressed as percentages or means with standard deviation,  LDL: lower than detectable limit 
a In South Africa, refers to individuals of mixed race ancestry 
b Significantly more transplant candidates than recipients were diabetic Fischer’s exact test, p = 0.017 
c transplant patients: n = 20 , dialysis patients: n = 52 
d transplant patients: n = 19, dialysis patients: n = 49  
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6.3.2 Clinical and nutritional characteristics of transplant candidates  
 
Transplant candidates had a lower mean serum albumin than transplant recipients (35.9 ± 4.5g/L 
and 37.2 ± 4.8g/L versus 43.1 ± 4.1g/L and 41.3 ± 4.1g/L) at baseline and six months 
respectively. The low mean values of the candidates classified the majority as 
hypoalbuminaemic, especially at baseline when significantly more had hypoalbuminaemia 
(62.5%), compared to transplant recipients (10.0%) with hypoalbuminaemia (χ2 (1) = 15.619, p 
< 0.0005). 
 
The mean weights and BMIs for transplant candidates at baseline was 73.9 ± 13.1kg and 26.3 ± 
4.8kg/m2 respectively. This classified 20/52 (38.5%) as overweight and 19/52 (36.5%) as 
normal weight. There were 11/52 (21.2%) in the obese class I category and one participant each 
(1.9%) who was underweight and obese class II. At six months, mean weights and BMIs 
decreased to 72.4 ± 13.1kg and 25.7 ± 4.8 kg/m2 respectively. Fifty one transplant candidates 
had weights at baseline and six month follow-up, to enable the longitudinal calculation of 
weight change from baseline to six months (figure 6.1). Eighteen out of fifty one (35.3%) 
experienced weight gain, while weight remained static in one candidate (1/51, 2.0%). The 
majority of candidates 32/51 (62.7%) had lost weight.  Paired samples t-test which was applied 
to analyse the weight change between the two time points, determined the mean weight lost 
from 73.1 ± 12.9 kg to 72.4 ± 13.1  kg, as statistically significant (t(50) = 2.072, p = 0.043).  
 
Only 36 and 46 patients had WC values at baseline and six months respectively.  Mean WC 
from baseline to six months also decreased slightly from 92.2 ± 14.1cm to 90.7 ± 14.2cm, 
although no significant difference in WC between the two time points could be found. The 
WHO cut-offs (WC ≥ 88cm for women and ≥ 102cm for men), classified 33.3% with central 
obesity at baseline and 30.4% at six months, whereas BMI (> 30.0 kg/m2) classified 23.1% as 
obese at baseline and 18.3% at six months. MetS was present in 19/40 (47.5%) of transplant 




        
 
Figure 6.1: Percentage change in weight after six months in the transplant candidates and 
recipients  
*Significantly more transplant recipients’ weight remained static (f = 9.918, p = 0.005) 
 
 
         
 
Figure 6.2: The prevalence of the metabolic syndrome in transplant candidates and recipients at 
                    baseline and six months 
 
Dietary intake of both treatment groups are shown in Table 6.4. The mean daily energy intake of 














































7849.0 ± 2093.9 kj/day). This amounted to 25.9 ± 7.8 and 26.4 ± 8.4 kcal/kg/day; lower than 
that recommended by the South African (SA) renal guidelines. Mean daily protein intake was 
72.5 ± 27.5g at baseline and increased to 76.3 ± 31.4g/day at six months, contributing 15.3 ± 4.2 
% and 15.9 ± 4.2 % of total energy respectively. Plant protein contributed about a third, while 
two thirds was sourced from animal protein. The mean daily protein intake was calculated at 1.0 
± 0.4g/kg/day and 1.1 ± 0.4 g/kg/day, which was lower than recommendations by the SA renal 
guidelines for HD (1.2g/kg/day) and PD (1.2-1.3g/kg/day). At baseline and at six months, the 
percentage carbohydrate intake was 54.0 ± 10.6 % and 51.2 ± 10.7 %, while fat contributed 28.5 
± 9.1 % and 30.6 ± 9.1 % towards daily energy. Both the percentage distribution of total 
carbohydrate and total fat were within the 50% to 60% and 25% to 35% recommended 
guidelines. There were no significant difference between nutrients at baseline and six months. 
Correlation analysis showed no significant relationships between macronutrients and weight or 
WC at either time point or with the weight change over six months. 
 
6.3.3 Clinical and nutritional characteristics of transplant recipients 
 
The mean weight and BMI of recipients at baseline was 70.2 ± 17.2kg and 24.5 ± 4.6 kg/m2 
respectively, classifying the majority as having a normal BMI (71.4%) (Table 6.3).  Compared 
to transplant candidates, the difference in BMI classification was most pronounced at baseline, 
when significantly more transplant recipients had a normal BMI (71.4%) while more transplant 
candidates were overweight (Fisher’s exact = 9.004, p = 0.033). No transplant recipient was 
underweight at baseline, while 2/21 (9.5%) and 4/21 (19.0%) were overweight and obese class I 
respectively. 
 
At six months, the majority of transplant recipients 11/21 (52.4%) experienced an increase in 
weight, while 6/21 (28.6%) lost weight and 4/21 (19.0%) showed no change in weight (Figure 
6.1). Significantly more transplant recipients’ weight remained static (f = 9.918, p = 0.005), 
compared to candidates. Consequently, mean weights and BMIs were higher from 70.2 ± 17.2 
kg to 71.1 ± 18.3 kg and from 24.5 ± 4.6 kg/m2 to 25.6 ± 5.8 kg/m2, although this increase from 
baseline was not  significant. At six months however, one transplant recipient was classified as 
underweight and fewer patients had normal BMIs (59.1%). Six out of twenty two recipients 
(27.3%) were classified as obese class I.  
 
WC values were available for 18 recipients. Mean WC increased from 89.6 ± 13.1cm to 95.8 ± 
12.3 cm. This increase in WC from baseline to six months was found to be statistically 
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significantly, paired samples t-test: t(14) = -2.861, p 0.013. WC cut-offs classified 33.3% as 
obese at baseline and 44.4% as obese at six months, whereas BMI only classified obesity at 
19.0% and 27.3% at baseline and six months respectively. MetS was less prevalent among 
transplant recipients than candidates (Figure 6.3), with 6/17 (35.3%) transplant recipients 
meeting the criteria for MetS at baseline and 7/20 (35.0%) at six months.   
 
The macronutrient intake of transplant recipients was very similar to that of transplant 
candidates with the mean daily intake of total energy and protein falling within the 25 - 30 
kcal/day and 1.0 -1.1g protein (maintenance)/kg/day recommendations.  The mean daily energy 
intake of transplant recipients was slightly higher than transplant candidates with baseline and 
six months values respectively being  8142.5 ± 2067.8 kj/day and 8029.9 ± 2361.6 kj/day. At 
28.6 ± 7.8 and 27.7 ± 9.1 kcal/kg/day, total energy requirements fell within the 
recommendations of 25 - 30 kcal/kg/day. Mean daily protein intake was 72.7 ± 26.8g at baseline 
and increased to 78.0 ± 22.2g/day at six months, contributing 14.6 ± 3.9% and 16.4 ± 3.8% of 
total energy respectively. Per kg per day, the mean value at baseline was 1.0 ± 0.3g, which met 
the guideline protein amount required for maintenance, namely 0.8-1.0g/kg/day.  At six months, 
mean daily intake increased to 1.1 ± 0.3g/kg/day exceeding these recommendations. Plant 
protein intake was 28.3 ± 14.6g/day and decreased slightly to 26.3 ± 13.7g at six months. Mean 
daily animal protein intake was 39.0 ± 19.2g/day increasing to 48.6 ± 20.0g/day.  At baseline 
and six months, percentage carbohydrate intake was 55.0 ± 10.7% and 51.3 ± 8.9%. Fat 
contributed 28.3 ± 9.3% and 30.2 ± 8.0% towards daily energy. Both the percentage distribution 
of total carbohydrate and total fat met the 50% - 60% and 25% - 30% recommended guidelines. 
There were no significant differences between nutrients at baseline and six months.  
 
The independent samples t-test was conducted to test if mean values differ across each group. 
There were no significant differences in any nutrient between the two treatment groups.  
Pearson’s correlation was used to identify relationships between macronutrient intake and 
anthropometric indices. Although none were found in the transplant candidate group, several 
correlations were identified among transplant recipients. At baseline, weight correlated with 
total protein (r = 0.609, p = 0.003), animal (r = 0.513, p = 0.017) and plant protein (r = 0.534, p 
= 0.013). At six months, a moderate to strong correlation was established between WC and 
animal protein (r = 0.517, p = 0.028). There was no correlation between any of the 
macronutrients and change in weight or WC.  There was also no relationship between energy, 
total fat and carbohydrate with weight or WC. 
 133 
 
Table 6.3: Nutritional and clinical characteristics of transplant candidates and recipients  
  Nutritional Characteristics Transplant candidates 
 
 Transplant recipients 
 
 n Baseline n 6 months  n Baseline n 6 months 
Albumin (g/L) 48 35.9  ± 4.5 52 37.2  ± 4.8  20 43.1 ± 4.1 22 41.3 ± 4.1 
Hypoalbuminaemia (<38g/L)  30 (62.5) a  26 (50.0) a   2 (10.0)  3 (13.6) 
Normal albumin (≥38g/L)  18 (37.5)  26 (50.0)   18 (90.0)  19 (86.4) 
Weight (kg) 54 73.9 ± 13.1 51 72.4 ± 13.1  21 70.2 ± 17.2 22 72.6 ± 19.1 
Weight change 51 73.1 ± 12.9b 51 72.4 ± 13.1b  21 70.2 ± 17.2 21 71.1 ± 18.3 
Height (cm) 52 167.4 ± 8.3    22 168.4 ±10.1   
BMI (kg/m2)  52 26.3 ± 4.8 49 25.7 ± 4.8  21 24.5 ± 4.6 22 25.6 ± 5.8 
Underweight   1 (1.9)  1 (2.0)     1 (4.5) 
Normal   19 (36.5)  19 (38.8)   15 (71.4) c  13 (59.1) 
Overweight   20 (38.5) c  20 (40.8)   2 (9.5)  2 (9.1) 
Obese Class I   11 (21.2)  8 (16.3)   4 (19.0)  6 (27.3) 
Obese Class II   1 (1.9)  1 (2.0)      
WC (cm) 36 92.2 ± 14.1 46 90.7 ± 14.2  18 89.6 ± 13.1c 18 95.8 ± 12.3c 
Central obesity prevalence 36 12 (33.3) 46 14 (30.4)  18 6 ( 33.3) 18 8 (44.4) 
Total cholesterol (mmol/l) 43 4.2 ± 0.9 49 4.1 ± 0.9  19 4.5 ± 1.2 21 4.4 ± 1.3 
HDL cholesterol (mmol/l) 37 1.2 ± 0.3 48 1.2 ± 0.4  17 1.3 ± 0.3 20 1.3 ± 0.5 
LDL cholesterol (mmol/l) 37 2.4 ± 0.8 48 2.3 ± 0.7  15 2.4 ± 1.0 18 2.2 ± 1.1 
Triglycerides (mmol/l) 37 1.57 ± 1.08 48 1.47 ± 0.96  17 2.09 ± 1.85 20 1.86 ± 1.34 
Fasting glucose (mmol/l) 41 5.5 ± 2.4 47 5.23 ± 1.9  21 5.4 ± 1.1 21 5.0 ± 0.7 
Metabolic syndrome 40 19 (47.5) 49 25 (51.0)  17 6 (35.3) 20 7 (35.0) 
Data expressed as means with standard deviation or frequencies with percentages 
a At baseline, significantly more candidates had hypoalbuminaemia than recipients, chi Square test:  χ2 (1) = 15.619, p <0.005) 
b Significant weight loss, paired samples t-test: t (50) = 2.072, p = 0.043 
c Significant WC increase, paired samples t-test: t (14) = - 2.861, p = 0.013 
Significantly more transplant recipients had normal BMI at baseline while transplant candidates were overweight, Fisher’s exact = 9.004, p=0.033. 




Table 6.4: Macronutrient intake of transplant candidates and recipients at baseline and six months 
   
Transplant candidates 
 
 Transplant recipients 
   Baseline 
n = 53 
6 months 
n = 51 
SA reference values†  Baseline 
n = 22 
6 months 
n = 22 
SA reference values† 
Total energy (kj/day)  7786.2 ± 1919.1 7849.0 ± 2093.9   8142.5 ± 2067.8 8029.9 ± 2361.6  
Energy (kj/ kg BW/day)  108.1 ± 32.4 110.5 ± 35.0   119.6 ± 32.5 115.7 ± 38.1  
Energy (kcal)/ kg BW / day  25.9 ± 7.8 26.4 ± 8.4 30 – 35 kcal/kg/day  28.6 ± 7.8 27.7 ± 9.1 25 -30 kcal/kg/day 
% Protein energy  15.3 ± 4.2 15.9  ± 4.2   14.6 ± 3.9 16.4 ± 3.8  
Total protein (g/day)  72.5 ± 27.5 76.3 ± 31.4   72.7 ± 26.8 78.0 ± 22.2  
Plant protein (g/day)  23.7 ± 9.2 23.1 ± 9.3   28.3 ± 14.6 26.3 ± 13.7  
Animal protein (g/day)  45.7 ± 29.4 51.5 ± 30.8   39.0 ± 19.2 48.6 ± 20.0  
Total protein /kg BW/day  1.0 ± 0.4 1.1 ± 0.4 HD: 1.2g/kg/day 
PD: 1.2-1.3g/kg/day 
 1.0 ± 0.3 1.1 ± 0.3 0.8-1.0g/ kg/ day 
Fat energy (%)  28.5 ± 9.1 30.6 ± 9.1 25 -35 %/day  28.3 ± 9.3 30.2 ± 8.0 25 -30 %/day 
Total fat (g/day)  62.3 ± 27.9 66.9 ± 27.3   64.6 ± 26.8 67.3 ± 30.6  
CHO energy (%)  54.0 ± 10.6 51.2 ± 10.7 50-60%/ day  55.0 ± 10.7 51.3 ± 8.9 50-60%/ day 
Total CHO (g/day)  229.9 ± 63.0 220.0 ± 66.6   245.0 ± 75.0 228.8 ± 79.3  
Data expressed as means with standard deviation 






Table 6.5: Correlation coefficients between macronutrients and weight and waist circumference 













The present study investigated overall and central obesity, through longitudinal observation of 
weight, BMI and WC in HIV-infected kidney transplant candidates and recipients from a HIV-
infected donor.  In addition, the macronutrient composition of the diet and their association with 
weight, WC and their respective changes after six months, was also explored. 
 
6.4.1 Transplant candidates 
In the present study, more transplant candidates were overweight than normal weight, which is 
in line with anthropometric characteristics of dialysis patients elsewhere (31), and is reflective 
of the trend, both globally and in South Africa, of increasing BMI in the general population (32-
34). 
Due to the paradoxical association between a high BMI and enhanced survival in the dialysis 
populations (35), a more pressing concern would be to patients with a low BMI or weight loss 
while on dialysis. A low BMI carries a two-fold higher mortality risk than HD patients with 
normal BMI (36), as weight loss and muscle loss over time is associated with a higher mortality 
rate. Furthermore, it has also been shown that of the two indicators, muscle loss is more serious 
as it is a stronger predictor of mortality than overall weight loss (35). In the current study, 
weight loss was experienced by the majority of candidates over the six month follow-up period. 
Furthermore, the magnitude of weight lost between the two assessment points was found to be 
statistically significant. Although, weight loss could mean a reduction in either fat, muscle, or 
 Weight  
(n = 21) 
 Waist circumference 
(n = 18) 
  r  p   r p 
Total energy (kj/day) 0.252 0.270  0.114 0.652 
Total protein (g) /day 0.609** 0.003  0.428 0.076 
Plant protein (g) /day 0.534* 0.013  - 0.158 0.532 
Animal protein (g) /day 0.513* 0.017  0.517* 0.028 
Total fat (g) / day 0.065 0.778  0.214 0.393 
Total CHO (g) /day 0.084 0.718  - 0.074 0.772 
r =Pearson’s correlation 
kj: kilojoule, CHO: carbohydrate 





both, it is highly likely that in the current study, the loss of weight seen at six months was not 
limited to adipose tissue.  The reasoning behind this is that decreases in weight are typically 
accompanied by decreases in WC when there is a reduction in body fat (37). In the present 
study, the decrease in overall weight was significant, while the decrease in WC after six months, 
was slight and not statistically significant. Therefore, the probability that some of the weight 
loss could be attributed to muscle mass is high, and would be important to investigate to enable 
the initiation of appropriate interventions.    
 
Abdominal obesity using the WHO WC cut-offs (WC ≥ 88cm for women and ≥ 102cm for 
men), identified 33.3% and 30.4% of transplant candidates, at both time points, with a high WC 
in the current study.  An Italian cohort of dialysis patients reported an even higher prevalence of 
abdominal obesity (39%) using the same cut-offs (38). The authors also documented that a WC 
of ten centimetres above the male and female cut-offs of 102 cm and 88 cm respectively, 
corresponded to a 26% and 38% higher risk for general and CVD-related mortality respectively. 
Moreover, it was noted that since BMI was inversely related to both these outcomes, patients at 
the greatest mortality risk had a low BMI and high WC. Conversely, better survival was 
observed in patients with a higher BMIs and a lower WC (38). 
 
The MetS definition used in the current study, stipulates an even lower cut-off than the WHO 
for WC, i.e ≥ 94cm for males and ≥ 80cm for females, which classified 47.5% and 51.0% of 
candidates with MetS at baseline and six months respectively. Differences in MetS definitions 
notwithstanding, the prevalence of MetS in other dialysis groups has been reported to range 
from 34.0% to 67% HD patients (39,40), and between 53.2% and 66.3% in PD patients (41).  
Wait-listed candidates with MetS are at a 2.6 fold risk of new-onset diabetes mellitus (NODAT) 
(39), which by itself is associated with graft loss and CVD risk and mortality (42), highlighting 
the importance of controlling individual MetS components (39). 
In terms of dietary adequacy, neither mean total energy nor protein intake met the recommended 
daily energy and protein intake for HD and PD (30), falling short in these nutrients at both 
assessments, despite a slight increase in protein intake at six months. Correlational analysis 
showed no relationship between macronutrients and weight, WC or weight change. This is not 
unusual, as weight loss in disease states is known to occur for reasons other than dietary intake. 
In CKD, a host of factors, including chronic inflammation, hypercatabolism, endocrine 
abnormalities and metabolic acidosis contribute to malnutrition (43), as does the presence of 




therapy, are known to live with chronic low grade inflammation (44). The possibility of illness 
related weight loss is further evidenced by the presence of hypoalbuminaemia, found in the 
majority of the present study’s transplant candidates. Hypoalbuminaemia is a recognised marker 
of illness and is usually not related to diet in CKD (45).  It fact it is a poor indicator of 
nutritional status due to poor correlation with other nutritional markers in dialysed patients (46). 
It is however a useful predictor of CVD. De Mustert and colleagues noted that in dialysis 
patients, each 1g/dL decrease in serum albumin increases the risk of mortality by 47% and 38% 
in HD and PD patients respectively (47), and as such, is an important marker to observe in terms 
of disease status.  Although diet was not linked to weight loss in the present study, a poor intake 
will no doubt exacerbate it (43), and will require attention to minimise weight loss and preserve 
muscle mass.  
 
6.4.2 Transplant recipients 
With a mean BMI of 24.5 ± 4.6 kg/m2, the majority of recipients (71.4%) fell within the normal 
BMI category.  After six months, 59.1% had a normal BMI, due to weight changes in all but 
19.0% of recipients, whose weight remained static. The proportion of recipients with weight 
gain was not unlike that seen in kidney transplant recipients in the general population.  The 
majority of recipients, (52.4%) showed increases in weight after six months, similar to previous 
studies that reported weight gain in 50.0% and 55.9% of recipients respectively (18,48). Twenty 
eight percent (28.0%) of transplant recipients lost weight at six month follow-up. Some weight 
loss occurs immediately following a transplant, due to increased surgery-related catabolism, 
fluid loss and inadequate dietary intake, although this is quickly restored (49).  According to 
Dujovonic et al, comorbidity is an important determinant of malnutrition following a transplant 
(50).  Indeed, HIV-related factors may have also contributed to the weight loss documented. In 
the current study,  recipients appear to be well managed, as was evident from their favourable 
HIV parameters (CD4 and VL), indicative of disease progression and response to anti-retroviral 
therapy (51). 
 
In the present study, WC identified 33.3% and 44.4% with central adiposity and high metabolic 
risk, whereas BMI classified 19.0% and 27.3% as obese at baseline and six months respectively.  
This increase in mean WC observed from baseline to six months was found to be statistically 
significant, and was a noteworthy finding in this study.  Interestingly, this occurred without 
significant increases in BMI over the same period. Similar outcomes were reported by Harada 
and colleagues who noted near static BMIs, despite significant increases in percentage body fat 




transplant recipients. According to Romegurro et al, when changes in WC occur independent of 
corresponding changes in weight or BMI, they are in all likelihood, reflective of changes in 
visceral adipose tissue (VAT) (54). This poses a concern for the present transplant recipients as 
VAT is metabolically active, and is associated with lipid abnormalities, hypertension and 
hyperglycaemia which are all risk factors for CVD (55,56). The clustering of these risk factors 
and central obesity identified about 35.0% of transplant recipients with MetS, which falls within 
the prevalence values of MetS in the HIV infected population (11.2% - 45.4%) (57). Moreover, 
in the transplant population, it appears that the prevalence of MetS increases over time (58). 
MetS was identified in 28.6% of recipients at one year post transplant (59), 37.7% at 18 months 
(17), and 63.0 % at six years post-transplant (16). In comparison, it appears that the 35.0% 
prevalence of MetS among the current study’s transplant recipients at a mean post-transplant 
time of 2.7 ± 2.3 years is seemingly in line, if not lower than the prevalence of MetS in 
transplant recipients in the general population. 
 
In the present study, the mean daily intake of total energy and protein was within the 25 - 
30kcal/day and 1.0 - 1.1g protein (maintenance)/kg/day recommendations (30).  At six months, 
there was an increase in total protein intake. This increase was not statistically significant, and 
still within the recommended limits. Total fat also increased, especially saturated fat, probably 
due to the greater proportion of animal protein consumed at the six month assessment. Unlike 
the transplant candidates, there was a significant association between total protein, animal and 
plant protein and weight at baseline. At six months, only animal protein showed a significant 
correlation with WC. There was no association between protein and change in weight or WC. 
 
The association between protein and weight has previously been described in the general 
population. In a small number of healthy subjects, a longitudinal study spanning six years found 
that higher intakes of protein was associated with weight gain. Using bioelectrical impedance, 
researchers also showed that most of the weight gained was fat mass (60). Similarly, in the 
larger European EPIC-PANACEA cohort with 373 803 healthy participants, a positive 
correlation with protein and weight over a five year follow-up period was also found. 
Specifically, it was noted that 5.0% more protein energy that replaced either fat or carbohydrate 
energy, was positively associated with weight gain when intakes exceeded 22.0% of energy, 
normal weight and overweight participants had a 23 % - 24% greater chance of becoming 
overweight or obese (61). In the current study, the mean intake of 14.6 ± 3.9% at baseline 




guidelines, it would be an important to ensure that total protein does not exceed the guideline 
limits, given the greater dietary freedom after the restricted protein intake while on dialysis. 
Bujnowski and colleagues, further investigated the source of protein linked to weight gain. 
Their results found a statistically significant positive association between dietary protein 
obtained from animal sources and obesity (62).  Halkjaer et al found that weight increases over 
the long term, was linked to a higher overall protein intake, and protein sourced from animal 
products, specifically red meat and processed meat as opposed to protein derived from fish and 
dairy produce (63). Unlike the results of the current study, these authors did not find any 
relationship between protein and WC (63). However, this association was observed in other 
research.  Moslehi et al, investigated the association between macronutrients and changes in 
visceral fat over three years. Their results showed that independent of total energy, higher 
overall protein intake as well as monounsaturated fats from animal sources may contribute to 
increases in harmful visceral fat (64).  Results from the EPIC study also point to dietary patterns 
that are important to consider in preventing harmful increases in WC. Foods with a high energy 
density and a high glycaemic index are most likely to contribute to the deposition of VAT (54). 
Therefore to reduce abdominal obesity, the diet should include low glycaemic index, low energy 
density, and high fibre foods. Dietary intakes high in fruit and dairy and low in white bread, 
processed meat, margarine, and soft drinks may also help to prevent abdominal fat accumulation 
(54,65). 
What is promising, is that diet is modifiable and long term interventions have shown some 
success. Transplant recipients that receive rigorous nutritional assessment and regular follow-
up, gain less weight after ten years than those who receive standard nutrition education 
immediately following the transplant (66). The results in the current study and the 
aforementioned research are useful in highlighting key areas for nutrition education.  With the 
exception of very low calorie diets (67), interventions that target diet only, have proven 
effective in decreasing weight and VAT by up to 35%, similar to interventions that include both 
diet and exercise (68). The authors caution, though, that interventions that only centre on diet, 
may produce undesired reductions in both lean tissue and skeletal muscle, which can be 
preserved if diet is combined with exercise (68). Moreover, exercise is important in that it helps 
maintain the weight lost. Hunter and colleagues specified that engaging in 80 minutes/week of 
aerobic or resistance activity prevented regain of VAT one year after weight loss, even if small 
regains in weight occurred. On the other hand, the diet-only group who did not include exercise 
as part of their weight loss programme, showed a 25% gain in VAT after one year (69). 




research conducted on transplant recipients found very little change activity levels after six 
months (70). Indiscriminate dietary intake, and a sedentary lifestyle could result in unchecked 
increases in weight, WC and harmful VAT.  
 
Limitations inherent to dietary intake studies are also applicable to the current study. This 
includes the inaccurate estimation of quantity, recall bias and misreporting (28). Furthermore, a 
single 24-hour recall is less likely to be a valid reflection of habitual intake, lowering the 
likelihood of significant correlations with individual nutrients. On the other hand however, 
intake information provided some constructive dietary insight for this study and for future 
research. For example, plant versus animal protein intake is important and was briefly 
mentioned within the scope of this study. However, given the emerging literature on animal 
versus plant protein distribution in CKD, future research with a focus in this area would be 
beneficial. Another drawback is that data on lipodystrophy was not collected, which could have 
affected the interpretation of the anthropometric measurement taken.  Strengths of this study are 
the inclusion of WC, which is a more valid measurement of abdominal obesity than BMI alone 
and the associated health risks. This study is the first to investigate adiposity in HIV infected 
pre- and post-transplant recipients from HIV infected donors.  
 
To summarise the present study, transplant candidates experienced significant weight loss. The 
underlying causes should be investigated and individual intervention planned accordingly. WC 
increased significantly for transplant recipients over the six month follow-up period, 
Furthermore, as WC increased without significant changes in BMI, it is possibly the result of 
increases in VAT. These results reinforce the importance of including WC as a routine 
anthropometric indicator when screening. Regular exercise and on-going nutrition assessment 
and education should aim not only to maintain a healthy BMI, but also to keep WC within 
healthy limits. The correlations of overall protein intake with weight at baseline, and animal 
protein with WC at six months amongst transplant recipients, is important for counselling. 
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HEALTH RELATED QUALITY OF LIFE AND ASSOCIATED FACTORS IN  
HIV-POSITIVE TRANSPLANT CANDIDATES AND RECIPIENTS FROM A  
HIV-POSITIVE DONOR  
 
ABSTRACT  
Background: The assessment of health-related quality of life (HRQOL) furthers the 
understanding of living with a disease and its treatment, beyond clinical indicators of health. A 
better HRQOL has been reported in kidney transplant recipients compared to transplant 
candidates on dialysis. Globally, HRQOL in transplant candidates and recipients who are also 
infected with HIV and are awaiting a kidney, or have received one from a HIV-positive donor, 
has not been previously investigated. 
Objective: To evaluate the HRQOL of HIV-positive kidney transplant candidates and 
recipients from HIV-positive donors at baseline and six months, and to determine the 
relationship between socio-demographic, clinical and nutritional status and HRQOL indicators. 
Methods: A six month longitudinal study was undertaken using a mixed methodology 
approach. The Short Form-36 (SF-36) questionnaire was used to quantitatively score patients’ 
perceptions of HRQOL. Face-to-face interviews provided a more in-depth understanding of the 
SF-36 scores. Nutritional status indicators were determined by mid arm muscle circumference, 
prealbumin and BMI. 
Results: 68 patients completed the SF-36 at baseline and 6 months.  
Transplant candidates: Transplant candidates had lower HRQOL than recipients. The main 
mental stressors were income, employment and waiting for a donor. Physical health complaints 
were body pain and fatigue. Prealbumin and BMI was positively correlated with general health 
(GH) at baseline (r = 0.401, p = 0.031 and r = 0.338, p = 0.025). Besides a positive association 
with role physical (RP) and body pain (BP), albumin was associated with overall physical 
composite score (PCS) (r = 0.329, p = 0.024) at six months. 
Transplant recipients: Transplant recipients had high HRQOL scores. The PCS and mental 
composite score (MCS) was above the average of 50 for the general population, with PCS being 
53.8 ± 10.0 and 56.6 ± 6.5 at baseline and six months respectively. MCS was 51.3 ± 11.5 and 
54.2 ± 8.5 at baseline and six months respectively. Albumin correlated positively with PCS (r = 
0.464, p = 0.034) at six months and role emotional (RE) (r = 0.492, p = 0.024). Higher 
prealbumin was associated with better RE and RP abilities and MCS (r = 0.495, p = 0.034). 
MAMC was associated with four domains of physical health and strongly correlated with PCS 




Conclusion: Kidney transplant recipients experience a better HRQOL than transplant 
candidates on dialysis, awaiting a transplant. Better nutritional status, indicated by prealbumin 
and MAMC was associated with better mental (MCS) and physical (PCS) HRQOL respectively. 
 
Keywords: Keywords: Kidney transplant candidates, Kidney transplant recipients, Human 








Human immunodeficiency virus (HIV) infection was formerly a contraindication for kidney 
transplantation, until outcomes similar to transplant recipients in the general population were 
observed (1,2). Initially, HIV-negative donors were used (3), until 2008, when South Africa was 
the first country to successfully transplant HIV- positive patients with donor kidneys from HIV- 
positive individuals. By all objective clinical measures the transplant was successful, and HIV 
parameters showed no evidence of hastened HIV disease progression (4).  
 
Traditional clinical markers of this medical breakthrough are important, and have paved the way 
for many more transplants in patients that would have otherwise demised. Recently though, it 
has also become increasingly important to evaluate the benefit-risk of a treatment from the 
perspective of the patient (5). Health related quality of life (HRQOL) refers to the way a patient 
perceives the functional impact of his illness and treatment, on multiple dimensions of his health 
and well-being (5,6). HRQOL in chronic disease and its treatment is very relevant because it 
becomes a part of an individual’s life, intertwining in one’s everyday personal and social 
context (7).  
 
HRQOL studies in end stage renal disease (ESRD) describe the adverse effects of dialysis on 
HRQOL and improvements post-transplant (8). Studies also show that HRQOL relates to 
clinical outcomes in that the physical components of HRQOL which are predictive of graft and 
patient survival in transplant recipients (9). As it is affected by multiple factors in ESRD (10),   
nutritional status is one such factor that is also associated with HRQOL in the general 
population and various patient groups, including HIV (11-14). It is relevant in ESRD as a 
potentially modifiable component of HRQOL. 
 
To date, there has not been a documented study exploring HQOL in ESRD patients, infected 
with HIV or the association with nutritional status. As these patients live with the burden of two 
debilitating diseases, incorporating HRQOL assessments in this group, will provide insight into 
psycho-social factors affecting health, and appraise their current health care, aiding decision-
making to improve all aspects of the patient’s life (15). Within this context, the aim of the 
current study was to evaluate the HRQOL of HIV-positive kidney transplant candidates and 
recipients from HIV-positive donors, and to determine the relationship between clinical, 








For this longitudinal study, observational study, participants were recruited through the renal 
transplant programme for HIV-positive patients at Groote Schuur Hospital.  HIV-positive 
kidney transplant recipients and those on the waiting list receiving dialysis, were contacted 
telephonically or in person at their outpatient clinic and invited to participate. Patients were 
excluded if they were severely ill, declined participation, were not contactable, uncooperative or 
missed several interview appointments (typically two or more without reason). Altogether 76 
patients agreed to participate after the study details were explained to them. Data collection 
commenced in June 2015 and ended in June 2016, during which time participants were followed 
up across six provinces. All measurements were taken at baseline and repeated at six months. 
During the study period, 68 patients completed the SF-36 at baseline and six months.  
 
Written informed consent was obtained from all patients. The study was approved by The 
University of KwaZulu-Natal’s Biomedical Research Ethics Committee (Approval number BE 
327/13), and where necessary from the provincial department of Health. Site permission was 
obtained from all institutions where patients were being followed up.  
 
7.2.2 Socio-demographic and clinical information 
Socio-demographic information was obtained during interviews using a questionnaire designed 
for the purpose of the study. The questionnaire was reviewed for content validity by the research 
supervisors and a research expert with experience in questionnaire design and experience within 
the context of HIV. Where possible, clinical information was obtained from medical records, or 
during patient interviews.  
 
7.2.3 Health related quality of life 
 
HRQOL was measured using mixed methods research to elucidate an in-depth understanding of 
the concept among study participants.    
 
Quantitative measure of HRQOL 
HRQOL was assessed using an interviewer-administered Short Form 36 (SF-36) version 2 (16). 




and is the most commonly used generic measurement of quality of life in renal replacement 
therapy (17). The 36 items on the questionnaire are categorised into eight domains (also called 
dimensions or subscales) of a patient’s health namely; physical function (PF), role physical 
(RP), bodily pain (BP), vitality (VT), social functioning (SF), role emotional (RE), mental 
health (MH), and general health (GH) (18).  Table 7.1 provides a brief description of what each 
domain assesses (19,20). The SF-36 software uses a scoring algorithm to translate the raw data 
into scores for each domain that ranges from 0 (worst health) to 100 (best possible health) 
(21,22). Higher scores reflect better daily functioning and well-being (18). The eight domains 
are further merged into two composite scores, the physical component score (PCS) and mental 
component score (MCS). The average PCS and MCS for the general population is 50 (23). 
Therefore scores above or below 50 suggest better or worse perceived mental or physical health 
respectively, than the average person. A decrease in PCS shows more adverse effects in the 
domains of physical health namely worse body pain, vitality and fatigue as well as greater 
limitations in physical, social and self-care roles and activities. A decreasing MCS shows higher 
levels of mental stress and greater limitations in social activities and functional due to emotional 
stress (24). 
 
The validity of the SF-36 has been shown in various groups across numerous nationalities and 
across different forms of renal replacement therapies (22,25). In the transplant population 
specifically, it has been found to be reliable i.e. internal consistency (22), valid (high correlation 
with general HRQOL assessments), discriminant (can distinguish changes in clinical status) and 
responsive (perceptive to variances in patients before and after transplantation) (26). 
 

















 Physical Functioning (PF) Limitations in daily physical activities such as 
walking and dressing 
Role Physical (RP) Limitations with daily or work related activities 
caused by physical health  
Bodily Pain (BP) Presence of pain and its limitations on daily 
activities 







General Health (GH) An evaluation of one’s general health status, 
compared to others and future expectations 
Vitality (VT) Loss of energy or presence of tiredness or fatigue 
 Social Functioning (SF) Limitations in the time available and type of social 
activities of  e.g. meeting friends 
Role Emotional (RE) Difficulties with daily or work related  activities 
due to emotional problems 
Mental  health (MH) Evaluations of  one’s mood depressive feelings, 
happy, anxious  or nervous 
 
         
Qualitative measure of HRQOL 
Face-to-face interviews were used to generate narratives on life experiences post-transplant or 
while awaiting one. Interviews were semi-structured, using a scope of inquiry developed for the 
purpose of the study with expert input from a clinical psychologist. Questions within the scope 
of inquiry were based on health experiences, support systems, challenges and concerns based on 
a theoretical framework of the literature. The interview guide, probing questions and 
introductory remarks were scripted to enhance reproducibility of the interview process between 
participants. However, questions posed were rephrased to include other constructs as they arose 
during the interview process, enabling the semi-structured interview to serve as a guide rather 
than an inflexible tool (27). The interview commenced with open-ended questions according to 
the scope of inquiry.  However, participants were given the freedom to express their thoughts 
and feelings as they arose.  As participants were not willing to have their interviews recorded, 
all narratives were manually recorded during the interview. Where necessary, areas of 
uncertainty expressed by participants were summarised by the researcher and repeated to allow 
for participant to amend, agree with or expand on content (27). The interviews were conducted 








7.2.4 Anthropometry  
 
Dietitians were recruited based on their training and experience with conducting anthropometric 
assessments. Furthermore, all dietitians received refresher training to further hone their skills, 
followed by a post-training test. All anthropometric measurements namely weight (WT), height 
(Ht), triceps skinfold thickness (TSF) mid upper arm circumference (MUAC) were taken using 
protocols described in the National Health and Nutrition Examination Survey (NHANES) 
anthropometry procedure manual (28). Height in centimetres (cm) and weight in kilograms (kg) 
were measured using available equipment at various outpatient and dialysis centres. Weight 
measurements of dialysis patients were taken post dialysis (dry weight). Arm measurements 
were taken on the non-access arm (29,30). All MUAC (cm) and TSF in millimetres (mm) were 
measured using the same callipers (Slim Guide, USA) and measuring tape (SECA 201, 
Germany). Measurements were taken to one decimal place and the mean of three readings were 
recorded. BMI was calculated as WT divided by Ht squared (kg/m2) and classified according to 
the World Health Organization categories: Underweight (≤18.5), normal (18.5 – 24.9), 
overweight (25.0-29.9), obese class I (30.0-34.9), obese class II (35.0-39.9) and obese class III 
(≥40) (31). Mid arm muscle circumference (MAMC) was a proxy measure of muscle mass. TSF 
and mid upper arm circumference (MUAC) were used to calculate mid arm muscle 
circumference (MAMC) using the equation: 
                 MAMC (cm) = MUAC (cm) – [3.1415 x TSF cm)] (32)  
 
7.2.5 Biochemistry 
Participants had their blood values analysed through the National Health Laboratory Services 
(NHLS), or through any one of three private laboratories across the six provinces. Laboratory 
choice was based on proximity to participant place of work or residence, whether a participant 
was a state or private patient or whether it was their usual laboratory service provider. Serum 
albumin was measured using the bromocresol green colour reaction method, with a cut-off of  
<38g/l set as a criterion for hypoalbuminaemia (33). Prealbumin was measured using the 
nephelometric assay technique as a biochemical marker of malnutrition, as good agreement, 
sensitivity and specificity was previously demonstrated, when compared to detailed nutritional 







7.2.6 Pilot study 
A pilot study was conducted on eight and four HIV-negative transplant candidates and 
recipients respectively. The socio-demographic and SF-36 questionnaires were tested for face 
validity (understanding and clarity of the questions), to evaluate for ambiguity (35,36) and for 
ease of administration. The semi-structured interview schedule was also piloted to determine 
participants understanding of the open-ended questions (37).  Both questionnaires and interview 
schedule were acceptable for use in the main study as they proved understandable and easy to 
administer. As this data was obtained from HIV-negative patients, it was not included in the 
main study data. 
7.2.7 Data analysis  
Quantitative data 
Quality Metric Health Outcomes™ Scoring Software 4.0 was used to generate the eight domain 
scores and the two component summary scores. The mean SF-36 scores were calculated per 
domain. Data was entered into and analysed using the Statistical Package for Social Sciences 
(SPSS®) version 25.0. Means and standard deviation were calculated for all continuous 
variables, and frequencies with percentages were analysed for categorical variables. Differences 
in the means of groups (gender and treatment) were compared at baseline and six months using 
the independent samples t-test. Paired samples t-test was used to calculate the change in 
HRQOL by calculating the difference in mean scores of each domain from baseline to six 
months. ANOVA (or independent samples t-test) was applied to test for significant differences 
in the measured SF-36 domains across demographic categories. Pearson’s correlation was done 
to determine the relationship between HRQOL and nutritional status (MAMC values) and 
continuous variables. A p value of <0.05 was taken as statistically significant.  The 
questionnaire items were tested for consistency and validity. Cronbach’s alpha was used to test 
the scale reliability.  
Interview analysis 
Scripts were manually coded, and categorised to extract themes (27), by the primary researcher 
followed by an independent expert in the field. Categories were discussed and agreed upon and 
merged into themes that most succinctly captured the thoughts, feelings and attitudes of the 
participants (38). These were reported as per the framework of the SF-36 domains. Quotations 







7.3.1 Participant characteristics 
 
Sixty eight participants completed the SF-36 at both baseline and six months. Two participants 
who participated in the baseline screening had demised before the six month follow-up. The 
remaining participants completed the questionnaire at one time point only due to time constraints, 
or missed appointments. However, there were no differences in the socio-demographic or clinical 
characteristics of participants who completed the questionnaire at both time points versus those that 
did not. 
 
Table 7.2 presents the socio-demographic and clinical characteristics of the study sample. All 
participants (N=68) were HIV-positive and suffered from end stage renal disease (ESRD).  Of 
these, 21 were recipients of a kidney transplant from a HIV-positive donor. There were 44/47 on 
haemodialysis (HD) and 3/47 on peritoneal dialysis while awaiting a transplant.  Six out of ten 
(61.8%, 42/68) were male, while the remaining 26/68 (38.2%) were female, with the majority 
being of black ethnicity 65/68 (95.6%). The mean age of patients was 43.5 ± 8.1 years,    31/68 
(45.6%) were unemployed, and 36/68 (52.9%) had full-time or part-time employment or were 
self-employed. The mean duration of treatment for the entire group was 3.7 ± 3.0 years, 
although transplant candidates were on dialysis slightly longer than transplant recipients had 
their transplants (4.1 ± 3.2 versus 2.8 ± 2.3 years). The majority of patients were hypertensive 
62/68 (91.2%). There were significantly more patients with diabetes 14/68 (20.6%) amongst 
transplant candidates compared to the one transplant recipient (p = 0.049). One participant in 
each group received treatment for hypercholesterolaemia.  Better HIV parameters were 
observed for transplant recipients, as the majority 35/43 (81.4%) had viral loads lower than 
detectable limits, while 100.0% of transplant recipients had viral loads lower than detectable 
limits. The mean CD4 count was higher among transplant recipients compared to those on the 




























7.3.2 Participant nutritional characteristics 
The nutritional characteristics of the study group are shown in Table 7.3.  
Transplant candidates 
The mean serum prealbumin of transplant candidates on dialysis, was 357.1 ± 84.9mg/L and 
369.1 ± 99.1 mg/L at baseline and six months respectively. The majority had normal prealbumin 






Age (years)  43.5 ± 8.1 44.6 ± 8.1 41.0 ± 7.7 
Gender     
 Male  42 (61.8) 28 (59.6) 14 (66.7) 
 Female  26 (38.2) 19 (40.4) 7 (33.3) 
Ethnicity     
Black  65 (95.6) 46 ( 97.9) 19 90.5) 
Coloureda  3 (4.4) 1 (2.1) 2 (9.5) 
Employment     
Unemployed  31 (45.6%) 20 (42.6) 11 (52.4) 
Employed part-time  1 (1.5%) 1 (2.1) 0 (0) 
Employed full-time  31 (45.6%) 23 (48.9) 8 (38.1) 
Self employed  4 (5.9%) 2 (4.3) 2 (9.5) 
Retired  1 (1.5%) 1 (2.1) 0(0) 
Type of treatment     
Transplant  21 (30.9)   
Haemodialysis  
47 (69.1) 
44 (64.7)  
Peritoneal dialysis  3 (4.4)  
Length of time on  
current treatment (years) 
 3.7 ± 3.0 4.1 ± 3.2 2.8 ± 2.3 
Chronic illness     
Diabetes  14 (20.6) 13 (27.7)a 1 (4.8)b 
Hypertension  62 (91.2) 44 (93.6) 18 (85.7) 
Hypercholesteraemia  2 (2.9) 1 (2.1) 1 (4.8) 
CD4 (cells/µL)1  394.9 ± 197.7  384.5 ± 166.4 419.6 ± 261.1 
Viral load (copies /ml)2     
 LDL  53 (86.9) 35 (81.4) 18 (100.0) 
≤ 10 000  6 (9.8) 6 (14.0)  
> 10 000  2 (3.3) 2 (4.7)  
Data expressed as frequency with percentages or means and standard deviation 
a In South Africa, refers to individuals of mixed race ancestry 
b Significantly more than expected of the dialysis patients have diabetes (p = 0.049). 
1 transplant patients: n = 19, dialysis patients: n = 45 
2 transplant patients: n = 18, dialysis patients: n = 43  




levels at both time points (76.7% and 73.2%). Low prealbumin was present in 7/30 (23.3%) of 
the transplant candidates at baseline which increased slightly to 11/41 (26.8%) at six months. 
Transplant candidates had a mean serum albumin of 35.8 ± 4.7g/l and 37.2 ± 5.0g/l. When using 
< 38g/l as a reference for hypoalbuminaemia, more candidates were hypoalbuminaemic than 
those with normal albumin levels at baseline and at six months (63.4% and 51.1%). 
There was a negligible change in mean BMI from baseline to six months (25.6 ± 4.1 and 25.2 ± 
4.3). At both time points, one patient was classified as underweight, approximately 40.0% had a 
normal BMI, while slightly more were overweight (42.2% and 43.2% at baseline and six  
months respectively).  Those in the obese class I category were 7/45 (15.6%) and 6/44 (13.6%) 
at both time points. MAMC, a surrogate measure of lean muscle mass decreased non-
significantly from 24.6 ± 4.5cm to 23.3 ± 5.5cm. 
 
Transplant recipients  
The mean prealbumin levels of transplant recipients were 296.9 ± 69.0mg/L and 306.4 ± 
68.0mg/L at baseline and six months respectively. These values were lower than that of 
transplant candidates, as 61.1% and 50.0% of recipients had low serum prealbumin at baseline 
and six months respectively. In addition, significantly more transplant recipients, 11/18 (61.1%) 
had low prealbumin levels compared to transplant candidates 7/30 (23.3%) (χ2 (1) = 6.850, p = 
0.009).  Transplant recipients had mean serum albumin levels of 43.1 ± 4.2g/L (baseline) and 
41.1 ± 4.1g/L (six months). When compared to transplant candidates, recipients had 
significantly higher serum albumin levels at baseline with more having normal serum albumin 
levels at this time point 7/19 (89.5%), compared to transplant candidates 15/41 (36.6%). χ2 (1) = 
14.592, p < 0.005).   
Like transplant candidates, transplant recipients had BMI values that were similar at the two 
time points (24.5 ± 4.7 and 25.6 ± 5.9 kg/m2), although more recipients had a normal BMI  
14/20 (70.0%), compared to 18/45 (40.0%) of transplant candidates at baseline. However, more 
transplant candidates were overweight at this time point, Fisher’s exact = 7.923, p= 0.031. At 
six months, 12/21 (57.1%) transplant recipients had a normal BMI, due to one patient with a 
lower BMI falling into the underweight category, and two more being classified as obese class I. 
The mean six month MAMC values indicated that transplant recipients’ mean MAMC had 




Table 7.3: Nutritional characteristics of transplant candidates and recipients  
 
Anthropometric Characteristics Transplant candidates  Transplant recipients 
 
 n Baseline n 6 months  n Baseline n 6 months 
Pre-albumin mg/L 30 357.1 ± 84.9  41 369.1 ± 99.1  18 296.9 ± 69.0  18 306.4 ± 68.0 
Low pre- albumin (< 30mg/L)  7 (23.3)a  11 (26.8)   11 (61.1)a  9 (50.0) 
Normal: pre-albumin (≥30mg/L)  23 (76.7)  30 (73.2)   7 (38.9)  9 (50.0) 
Albumin (g/L) 41 35.8 ± 4.7 47 37.2 ± 5.0  19 43.1 ± 4.2 21 41.1 ± 4.1 
Hypoalbuminaemia (<38g/L)  26 (63.4)  24 (51.1)   2 (10.5)  3 (14.3) 
Normal: albumin (≥38g/L)  15 (36.6) b  23 (48.9)   17 (89.5)b  18 (85.7) 
Weight (kg) 47 72.4 ± 12.1 46 71.1 ± 12.0  20 70.5 ± 17.6 21 73.0 ± 19.5 
Height (m) 45 167.9 ± 8.3    21 168.6 ± 10.3 21  
BMI (kg/m2)  45 25.6 ± 4.1 44 25.2 ± 4.3  20 24.5 ± 4.7 21 25.6 ± 5.9 
Underweight   1 (2.2)  1 (2.3)    -  1 (4.8) 
Normal   18 (40.0)  18 (40.9)   14 (70.0)  12 (57.1) 
Overweight   19 (42.2)  19 (43.2)   2 (10)  2 (9.5) 
Obese Class I   7 (15.6)  6 (13.6)   4 (20.0)  6 (28.6) 
TSF (mm) 34 14.92 ± 9.17 45 14.30 ± 9.56  18 10.19 ± 5.1 18 14.1 ± 7.8 
MUAC (cm) 34 29.1 ± 4.9 45 27.8  ±  6.0  17 28.4 ± 5.3 18  31.4 ± 4.7 
MAMC (cm) 33 24.6 ± 4.5  44 23.3  ± 5.5  17 25.2 ± 4.3 18 26.6 ± 3.3 
Data expressed as percentages or means with standard deviation or frequency with percentages 
BMI: Body mass index, TSF: triceps skinfold, MUAC: mid upper arm circumference, MAMC: mid arm muscle circumference 
a At baseline, a significant number of the transplant recipients had low pre-albumin (< 30mg/L), χ2 (1) = 6.850, p = 0.009. 




7.3.3 Health related quality of life – Quantitative results 
  
Before data analysis was conducted, reliability and validity tests were performed on the SF-36 
questionnaire, showing suitability as measure of HRQOL. The results are presented in Table 
7.4. 
 
Reliability and validity 
 




Validity and reliability criteria SF-36 results 
Item internal 
consistency  
If the correlation between an item and its 
hypothesised scale score is > 0.4, internal 
consistency is established.  
Item internal consistency is considered 
satisfactory if at least 90% of the item-scale 
correlations are at least 0.4. 
Of the items analysed, 92.8% had an item-scale 
correlation > 0.4, thereby indicating satisfactory 




Cronbach’s alpha was used to determine scale 
reliability. An alpha of > 0.7 is considered to 
indicate a reliable scale. 
 
The only scale with alpha < 0.7 was general 
health, baseline (alpha =.641). This value was  
considered as acceptable. As alpha is sensitive to 
the number of items and only five items 
represented the general health domain, it is 






To check for item discriminant validity, 
correlations between items in a scale and the 
scale scores are calculated. If items correlate 
more highly with their own scale than with the 
other scales, discriminant validity is established. 
Item discriminant validity is considered to be 
satisfactory when at least 80% of items correlate 
higher with their own scale than with the other 
scales. 
PF, RP, BP, GH, VT, SF, RE and MH items 
correlated higher with their own scale than with 
the other scales at baseline and six months. As 
100% of the correlations between items and their 
scales were greater than between the items and 





SF-36 HRQOL scores  
 
SF-36 scores separated by treatment modality (candidates and recipients) and gender at both 
baseline and six months are displayed in Figures 7.1, 7.2, 7.3, and 7.4. These domain scores 






From Figure 7.1 and 7.2, it is evident that transplant candidates on dialysis experienced a lower 
HRQOL across all HRQOL domains when compared to transplant recipients. Lowest mean 
scores were VT domain for candidates on dialysis (57.1 ± 19.6 and 60.1 ± 19.7) at both time 
points. Candidates’ subjective appraisal of their general health, as indicated by the GH score, 
was also low (59.5 ± 19.6 and 62.3 ± 22.2) at both time points. At six months, the GH domain 
had the largest significant difference in domain scores between candidates and recipients (d = 
4.352, p = 0.000). For candidates, subjective perception of mental health had a score of 74.2 ± 
19.3 at baseline, improving to 79.0 ± 14.1 at six months. The differences between MH scores 
for candidates versus recipients were not significant. Among recipients, HRQOL scores 
improved by the second assessment, especially in RP, BP, GH and SF. Similar to that of  
candidates, the low scores of recipients was for VT (73.3 ± 20.2 and 73.6 ± 21.5). GH was also 
low at baseline (71.3 ± 24.4) but improved considerably by six months (86.2 ± 17.5). 
 
When the study sample was divided according to gender, females had lower scores than males 
(Figure 7.3 and 7.4). Differences between scores for the two groups were significant either at 
baseline, six months or both, for all domains (Table 7.5). The significant differences between 
scores for males and females were in the domain of RP (80.4 ± 35.6 and 49.0 ± 46.1, df = 2.961, 
p = 0.005), at baseline and at six months (84.5 ± 32.6 and 54.8 ± 48.0, df = 2.785, p = 0.08). The 
implication of this finding was that compared to males, females were most severely limited in 
their physical ability to perform daily activities. 
 
For the physical and mental composite scores, the PCS for candidates was 47.4 ± 8.6 and 47.7 ± 
9.5, while MCS was 47.6 ± 10.3 and 51.5 ± 8.7 at each time point. The PCS for transplant 
recipients was 53.8 ± 10 and 56.6 ± 6.5, while MCS was 51.3 ± 11.5 and 54.2 ± 8.5 at baseline 
and six months respectively. Differences between the two groups were significant for PCS only 
at baseline and six months (df = 2.708, p = 0.009 and df = 4.464, p = 0.000). There was no 
significant difference between candidates and recipients at either time point for MCS.  
 
Over the six month period, SF-36 scores in each HRQOL domain increased, signalling 
improvements in HRQOL from baseline to six months for the study sample. Statistically 
significant differences between baseline and six months for all participants were GH: (t = -
2.351, p = 0.022), SF: (t = -2.139, p = 0.036), RE: (t = -2.230, p = 0.029), MH: (t = -2.327, p = 






Correlations of HRQOL with socio-demographic, nutritional status and clinical variables 
 
Table 7.6 shows HRQOL correlations with clinical and nutritional variables. The association 
between HRQOL and albumin was demonstrated in both candidates and recipients in the overall 
PCS at the six month assessment, but not the MCS. For the candidates, there was a significant 
association with low albumin levels and low HRQOL scores in the physical domains of RP (r = 
0.304, p = 0.038) and BP (r= 0.358, p = 0.014). This finding illustrated that candidates with 
lower albumin levels experienced more limitations in daily activities and were in more pain. 
Transplant recipients were also influenced by albumin at six months in the physical domains of 
PF (r = 0.514, p = 0.017) and RP (r = 0.543, p = 0.011), but were also limited in daily activities 
by emotions (RE) at lower levels of albumin (r = 0.492, p = 0.024). There was a lack of 
correlation with CD4+ count or significant differences in HRQOL between the VL categories. 
In transplant recipients only, MCS (r = - 0.451, p = 0.040) was negatively associated with 
treatment duration, with the implication being that mental health deteriorated in accordance with  
a greater time lapse since transplantation. 
In candidates, indicators of nutritional status such as pre- albumin and BMI, correlated with GH 
at baseline (prealbumin: r = 0.401, p = 0.031 and BMI: r = 0.338, p = 0.025). Among transplant 
recipients on the other hand, indicators of nutritional status were significantly associated with 
more HRQOL domains at six months i.e. RP (r = 0.493, p = 0.038), RE (r = 0.493, p 0.038) and 
the MCS (r = 0.495, p = 0.037). Correlations of MAMC, a proxy of muscle mass, with HRQOL 
scores was evident in the transplant group, but not the dialysis group. There was a strong 
positive relationship between MAMC and the PCS (r = 0.821, p = 0.000) at baseline. MAMC 
also correlated with individual domains of physical; PF, RP, BP, and GH. There was a weak 






        
 
                 Domains of HRQOL  
 
Figure 7.1: HRQOL domain scores for transplant candidates and recipients at baseline 
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Figure 7.3: HRQOL domain scores for males and females at baseline 
    
 



















































  Table 7.5: SF-36 scores with significant differences according to treatment group and gender expressed as means ± SD 
                                                               
     
Domains All Candidates Recipients d P  Male Female d  p 
PF (B) 80.4 ± 21.2 74.6 ± 19.7 93.6 ± 18.7 3.726 0.000  84.0 ± 20.1 74.6  ± 22.0 - - 
PF (6 M) 81.1 ± 21.3 76.2 ± 20.5 92.1 ± 19.0 3.123 0.003  85.8 ± 18.2 73.5 ± 23.8 2.414 0.019 
           
RP (B) 68.4 ± 42.5 61.7 ± 43.9 83.3 ± 35.6 2.147       0.037  80.4  ± 35.6 49.0  ± 46.1 2.961 0.005 
RP (6 M) 73.2 ± 41.5 64.9 ± 44.4 91.7 ± 26.6 3.076 0.007  84.5 ± 32.6 54.8 ± 48.0 2.785 0.008 
           
BP (B) 77.8 ± 27.2 76.0 ± 28.2 81.9 ± 24.9 - -  84.6  ± 23.3 66.8  ± 30.0 2.747 0.008 
BP (6 M) 85.3 ± 24.5 81.6 ± 26.7 93.5 ± 16.3 2.258 0.028  92.0 ± 15.0 74.5 ± 32.4 2.595 0.014 
           
GH (B) 63.2 ± 21.7† 59.5 ± 19.6 71.3 ± 24.4 2.113 0.038  69.0  ± 20.1 54.2  ± 21.5 2.857 0.006 
GH (6 M) 69.8 ± 23.7† 62.3 ± 22.2 86.2 ± 17.5 4.352 0.000  71.0 ± 24.9 67.7 ± 21.5 - - 
           
VT (B) 62.1 ± 21.0 57.1 ± 19.5 73.3 ± 20.2 3.135 0.003  66.4  ± 20.8 55.2  ± 19.7 2.210 0.031 
VT (6 M) 64.3 ± 21.1 60.1 ± 19.7 73.6 ± 21.5 2.528 0.014  67.3 ± 20.5 59.4 ± 21.6 - - 
           
SF (B) 75.6 ± 27.6† 71.8 ± 26.1 83.9 ± 29.6    79.2  ± 27.1 69.7  ±27.9 - - 
SF (6 M) 82.9 ± 24.6† 78.2 ± 25.5 93.5 ± 19.2 2.725 0.009  88.4 ± 20.0 74.0 ± 28.9 2.223 0.032 
           
RE (B) 73.5 ± 42.5† 70.2 ± 43.5 81.0 ± 40.2 - -  82.5  ± 36.2 59.0  ±  48.4 2.140 0.038 
RE (6 M) 85.8 ± 31.2† 83.7 ± 31.8 90.5 ± 30.0 - -  88.1 ± 28.3 82.1 ± 35.6 - - 
           
MH (B) 76.2 ± 20.2† 74.2 ± 19.3 80.6 ± 22.1 - -  80.3  ± 18.4 70.0  ± 21.7 2.188 0.032 
MH (6 M) 80.8 ± 14.3† 79.0 ± 14.1 85.0 ± 14.2 - -  82.5 ± 13.8 78.2 ± 14.8 - - 
Composite           
PCS (B) 49.4 ± 9.5 47.4 ± 8.6 53.8 ± 10.0 2.708 0.009  51.8  ± 8.0 45.5  ± 10.5 2.786 0.007 
PCS (6 M) 50.4 ± 9.6 47.7 ± 9.5 56.6 ± 6.5 4.464 0.000  53.1 ± 6.3 46.1 ± 12.2 2.744 0.010 
           
MCS (B) 48.7 ± 10.8† 47.6 ± 10.3 51.3 ± 11.5 - -  50.9  ± 9.9 45.4 ± 11.4 2.095 0.040 
MCS (6 M) 52.3 ± 8.7† 51.5 ± 8.7 54.2 ± 8.5 - -  53.0 ± 8.2 51.4 ± 9.4 - - 
B: baseline, 6 M: six months, PF: physical functioning, RP: role physical, BP: bodily pain, GH: general health, VT: vitality, SF: social function, RE: role emotional, MH: mental health, d:difference, p (p value) 
†Statistically significant difference between baseline and six month follow up for all participants, paired samples t-test:  





Table 7.6:   Correlations of SF- 36 scores with clinical and nutritional variables for transplant candidates and recipients 
 Transplant candidates 
 












PF      0.514* (0.017)  [6M] 0.675**(0.003) [B] 
RP  0.304* (0.038) [6M]   0.493* (0.038) [6M] 0.543* (0.011)  [6M] 0.558* (0.020)  [B] 
BP  0.358* (0.014) [6M]     0.757** (0.000) [B] 
GH 0.401* (0.031) [B]  0.338* (0.025) [B]    0.608** (0.010) [B] 
VT        
SF        
RE     0.493* (0.038) [6M] 0.492* (0.024) [6M]  
MH        
        
MCS     0.495* (0.037) [6M]  -0.484*(0.042) [6M]  
PCS  0.329* (0.024) [6M]    0.464* (0.034) [6M] 0.821**(0.000) [B] 
B: baseline, 6 M: six months 
PF: Physical functioning, RP: Role physical, BP: bodily pain, GH: general health, VT: vitality, SF: social function, RE: role emotional, MH: mental health, MCS: 
mental component score, PCS: physical component score 





7.3.4 Health related quality of life – Qualitative results  
 
Fifty six patients participated in the semi-structured interviews. Of these, 33 were male and 23 
were female, with 38 on dialysis and 18 being transplant recipients. The narratives that 
participants provided were broadly aggregated into themes similar to those evaluated in the SF-
36.   
 
General impact of health on life 
 
Transplant candidates: When expressing general feelings about their health and treatment, 
transplant candidates associated dialysis with a sense of loss and lifestyle limitations imposed 
by time constraints and a lack of energy. 
 
“I cannot do the things I used to” (TC female 30) 
“I used to be able to do everything. I felt free, but not anymore” (TC male 27) 
“It has changed my life 100%” (TC male 2) 
“I just feel like my kidney failure has taken over my life” (TC female 25) 
“With HIV, it’s up to you – but this dialysis!” (TC female 7) 
“It takes up so much time in your day” (TC female 23)  
 
Transplant recipients: Narratives of transplant recipients where indicative of how receipt of a 
donor kidney enhanced their quality of life and health.  
 
 “I feel alive and in good health after many years” (TR male 6)  
 “I have a second chance at life” (TR male 5) 
 “My life now is amazing. I was very sick on dialysis. I nearly died” (TR female 9) 
  “My health is excellent compared to how I used to be” (TR male 16) 
 
Physical aspects of health 
 
Transplant candidates: With the exception of one or two candidates, most reported how dialysis 
had a negative impact on physical health including fatigue, weakness and body pain. These side 
effects of dialysis had an impact on activities related to daily living, sport and leisure, 





Narratives ranged from being cautious to feeling more severely impaired (the majority of 
candidates).   
 
“I can do everything, but I have to be cautious of the fistula” (TC male 28) 
“I can’t take care of my child properly” (TC female 1) 
“Work became too difficult. I lost my job” (TR male 20) 
“Always I’m in pain” (TC female 9) 
“I can’t do strenuous activities; I have to take more breaks” (TC male 31) 
“After dialysis I also feel very tired and weak, and sometimes get cramps” (TC female 22) 
 
Mental aspects of health 
 
Transplant candidates: Participants reported a number of concerns and fears and coping 
strategies that affected their mental well-being. Firstly, financial constraints related to travel 
expenses incurred to and from dialysis as well as medical expenses were often referred to as a 
source of stress, as was the loss of employment and the inability to work. This caused feelings 
of frustration due to an inability to support family members. Secondly, candidates also 
expressed various emotions associated with the wait for a donor namely anxiety, desperation, 
uncertainty and hope.  Thirdly, they expressed their means of coping with mental and emotional 
stress.  
 
“It is 66km (to dialysis). I leave at 7am and get there at 8am. I take public transport which costs 
me R100.00 a day. After dialysis, I leave at 4pm and get home at 6pm. I am very tired after 
dialysis” (TC female 15) 
“My main problem is that I am not working. It doesn’t feel good that my wife has to do 
  everything” (TC male 4) 
“Some towns don’t have dialysis clinics so I can’t sleep over (for work). It’s a big 
inconvenience” (TC male 16) 
“I was a man supporting my family, now they are supporting me” (TC male 20) 
 
“Every time I wake up, I’m thinking about when I will get a transplant” (TC male 8) 
 “I wish for a kidney to come, I will take that kidney” (TC female 23) 
“Most of the time I close my door and sit alone because I’m always thinking about one day I’m  
going to die. So I just wish I could get a donor” (TC female 7) 






“These thoughts (worries) don’t affect my life, they just come and go” (TC male 2) 
“I just go and pray and feel so much lighter” (TC female 21) 
 “After dialysis I feel very emotional. I prefer to be on my own sleeping” (TC female 30) 
“I have lots of support from my kids” (TC female 19) 
 
Transplant recipients: With regards to the psychological health of transplant recipients, several 
expressed frustrations and stress regarding finances and unemployment. A few recipients had 
concerns regarding the donor kidney. However, the majority expressed gratitude. 
 
 “I do feel depressed. How can you be happy when you can’t afford anything?” (TR male 14) 
“I feel anxious, stressed and worried because of not having enough money” (TR female 7) 
 
“My only worry is what will happen if my kidneys fail“(TR male 5) 
“I was so worried when I got sick because I thought that I would maybe lose my kidney” (TR 
female 13) 
“Osteoporosis revealed itself…I am afraid that the doctor won’t be able to fix my bones” (TR 
female 8)  
 
“I am very grateful for everything. I don’t want to ask for more” (TR female 18) 
“I got my kidney, it’s my child, and she is my princess” (TR, female 2)  





Transplant candidates:  A handful of candidates were still going out, however the majority of 
candidates stated that being on dialysis has a negative impact on their social life, and that they 
prefer to keep a smaller social circle where they gain supportive social interactions, rather than 
place themselves in awkward social situations. Social interaction that served as a source of 
emotional support included parents, a spouse, partner, children, church members, colleagues, 
employers, renal staff and other patients. 
 
“They (family) can’t involve me with their things, sometimes they say, ‘you’re sick!’” (TC 





“I don’t want to go out with friends or have a boyfriend; it makes me stressed to be with people 
because I can’t have those drinks or food. So I’d rather just not be with them because I don’t 
want the questions (TC female 23) 
“I spend most of my time alone” (TC male 5) 
“When I go to the renal unit, we are a family, nurses, doctors and patients” (TC female 19)  
“I have great family support so I do not feel down at all” (TC male 29) 
“I take it to God to sort it out for me” (TC female 21) 
 
Transplant recipients: Without limitations, recipients felt free to participate in more activities. 
Like candidates, they rely on similar social support structures such as family, colleagues and the 
Church. They also felt strongly supported by the transplant team. 
 
 “There is a lady at work…we keep each other positive” (TR female 18) 
“I was worried about my job, but the doctors and managers (work) had a meeting, and 




7.4 Discussion  
There are currently no published data regarding the HRQOL of HIV-positive kidney transplant 
recipients who have received a kidney from a HIV-positive donor, or for HIV-positive 
candidates on the waiting list to receive a donor kidney. The current study was a longitudinal 
investigation of HRQOL in this unique group, employing a mixed methods study design. The 
quantitative generic SF-36 instrument demonstrated reliability and validity prior to analysis and, 
in agreement with numerous other studies (21,39,40,41), was considered a suitable measure of 
HRQOL. However, given the complexity of HRQOL, no single method can evaluate this 
concept with sufficient depth (42). Therefore, triangulation, using a mixed method approach was 
used. Triangulation not only corroborates the findings of either method, but also provides a 
greater depth of understanding regarding the HRQOL of this previously unexplored study 
sample. To this end, the study incorporated face-to-face semi-structured interviews into the 








7.4.1 HRQOL of transplant recipients 
 
In the present study, SF-36 scores were higher for transplant recipients, indicating a better QOL 
than transplant candidates at both time points. Previous HRQOL research also documented 
superior HRQOL in transplant recipients, when compared to transplant candidates on dialysis 
(44), or in prospective HRQOL assessments of transplant recipients conducted before and after 
their transplant (8), In a similar comparative study of transplant candidates and recipients, 
Kovacs et al reported that recipients had a significantly overall better QOL, although this was 
not consistent across all domains (45), thereby drawing attention to the concept that receipt of a 
transplant cannot categorically be viewed as an entirely positive event for all transplant 
recipients. Persisting issues that are not necessarily resolved by undergoing a transplant include 
side effects of treatment, unresolved psychological problems and difficulties in resuming 
employment, which may overshadow the expected gains from the transplant (45). In addition, 
psychological problems like depression occurs, with the prevalence thereof ranging from 11.8% 
to 75% (46-48). Mental health has been an important investigative area among transplant 
recipients due to the association of depressive symptomatology with negative outcomes such as 
sleep problems (49) and poor adherence to treatment (50). A meta-analysis by Dew et al found 
that depression increased the relative risk of mortality in organ transplant recipients with a 65% 
greater risk of mortality (8). 
 
In the present study, the majority of transplant recipients did not display symptoms indicative of 
depression (51). This was supported by the high MH score. Moreover, the MCS, which 
encompasses multiple aspects of psychological health, was scored above the average for the 
general population (52). Transplant recipients recalled how terminally ill they were, and the 
devastating impact their ESRD diagnosis had on their lives. Hence, their current health 
experience could not be compared to that experienced while on dialysis. Although some 
anxieties and physical limitations persisted, these were mainly related to financial constraints, 
unemployment and a concern regarding graft rejection.  However, these fears were outweighed 
by positive changes resulting from the transplant. The majority of participants associated their 
transplant with freedom, opportunities, and a second chance at a normal life, which was in stark 
contrast to the recollection of their lives while on dialysis.  A similar observation by De 
Pascuale et al documented that the mental freedom attained once dialysis ceased, resulted in 
feelings of psychological well-being which remained undiminished by other problems recipients 






In addition, all transplant recipients referred to social networks at church, family or friends 
which likely contributed to their social, emotional and mental well-being. In a Chinese study of 
renal transplant recipients, 59.2% of the sample had depressive symptoms, resulting in Lin et al 
to report that apart from financial and employment stressors, a lack of social support was a key 
factor contributing to depressive symptoms (48). In the present study, the SF score indicated 
good social interaction, which further improved by the second assessment. A possible reason for 
this finding is that patients are most likely to face their greatest limitations related to social and 
emotional aspects of life in the initial months post-transplant, which Espisito and colleagues 
speculate is due to numerous hospital procedures and protocols in the immediate post-transplant 
period (54).  Thereafter, following the transition period, SF as well as other domains is likely to 
improve.  
 
7.4.2 Transplant candidates 
 
A distinction between HD and PD among candidates awaiting a transplant in the current study 
was not made, as it was previously shown that there are no significant differences in overall 
QOL between HD and PD patients (55-57). 
 
The poorer HRQOL of candidates participating in the current study could be attributed to the 
effect of ESRD and dialysis, which is known to have a significant impact on physical and 
mental wellbeing (58). In the current study, the SF-36 score among recipients that differed most 
significantly from that of the general population , was the PCS representing aspects of physical 
health at six months (d = 4.464, p = 0.000). The PCS of 47.7 ± 9.5 was below the average of 50 
in the general population (23). There are no South African studies for comparative purposes.  
However, US studies indicate that a PCS or MCS between 47 and 53 could be considered as 
within a normal range (5).  
A decrease in PCS typically occurs in relation to a deterioration of kidney function of CKD 
patients (59,60) which when gathered from the present study’s interviews, was partly due to 
bodily pain, but mainly due to fatigue and a lack of energy. This was also clearly evident from  
candidates’ lowest scores being in the VT domain, as they felt greatly limited in their ability to 
continue with the activities of daily living and work when compared to before the onset of 
ESRD. 
The MCS, although lower among candidates than recipients, did not differ significantly between 





social activities and the provision of emotional support. This is important as candidates are 
known to have higher rates of depression than recipients (61). Social interaction improves mood 
and reduces symptoms of depression and anxiety, and improves compliance with treatment (62). 
All candidates in this study indicated the presence of a support system ranging from a 
supportive partner to extensive church and work communities. However, they did express 
frustration that dialysis and post-dialysis recovery restricts time available for engaging in social 
and leisure activities. The support from the renal unit, including from staff as well as other 
patients on dialysis, appeared to be highly valued.  
Although MCS improved by the second assessment, candidates expressed anxieties and 
concerns as causes of varying degrees of mental stress. Foremost among these, was the financial 
burdens due to a reduced income or unemployment.   
 
7.4.3 Socio-demographic factors associated with HRQOL in transplant candidates and 
         recipients 
Income is a known socio-demographic factor having an impact on QOL. A lower income 
corresponds to a lower QOL in the general population (63), as do financial and employment 
concerns among HD and PD patients without HIV in Cape Town (55).  Among transplant 
recipients, occupational status and financial burdens were associated with symptoms of 
depression (48). 
In the present study, 31/68 (45.6%) of participants were unemployed. More candidates than 
recipients indicated that this was a source of considerable stress and depression, as the travel 
expenses incurred for HD, compounded by unemployment, limited available money that would 
normally be spent on food, socialising and education. The prevalence of unemployment 
amongst the current study sample, was higher than the 38.5% reported for  HD and PD patients 
in Iran (64). Through doctors’ correspondence with employers, some participants were able to 
continue working, albeit part-time.  However, seeking employment was also impacted by the 
broader labour market in South Africa, where unemployment in the general population has 
increased over the last decade to 27.7% by the middle of 2017 (65). Candidates expressed their 
frustration about the time required for dialysis and loss of energy, making it challenging to 
retain employment.  
Studies show that being employed has numerous benefits. It reduces stress through feelings of 





used to be the main provider (66). The feeling of guilt was indeed voiced by some candidates. 
Employment also contributes to a higher self-esteem, as one is functioning as a contributing 
member of society (66).  In a study of dialysed patients in Poland, QOL was most adversely 
affected by the inability to pursue work or study options (67).  Again, in a sample of 34 Dutch 
transplant recipients, those that were not employed had significantly lower PF, RP, SF GH than 
those that were working as well as a poorer graft function (68). 
In the present study other notable socio-demographic factors were gender and age, with a 
reduced PF being observed with increasing age. A Malaysian study of transplant recipients also 
reported a negative correlation between age with physical health (PCS) (22). The correlation in 
the present study was weak (r = - 0,277, p = 0.022) (not shown), probably because the study 
sample was still young (mean age 43.5 ± 8.1). Male participants had significantly better 
HRQOL across all domains either at baseline, six months or both. These results are not unique 
to the transplant population, as similar results were documented among non-renal patients, in 
South African and elsewhere (5,6,21,44). Level of education was positively correlated with 
MCS in Chinese HD and PD patients (69). It is thought that more educated patients have a 
better QOL, as they possess a better understanding of their disease and management. This 
emphasises the value of patient education on all aspects of their disease and management as an 
important way to improve QOL. Participants in the current study consistently reported that their 
initial anxieties subsided after being spoken to by the nursing staff about their treatment, 
especially dialysis. 
 
7.4.4 Comorbidity and HRQOL  
The presence of comorbidity has been shown to affect HRQOL. Transplant recipients with 
hypertension and diabetes have lower PCS (66). In all probability, comorbid HIV will have a 
similar influence, as HIV independently affects multiple dimensions of health and wellbeing 
(70). 
 
Despite the presence of HIV, the HRQOL scores and interviews did not reflect the burden of 
two diseases. In fact, transplant candidates on HD and PD scores were higher than that of other 
South African HD and PD patients without HIV (55). Similarly, transplant recipients also had 
higher HRQOL when compared to kidney transplant recipients that are not infected with HIV 
(Figure 7.5), measured using the SF-36 tool in Italy (54), Brazil (66), Norway (71) and Portugal 
(72). Moreover, the PCS and MCS for transplant recipients were above the average of the 





depending on how the questionnaire is administered.  Interviewer- administered questionnaires, 
as was the case in the current study, yield higher scores than self-administered ones (21). 
However, based on the semi-structured interviews conducted in the current study, it would seem 
that the high scores documented, depicted the magnitude of change recipients perceived the 
transplant to have  made to their lives.  It could be assumed that recipients were most likely 
aware of the bleak outcome they would have faced without the option of a transplant.  
 
 
Figure 7.5: HRQOL domain scores for transplant recipients at baseline and at six months 
compared to other countries 
 
7.4.5 Nutritional parameters associated with HRQOL 
 
In the current study, BMI, MAMC and prealbumin were indicators of nutritional status. 
Although albumin was previously considered an indicator of nutritional status, it has been 
shown to be unrelated to dietary intake in CKD and poorly correlates with other nutritional 
markers in dialysed patients (73,74). Hence, it is of value as an indicator of illness and 
inflammation (33). Hypoalbuminaemia was present in more dialysis participants than recipients. 
Serum albumin showed significant association with PCS and physical health domains RP and 































with RE, but only among recipients.  As an indicator of disease activity or illness, 
understandably, sicker participants would have lower QOL.  
As an alternative indicator of protein stores, The National Kidney Foundation Kidney Disease 
Quality Initiative (K/DOQI) recommends the use of prealbumin as a biochemical indicator of 
nutritional status (33). In the current study, the majority of candidates had prealbumin levels 
that were within the normal range. GH, a subjective perception of one’s health status, and a 
domain of physical health, was better at higher prealbumin and BMI values. Other studies have 
also shown associations with several domains of physical aspects of health (75,76), However in 
transplant recipients, prealbumin correlated with more dimensions of health, i.e. not only with 
physical (RP), but also emotional (RE) and psychological (MCS) health.  
  
In the present study, measures of lean muscle namely MAMC, strongly correlated with the PCS, 
albeit only amongst transplant recipients. Recipients with a higher muscle mass had better 
HRQOL in the PCS domains of PF, RP, BP and GH. In the general population, similar changes 
in muscle mass occur in the elderly, where a low muscle mass affects strength and impairs 
physical functional status and daily life (13). In turn, physical functional ability is also related to 
psychological distress and well-being and has bearing on subjective views of health (77). The 
finding that MAMC correlated inversely with MCS in transplant recipients, was unexpected. It 
is possible that MAMC increased over six months in relation to greater ambulation.  
 
The validity of the study results were enhanced by its longitudinal design and use of mixed 
methods. The SF-36 used in the present study, has good psychometric properties and, as the 
most widely used generic HRQOL tool, allows comparisons between numerous populations. 
Despite the small sample size, the findings of this study are still generalisable, as the majority of 
patients on the transplant lists were included, thus being a fair representation of the group that 
was studied. Furthermore, the heterogeneity of the sample proved to be insightful as it was 
representative of the patient complement awaiting transplant and receiving a kidney from a 
HIV-positive donor, providing insight into the experiences of participants from varied 
backgrounds.  For example, sample characteristics, which are subject to regional variability 
(21), were offset in this multicentre study. Similarly, the study included participants from areas 
with fewer resources compared to areas with better resources as well as including participants 
with varying levels of education and occupational background.  
 
In conclusion, the current study findings, in agreement with other studies, showed that 





indicated that despite the presence of HIV, participant SF-36 scores were higher, indicating a 
good HRQOL when compared to other samples of HIV-negative transplant recipients. The 
experiences of candidates and recipients relayed through the semi-structured interviews, 
increased awareness of patients’ subjective health experience and reinforce current healthcare 
practices or highlight opportunities for optimising patient management. For example, education 
from renal staff helping candidates and recipients to adjust to their disease and treatment is an 
important HRQOL strategy with implications for improving compliance and clinical health. The 
findings also suggest that clinicians should be aware of the significant impact of financial stress 
and unemployment on mental wellbeing. The provision of patient assistance to facilitate 
continued employment is of significant importance and should form part of the routine enquiry 
when assessing patient mental health. Referral to a social worker or psychologist may be 
beneficial. Finally, prealbumin and MAMC was associated with SE, MCS and PCS, and as 
such, nutritional status impacts on physical, mental and emotional health. Therefore regular 
assessment of these indicators and intervention through diet and physical activity may be 
effective behavioural approaches to improving HRQOL. 
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CONCLUSION AND RECOMMENDATIONS  
 
Kidney transplantation only became an available treatment modality for end stage renal disease 
(ESRD) among HIV-positive individuals in recent years with outcomes having surpassed all 
expectations (1). Nutritional comorbidities are common among the kidney transplant population 
and impact on patient and graft survival (2). Those who are also infected with HIV, live with the 
burden of two debilitating diseases. Fortunately, nutrition is a modifiable factor and 
improvements in nutritional status can contribute to meaningful changes in health and quality of 
life. However, there is an absence of data regarding the state of nutritional health in this group, 
despite the fact that it can be used to optimise nutrition therapy. Hence, this research set out to 
explore the nutritional status and quality of life of HIV-positive kidney transplant candidates 
and recipients from HIV-positive donors, by conducting assessments to determine numerous 
measures of nutritional health at baseline and at six month follow-up.   
 
8.1 Objectives and methods 
Guided by the “ABCD” (anthropometry, biochemical, clinical and dietary) assessment method 
(3), a number of nutritional status indicators were selected to describe the existence and extent 
of nutrition-related problems typically found in transplant candidates and recipients.  These 
included the following variables:   
 
 Clinical symptoms of gastrointestinal health were determined using a validated 
questionnaire, namely the gastrointestinal symptoms rating scale. 
 
 Anthropometry was used to determine body composition and changes thereof over a six 
month period. In addition, body composition and bone mineral density was also 
measured by dual energy X-ray absorptiometry (DEXA) in a subset of participants.  
 
 Biochemical parameters indicative of protein status, serum 25(OH)D, fasting glucose 
and lipid profile were selected for investigation. 
 
 Dietary intake was evaluated using the retrospective 24-hour recall method.  
 






 The SF-36 questionnaire quantitatively determined HRQOL 
 
 A qualitative evaluation using semi-structured interviews provided a more 
comprehensive understanding of HRQOL 
 
8.2 Summary of findings and implications for practice  
 
This research provides for the first time, a view of the nutritional health of kidney transplant 
candidates and recipients who are also infected with HIV. Overall, the cumulative findings are 
broadly aligned with that observed in the uninfected kidney transplantation population. In 
chapter three, the investigation regarding the frequency and prevalence of gastrointestinal 
symptoms, confirmed a high frequency of gastrointestinal symptoms in both groups, with a 
greater severity of symptoms in transplant candidates. Since ongoing gastrointestinal symptoms 
have previously been shown to place patients at nutritional risk (4), and affect quality of life (5), 
it is recommended that firstly, periodic regular enquiry about gastrointestinal symptoms should 
be included in patient consultations. This could be by means of open-ended questions or using a 
validated tool such as the gastrointestinal rating scale (GSRS), which performed well in this 
study.  Secondly, consideration should be given to feasible intervention strategies. Identification 
of unhealthy dietary practices and implementing changes via dietetic counselling is often a first-
line approach. Failing this, the use of pharmaceuticals or probiotics is an option, albeit an 
ambivalent one, as polypharmacy and drug interactions have previously posed challenges for 
this group (6). Bone mineral density and the prevalence of osteoporosis were investigated in 
a cross-sectional study. The results indicated a higher prevalence of osteopenia and osteoporosis 
in transplant candidates and recipients respectively. Surprisingly, when compared to several 
other studies in chapter four, more participants had a normal bone density than transplant 
recipients elsewhere. As dietary calcium intake was associated with bone density, ensuring 
adequate dietary calcium intake should be an important take-home message forming part of 
nutrition education.  Bone mineral density assessments are costly and therefore not a viable 
option for most patients.  However, based on available evidence and the current study’s results, 
that a lower lean muscle mass is associated with a lower bone density, individuals can optimise 
bone density through a lifestyle that promotes general physical activity and exercise to preserve 
muscle mass. The most suitable anthropometric methods for measuring and monitoring muscle 
mass as well as adiposity, were investigated in the chapter five entitled: correlation of 





body mass index, waist circumference and mid arm muscle circumference were suitable proxy 
measures of overall and regional adiposity (including visceral adipose tissue) as well as 
musculature based on correlations with body composition derived from DEXA as a reference 
standard. Thus, the suitability of these measures for bedside and field investigation was 
established.  In the study that followed, BMI and waist circumference evaluated overall and 
regional adiposity. Differences in body composition and its changes were observed in 
candidates and recipients. The majority of candidates were found to be overweight and obese. 
However, a significant mean weight loss was observed after six months. Although weight and 
weight change was not linked to diet, a comparison to daily recommendations revealed that the 
daily dietary intake was inadequate in terms of total protein and energy. Dietitians and clinicians 
are therefore encouraged to evaluate patients for weight loss as it increases mortality risk. 
Relying solely on BMI may be misleading if patients are overweight, as the single index might 
still be within an acceptable BMI range. It is also recommended that dietary inadequacy and 
weight loss should be promptly addressed through intervention via education and/or 
supplementation, even before changes in other nutritional indicators become visible. Among 
recipients, waist circumference increased significantly after six months, without significant 
changes in BMI. A correlation between waist circumference and animal protein intake was 
detected at the six month follow-up. Steps that could be implemented to improve nutritional 
status, include ongoing education to encourage a healthy diet. In addition to education, it is 
proposed that like BMI, waist circumference should be a mandatory measurement. Furthermore, 
taking of this measurement could potentially be taught to patients as a self-monitoring tool. The 
final chapter reported on participants’ health related quality of life. Consistent with the 
literature (7), patients on dialysis had a lower HRQOL than transplant recipients. The semi-
structured interviews and variables that correlated with HRQOL scores highlighted modifiable 
factors that if addressed, can improve HRQOL. Most notably from the interviews, stressors 
related to a lack of income and unemployment were perceived as major stressors impacting on 
mental health. The current support provided by clinicians by through corresponding with 
employers, is highly valued and must be continued as a major HRQOL intervention. Correlation 
analysis with SF-36 scores showed that muscle mass was significantly associated to several 
domains of physical function, reinforcing the importance of diet and exercise in maintaining 









8.3 Strengths and Limitations 
 
The strengths and limitations for each study were alluded to as part of the discussion in chapters 
three to seven. However, strengths and limitations as they apply to the overall research project 
include the following. Firstly, the major strength of the research was that it is the first study to 
investigate nutritional health in kidney transplant candidates and recipients who are also 
infected with HIV. Secondly, the accuracy of data was enhanced by using trained and 
experienced health professionals in the form of dietitians for fieldwork. Thirdly, the use of 
validated tools such as the SF-36 and the GSRS enabled comparison with uninfected patient 
groups elsewhere. It should be emphasised that the scope of this research focused on the major 
nutritional abnormalities that usually threaten graft and patient morbidity and mortality. Dietary 
analysis was purposely limited to the investigation of macronutrients and selected 
micronutrients. However, although multiple micronutrients play a role in optimising nutritional 
status, it was beyond the scope of this research. It is also acknowledged that it was the intention 
to obtain three non-consecutive 24-hour recalls. Indeed three were obtained during the pilot 
study in Cape Town. However, when the main study was conducted over multiple locations, 
logistical reasons rendered it impossible for many patients to complete three 24-hour recalls.  
The study sample was 93.4% black. Hence, these results are generalizable to the South African 
population as it is reflects the racial distribution of HIV infection. However, the applicability of 
the results to other ethnicities and other countries was not investigated.  
 
8.4 Recommendations for future research 
 
8.4.1 Logistical and design considerations 
 
Problems encountered that were related to patient retention, missed patient appointments, 
fieldworker dropout and poor compliance of staff with research requests, are not uncommon in 
field research. However, despite careful planning and a pilot study, other problems encountered 
that should be taken into consideration when executing a multi-centre study in South Africa are 
related to the following. 
 
a) Access to data 
Prior to the commencement of data collection, all relevant stakeholders were contacted.  Hence 
problems related to data access were not anticipated. However, in the course of data collection, 





incorporated into clinic and hospital policies. At the time, the act was fairly new, and in the 
absence of set protocols being put in place, many facilities (especially private clinics) became 
reluctant to release patient information. In addition, the sensitive nature of the research due to 
the HIV status of participants, further complicated access to patient information. However, the 
majority of patient data was eventually obtained, but resulted in major time delays that could 
not be foreseen in the planning of time lines for the research.    
 
b) Unequal distribution of resources between the provinces 
A lack of motivation to remain in the study, fieldworker drop out, lost data, geographical access 
and technological difficulties had financial implications and extended the data collection phase. 
It was of interest to note that the majority of these setbacks primarily occurred in regions with a 
known lack of healthcare resources and infrastructure, pointing to social inequality across South 
Africa. When conducting future research, it should be borne in mind that these areas may 
require additional financial and fieldworker resources during the data collection phase of multi-
centre studies (9). 
 
c) Longer follow-up period 
As is the nature of chronic conditions, the clinical course of the disease and treatment is seldom 
static and hence problematic to predict. In addition, symptom burden, nutritional status and 
quality of life are dynamic, changing in nature and magnitude. With the available resources, the 
study prospectively spanned over six months with significant changes being observed. 
However, given a longer follow-up period, it is highly probable that further changes would be 
observed. Hence it would be highly desirable for future research to source the necessary 
resources to facilitate a longer follow-up period.  Furthermore, it would be advisable to capture 
baseline data from the time of acceptance onto the waiting list as a candidate, and from the time 
of transplantation for recipients. 
 
8.4.2 Suggestions for future research 
 
This research was the first nutritional study conducted among this group of study participants.  
Undoubtedly, more research is needed as the programme expands. Suggestions for future 
studies include: 
 





 Evaluating the feasibility of using tools and practices recommended by the current 
study. 
 Conducting intervention studies to improve muscle mass, metabolic syndrome and 
prevent weight loss. 
 
8.5 Conclusion 
Nutrition has always formed a vital part of patient care in both pre- and post-kidney transplant 
patients as well as in those with HIV. Nutrition therapy is aimed at minimizing the effects of the 
disease, its complications, side effects of medication and optimising quality of life. As diet is a 
modifiable factor, prevention of post-transplant complications and HIV-related morbidity can be 
achieved through nutrition and lifestyle support. However, timeous identification of nutritional 
abnormalities is the first step in nutrition therapy.  The current study has shown the extent to 
which nutritional status is altered in HIV-positive patients with ESRD undergoing dialysis and 
transplantation. Given the associated morbidity and mortality risks, early and ongoing 
assessment, followed by prompt intervention is crucial in optimising long-term health and 
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ADDENDIX B:  Participant information and informed consent 
 
Date……………………………….     




My name is Claire Martin. I am a dietitian and a student at the University of KwaZulu-Natal 
(UKZN). The department I am studying with, their contact details as well as my personal details 
are listed below. 
 
You are invited to consider participating in a research project, which is being conducted by 
myself, through the University of KwaZulu Natal (UKZN) in conjunction with the Renal Unit at 
Groote Schuur Hospital.  All HIV positive patients that have had a kidney transplant from a 





Study aim: The study will focus on finding out about the nutritional well-being of all HIV 
positive patients after they have had a kidney transplant, as well as those that are receiving 
dialysis and are on the waiting list to receive one. 
. 
Procedures: The study would involve collecting information about your medical history from 
your files, interviews about your health and food intake, and a series of body measurements and 
blood tests. This will give us an indication of your nutritional status and its impact on your 
health.   
 
a) Dietary intake assessment: During this interview, a dietitian will ask you questions 
about the food you eat.  
b) Body measurements:  These measurements are non-invasive and will include height, 
weight, waist, hip and arm measurements using a tape measure and calipers.  
c) Quality of life assessment: During this interview you will be asked questions about how 
you feel about your current health and its effect on your daily life. 
d) Laboratory tests: Your routine blood test results will be used together with an additional 
two blood tests. These blood samples will be drawn at the same time as your routine 
blood tests.  
 
e) Bone Density:  This is a test that uses a machine to take an X-ray of your body. It 
provides an indication of how strong your bones are, and your fracture risk. The amount 
of radiation is very low, less than you get in daily life. 
 
Duration and cost: The study will run for two years. In that time, your participation will be 
required every six months i.e. 4 times in total. All assessments will take between half an hour to 
one hour each. Only the dietary interviews will require that you be interviewed on three 
different days, to find out what you had eaten the day before. Every effort will be made to 
conduct all other assessments on the days of your usual hospital visit. For additional 





you. You will be reimbursed for any additional transport costs that you may incur. Funding will 
be sought from the University.  
 
Risks: The bone density test is safer than an X-ray of the bones as there is no exposure to 
radiation. The study will not expose you to any additional health risks. In the event of further 
questions or concerns, you could contact me or the UKZN Biomedical Research Ethics 




Researcher: Claire Martin 
Department of Dietetics and Human Nutrition 
Discipline of Dietetics and Human Nutrition 
College of Agriculture, Engineering & Science 
University of KwaZulu - Natal 
Pietermaritzburg 
Cell: 0723862358     
Email: clairejm32@gmail.com 
Biomedical Research Ethics Administration 
Research Office, Westville Campus 
Govan Mbeki Building 









Benefits:  Results from this study will be available to all patients, which they could use to seek 
assistance in improving their nutritional and overall health. 
Voluntary Participation:  Participation in the study is voluntary and you have the option to 
refuse to participate at any stage; and if you do, it will not affect your usual care/treatment in 
any way. 
Confidentiality: All personal and medical information will be stored and utilized confidentially. 
No names will be used in analysis or reporting of any results. 
Findings: The study results will be used for the researcher’s a thesis write-up for the researcher 
and will be published without any breach of confidentiality. 
This study has been ethically reviewed  and approved by the UKZN Biomedical Research 
Ethics Committee (Approval number_________________________) 




I, ____________________________________________________________ declare that the 
details of the study have been explained to me by_____________________________________. 
I understand the aim and assessments required of me in the study and I have been given the 
opportunity to ask questions. I understand that my participation is entirely voluntary, and that I 
can choose to exit at any time without effect to my healthcare. 
I am aware that I can contact the researcher at any time for any queries related to the study. 
Should I have any concerns about my rights as a participant, I can contact the Biomedical 
























APPENDIX C:  SOCIODEMOGRAPHIC QUESTIONNAIRE 
 (All information in this questionnaire is confidential) 
 













Please tick appropriate block 
 
1. Patient group 







2. Home language  
1 2 3 4 
English Afrikaans Xhosa Other (Specify) 
 
 
3. Marital status  
1 2 3 4 5 6 7 8 








4. Educational Status  
1 2 3 4 
None Primary school High school Tertiary education 






5. Type of house 
1 2 3 4 5 







6. Who does the house belong to? 
1 2 3 4 5 
My own Sibling Parents Rented Other (specify) 
 
 
7. Number of bedrooms if separate from the rest of the house  
1 2 3 4 5 6 
There is no separate 
bedroom 
1 bedroom 2 bedrooms 3 bedrooms 4 bedrooms More than 4 
bedrooms 
 
8. Employment Status 
1 2 3 4 5 6 7 




retired Other (Specify) 
 
 
Describe current employment 
 
If no longer working, describe previous employment 
 
 
9. Household occupancy 
Names of people that live at home M/F Age 
(yrs) 
Relationship to you 
    
    
    
    
    
    
    
 
10. How many people are there living at home that are working, and contribute to the 
monthly household income? 
1 2 3 4 6 
1 person 2 people 3 people 4 people 5 people or more 
 
 
11. How many people living at home are receiving State Grants?  
1 2 3 4 6 
1 person 2 people 3 people 4 people 5 people or more 




















14. Living circumstances 
 Y N 
Do you have electricity?   
Do you have a refrigerator?   
 
15. Where do you get drinking water? 
1 2 3 4 5 
Own tap Outside tap Communal tap River/dam Other (specify) 
 
 
16. Which of these do you have at home and use to cook with? 
1 2 3 4 5 6 7 8 










17. Food provision 
 Relationship to participant 
Who does the food preparation and cooking?  
Who decides what food to buy?  
Who buys the food?  
 
 
18. How many visits do you make to the hospital  
 Number of visits Reason 
per week   
Per month   
Per year   
 
19. How do you get to the hospital? 
1 2 3 4 5 
Car (own) Taxi Bus bicycle walking 
 
20. Distance from home to hospital 








Appendix D : SCOPE OF INQUIRY: SEMI – STRUCTURED INTTERVIEW GUIDE 
 
Introduction: 
Thank you for agreeing to talk to me. I would like to find out more about your experiences so 
far, as you await a donor/ after your transplant. By talking about your life, its difficulties, 
improvements and other changes, we hope that we (clinical staff and other health professionals) 
can be more understanding about what you are going through. Knowing how your health has 
affected your life may improve our management of patients on dialysis/ after transplantation. 
All that you say is completely confidential. 
 
I will ask you a few a questions about your daily living experiences dealing with HIV and 
dialysis/ transplantation, but feel free to say anything at all.  I want to record all that you say 
completely and accurately but I cannot write it all down quickly and accurately. Would you 
mind if I record this talk between us? Once again, no one will know that it is you on the 
recorder. Can I go ahead and put it on?  
 
Questions: Health and daily living 
1. How do you feel about your health? 
2. What are your health concerns? 
(Probe: What worries do you have about your health now?) 
3. How has your life changed since you started dialysis/or since the transplantation 
4. How has it affected your everyday life? 
(Probe: Are you still able to do all the things you used to? 
             Are there things you no longer can do?) 
5. How has your family been affected? 
6. What else do you feel worried or anxious about? 
(Probe: What are you afraid of? 
            What is worrying you the most?) 
7. What are you most grateful for? 
8. Who has been your greatest support and how have they helped you? 
9. What is a positive aspect of your life? 
10. Did you have a bad experience that you want to talk about? 




Thank you very much for agreeing to talk to me. If at any stage you would like to add anything 
or feel you want to say something more, please call me on this number. I would like to get an 









SF-36 QUALITY OF LIFE HEALTH SURVEY 
 









Please answer every question. Some questions may look like others, but each 
one is different. Please take the time to read and answer each question carefully by filling in the 
block that best represents your response. 
 






2. Compared to one year ago, how would you rate your health in general now? 
Much better now than a year ago 
Somewhat better now than a year ago 
About the same as one year ago 
Somewhat worse now than one year ago 
Much worse now than one year ago 
3. The following items are about activities you might do during a typical day. 
Does your health now limit you in these activities? If so, how much? 
a. Vigorous activities, such as running, lifting heavy objects, participating in strenuous 
sports. 
Yes, limited a lot. 
Yes, limited a little. 
No, not limited at all. 
b. Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or 
playing golf? 
Yes, limited a lot. 
Yes, limited a little. 
No, not limited at all. 
c. Lifting or carrying groceries. 
Yes, limited a lot. 
Yes, limited a little. 
No, not limited at all. 
d. Climbing several flights of stairs. 
Yes, limited a lot. 
Yes, limited a little. 
No, not limited at all. 
e. Climbing one flight of stairs. 
Yes, limited a lot. 
Yes, limited a little. 
No, not limited at all. 





Yes, limited a lot. 
Yes, limited a little. 
No, not limited at all. 
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g. Walking more than one mile. 
Yes, limited a lot. 
Yes, limited a little. 
No, not limited at all. 
h. Walking several blocks. 
Yes, limited a lot. 
Yes, limited a little. 
No, not limited at all. 
i. Walking one block. 
Yes, limited a lot. 
Yes, limited a little. 
No, not limited at all. 
j. Bathing or dressing yourself. 
Yes, limited a lot. 
Yes, limited a little. 
No, not limited at all. 
4. During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of your physical health? 
a. Cut down the amount of time you spent on work or other activities? 
Yes No 
b. Accomplished less than you would like? 
Yes No 
c. Were limited in the kind of work or other activities 
Yes No 
d. Had difficulty performing the work or other activities (for example, it took extra time) 
Yes No 
5. During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of any emotional problems 
(such as feeling depressed or anxious)? 
a. Cut down the amount of time you spent on work or other activities? 
Yes No 
b. Accomplished less than you would like 
Yes No 
c. Didn't do work or other activities as carefully as usual 
Yes No 
6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbours, or groups? 
Not at all 
Slightly 
Moderately 
Quite a bit 
Extremely 
7. How much bodily pain have you had during the past 4 weeks? 
Not at all 
Slightly 
Moderately 







8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
Not at all 
Slightly 
Moderately 
Quite a bit 
Extremely 
9. These questions are about how you feel and how things have been with you 
during the past 4 weeks. For each question, please give the one answer that 
comes closest to the way you have been feeling. How much of the time during 
the past 4 weeks. 
a. did you feel full of pep? 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 
A little of the time 
None of the time 
b. have you been a very nervous person? 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 
A little of the time 
None of the time 
c. have you felt so down in the dumps nothing could cheer you up? 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 
A little of the time 
None of the time 
d. have you felt calm and peaceful? 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 
A little of the time 
None of the time 
e. did you have a lot of energy? 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 
A little of the time 
None of the time 
f. have you felt downhearted and blue? 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 





None of the time 
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g. did you feel worn out? 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 
A little of the time 
None of the time 
h. have you been a happy person? 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 
A little of the time 
None of the time 
i. did you feel tired? 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 
A little of the time 
None of the time 
10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting friends, 
relatives, etc.)? 
All of the time 
Most of the time 
Some of the time 
A little of the time 
None of the time 
11. How TRUE or FALSE is each of the following statements for you? 







































a) Answer all questions 
b) Think about whether these symptoms have worried you in the past week? 
c) Mark a tick in the block that most describes your symptoms 
 






























(Stomach ache refers to all kind of aches or pains in your stomach or belly) 
 
 






























(Heartburn refers to a burning pain or discomfort behind the breastbone in your chest)  
 
 






























(Acid reflux refers to regurgitation or flow of bitter fluid into your mouth) 
 
 






























(This hollow feeling in the stomach is associated with the need to eat between meals) 
 
 






























(By nausea we mean a feeling of wanting to be sick) 
 
 
6. Have you been bothered by a rumbling in your tummy or belly? 
 


























(Rumbling refers to vibration or noise in the stomach) 
 
 






























(Feeling bloated refers to swelling in the stomach or belly) 
 
 






























(Burping refers to bringing up gas or air through the mouth) 
 
 






























(Passing gas or flatus refers to the release of air or gas from the bowel) 
 






























(Constipation refers to a reduced ability to empty the bowels) 
 
 







































































(If your stools have been alternately hard and loose, this question only refers to the extent you have been bothered by 
the stools being loose) 
 
 






























(if your stools have been alternately hard and loose, this question only refers to the extent you have been bothered by 
the stools being hard) 
 
 






























(This urgent need to open your bowels makes you rush to the toilet) 
 
 
15. When going to the toilet during the past week, have you had the feeling of 






























(The feeling that after finishing a bowel movement, there is still more stool that needs to be passed) 
 






























(vomiting refers to food that has been spewed out) 
 
                        
 
 
